Teva Pharmaceuticals News
632 articlesTeva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November
growth-negative
Net zero tax ‘will drive up NHS medicine prices’
Teva Pharmaceuticals has raised concerns over a new net zero recycling tax that could increase NHS drug prices. The company, which supplies a significant portion of prescriptions in the UK, argues that the eco levy imposes a heavy financial and operational burden on pharmaceutical companies. The tax requires producers to pay for packaging disposal, potentially leading to increased costs for the NHS and operational challenges for Teva. The company warns that the tax could force changes in medicine packaging, impacting affordability and accessibility for patients. Teva is calling for exemptions for drugmakers producing low-cost medicines for the NHS to mitigate the financial impact.
growth-positive
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation: Is There Untapped Value After Recent Uptrend?
Teva Pharmaceutical Industries has experienced a positive trend in its stock performance, with a 5% gain over the past month and a 31% return over 90 days. The companys share price is currently $20.23, with a fair value estimated at $24.44, indicating potential undervaluation. This optimism is driven by the expansion of innovative branded products like AUSTEDO, AJOVY, UZEDY, and an upcoming olanzapine LAI, which are expected to enhance profitability and margins. Despite these positive indicators, Teva faces challenges such as reliance on a few branded drugs and debt pressures, which could impact its momentum if market conditions change.
growth-positive
Trump Administration Eases Approval Process for Biosimilar Drugs
The Trump administration is proposing changes to FDA guidelines to make it less expensive for drugmakers to develop biosimilar medicines. The new draft guidance suggests that the FDA would no longer require all biosimilar manufacturers to conduct clinical trials for approval. Instead, the FDA will consider analytical studies to determine if the biosimilar matches the branded drug it aims to replicate. This change is expected to reduce costs and streamline the process for developing biosimilars, potentially benefiting drugmakers and increasing the availability of these medicines.
growth-positive
Teva Pharmaceutical (TEVA) Enters Into a License Agreement With Prestige Biopharma for the Commercialization of Tuznue in Europe
Teva Pharmaceutical Industries Limited has entered into a license agreement with Prestige Biopharma for the commercialization of Tuznue, a biosimilar to Herceptin, across most European markets. Tuznue is an approved treatment for breast cancer and metastatic gastric cancer, with Prestige Biopharma having received European Commission marketing authorization for it in September 2024. Teva will leverage its extensive commercial network to distribute and market Tuznue, while Prestige Biopharma will handle production and supply. This partnership is expected to enhance Tevas presence in the European biosimilars market.
Partners
growth-positive
Deckers Brands Reports Second Quarter Fiscal Year 2026 Financial Results
Deckers Brands reported a 9% increase in revenue for the second quarter of fiscal year 2026, reaching $1.43 billion. The companys diluted EPS rose by 14% to $1.82. The growth was driven by strong performances from the HOKA and UGG brands, which saw double-digit sales increases. While domestic sales slightly decreased, international sales surged by 29.3%. The company maintains a strong financial position with no outstanding borrowings and increased cash reserves. Deckers provided a positive outlook for the full fiscal year 2026, emphasizing its ability to connect with consumers through innovative products.
growth-positive
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Teva Pharmaceutical Industries Limited is experiencing a positive transformation, shifting from a debt-heavy generics company to a focused branded and specialty pharmaceutical firm. The company is gaining momentum in neuroscience, with Ajovy, its migraine prevention therapy, showing steady growth. Additionally, Tevas long-acting injectable olanzapine program, TEV-749, has demonstrated robust efficacy in Phase 3 trials, with significant market potential. Financially, Teva is strengthening, with projected revenues of $17 billion by 2025 and a significant reduction in net debt. Institutional investors are showing bullish interest, and the companys stock has appreciated by 20% since May 2025. The convergence of pipeline progress and improving fundamentals positions Teva for potential growth.
Product StageInvestment
growth-negative
UBS Maintains Bullish Outlook on Deckers Outdoor Corporation (DECK) as Analysts Monitor HOKA’s U.S. Growth Recovery
Deckers Outdoor Corporation, a company focused on premium footwear, apparel, and accessories, is experiencing slower-than-expected growth in its HOKA brands U.S. direct-to-consumer segment. UBS has adjusted its price target for Deckers from $158 to $157, maintaining a Buy rating despite the modest quarter-over-quarter sales progress. While the HOKA brand faces challenges domestically, its demand remains steady internationally. Deckers other premium brands, UGG and Teva, continue to perform well, supporting overall revenue stability. Fisher Asset Management holds a significant investment in Deckers, but analysts suggest that AI stocks might offer better short-term upside potential.
growth-positive
Teva (TEVA) Gains FDA Approval for UZEDY Injectable in Bipolar I Disorder Treatment – What's Changed
Teva Pharmaceuticals has received FDA approval for UZEDY, a once-monthly injectable treatment for bipolar I disorder, marking a significant step in its strategy to expand its branded drug portfolio. This approval, alongside the recent approval of AJOVY for pediatric migraine prevention, highlights Tevas focus on innovative therapies to offset challenges in its generics segment. The introduction of UZEDY is expected to enhance Tevas presence in the central nervous system treatment market and support its long-term growth prospects. However, the company still faces risks related to revenue concentration and balance sheet pressures.
FDA approved/pending approval
growth-positive
JPMorgan and UBS Raise PT for Teva Pharmaceutical (TEVA)
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has received a positive outlook from analysts, with both JPMorgan and UBS raising their price targets from $23 to $26. This comes ahead of Tevas Q3 earnings report, with expectations of no surprises. UBS has also increased its sales forecast for Teva, projecting $6.6 billion by 2030, partly due to the anticipated success of its Dual-Action Asthma Rescue Inhaler, expected to launch in 2028. The inhaler is projected to reach peak sales of $700 million by 2032. Despite Tevas potential, the article suggests that certain AI stocks may offer greater short-term upside.
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar
growth-positive
Bank of America Securities Raises PT on Teva Pharmaceutical Industries (TEVA), Keeps a Buy
Teva Pharmaceutical Industries Limited is highlighted as a promising growth stock under $25. On October 9, Bank of America Securities raised its price target for Teva from $22 to $24, maintaining a Buy rating. The company is expected to report Q3 results on November 5, 2025, with anticipated full-year revenue between $16.8 billion and $17.2 billion, reflecting a 2% to 4% year-over-year increase. Despite Tevas potential, the article suggests that certain AI stocks may offer greater upside potential. Teva is an international drug maker with a diverse product range, including generic, specialty, and OTC products.
growth-positive
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
Johnson & Johnson (J&J) discussed its optimistic outlook for 2026 during its third-quarter earnings call on October 14. The company expects top-line growth of over 5%, surpassing the consensus estimate of 4.6%. J&J anticipates similar growth in EPS, projecting it to be 5 cents higher than the consensus of $11.39 per share. Despite the loss of exclusivity for Stelara, J&J expects growth in its Innovative Medicine and MedTech segments, driven by key products and new launches. The MedTech segment is expected to benefit from increased adoption of new products and a focus on high-growth markets. J&Js guidance reflects a strategic shift towards innovation-led growth.
growth-positive
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
The article discusses Teva Pharmaceutical Industries (TEVA) as a strong candidate for value investing, highlighting its favorable valuation metrics. TEVA is currently rated as a Buy with a Zacks Rank #2 and an A grade for Value. The companys Forward P/E, PEG, and P/B ratios are all lower than the industry averages, indicating that the stock may be undervalued. The article suggests that TEVAs strong earnings outlook and attractive valuation metrics make it an impressive value stock at the moment.
growth-positive
Does Teva Pharmaceutical Industries (TEVA) Have the Potential to Rally 28.12% as Wall Street Analysts Expect?
Teva Pharmaceutical Industries Ltd. (TEVA) has shown a 2.9% increase in its stock price over the past four weeks, closing at $19.42. Analysts have set a mean price target of $24.88, indicating a potential upside of 28.1%. The price targets range from $20.00 to $29.00, with a standard deviation of $2.53, suggesting a high degree of agreement among analysts. Despite skepticism about the reliability of price targets, the consensus among analysts is that TEVA will report better-than-expected earnings, which could further drive the stocks price upward. The article highlights the potential for growth in TEVAs stock, driven by positive earnings estimate revisions.
growth-positive
All You Need to Know About Teva Pharmaceutical Industries (TEVA) Rating Upgrade to Buy
Teva Pharmaceutical Industries Ltd. has recently been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook for its earnings. This upgrade is based on an upward trend in earnings estimates, which is a significant factor influencing stock prices. The Zacks rating system, which tracks EPS estimates from sell-side analysts, highlights the potential for favorable stock price movement due to improved earnings outlook. Institutional investors often adjust their valuation models based on these estimates, leading to stock price changes. The upgrade suggests an improvement in Tevas underlying business, which could attract investor interest and drive the stock higher. The Zacks Rank system has a strong track record of predicting stock performance based on earnings estimate revisions.
growth-positive
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
Teva Pharmaceutical Industries Ltd has entered into a license and supply agreement with Prestige Biopharma to commercialize Tuznue®, a biosimilar to Herceptin®, across a majority of European markets. Tuznue® received European Commission marketing authorization in September 2024 and is approved for treating breast and metastatic gastric cancer. Teva will leverage its commercial network to market and distribute Tuznue®, while Prestige Biopharma will handle production and supply. This partnership aims to expand access to cost-effective treatments in Europe and marks a significant step for Prestige Biopharma in establishing itself as a global biopharmaceutical leader.
Partners
growth-positive
What Recent Earnings Reveal About Teva’s Valuation in 2025
Teva Pharmaceutical Industries has experienced significant stock growth, with a 9.3% increase over the past year and a 142% rise over three years. Despite a recent 2% dip, the companys long-term growth trajectory remains strong, driven by trends in the generic drug market and changing investor perceptions of risk in big pharma. Teva is considered undervalued, scoring a perfect 6 out of 6 in a well-known valuation method. The Discounted Cash Flow (DCF) model suggests that Tevas intrinsic value per share is $58.33, indicating a 66.3% discount from its current trading price. Analysts forecast significant growth in Tevas Free Cash Flow, potentially reaching $3.83 billion by 2029.
growth-positive
Teva Pharmaceutical Receives FDA Approval to Expand UZEDY Indication for Maintenance Treatment of Bipolar I Disorder
Teva Pharmaceutical Industries Limited has received FDA approval for an expanded indication of UZEDY, a risperidone extended-release injectable suspension, for the maintenance treatment of bipolar I disorder in adults. This approval allows UZEDY to be used as a monotherapy or adjunctive therapy to lithium or valproate. The drug, which uses Medincells SteadyTeq technology, offers three once-monthly dosing options. This expansion is a significant step in addressing the unmet needs of those living with bipolar I disorder. The article also mentions the potential of AI stocks, suggesting they may offer greater upside potential than Teva.
FDA approved/pending approval
growth-positive
Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock
Teva Pharmaceutical Industries Limited, headquartered in Tel Aviv, Israel, is a global pharmaceutical company known for developing, manufacturing, and marketing both branded and generic drugs. The company plans to separate its API unit into a standalone business through a sale. Teva is rated as a Zacks Rank #3 (Hold) stock with a Value Style Score of B and VGM Score of B. The stock is currently trading at a forward P/E of 7.8X, which is lower than the industry average. Analysts have revised their earnings estimates upwards, contributing to a positive outlook for the company. With strong valuation and earnings metrics, Teva is considered a potential addition to investment portfolios.
growth-positive
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit
Johnson & Johnson reported strong third-quarter 2025 earnings, with earnings per share of $2.80, surpassing the Zacks Consensus Estimate of $2.77. This marks a 15.7% increase from the previous year. The companys sales reached $24.0 billion, exceeding expectations and reflecting a 6.8% rise from the prior year. The growth was driven by increased sales in the Innovative Medicines segment, particularly from key products like Darzalex, Tremfya, and Erleada. Despite some challenges from generic competition affecting drugs like Imbruvica, the overall performance was robust. The companys international sales also showed significant growth, contributing to the positive outlook.
Deckers Brands Announces Conference Call to Review Second Quarter Fiscal 2026 Earnings Results
growth-positive
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
Teva Pharmaceutical Industries Limited recently received FDA approval for expanded use of its product, Uzedy, for treating bipolar I disorder. This approval is expected to boost Uzedys sales, which have already seen significant growth. Tevas shares have declined year-to-date, but the company is experiencing market share growth with its branded drugs, including Uzedy, Austedo, and Ajovy. Teva has partnered with Sanofi to develop duvakitug for inflammatory bowel diseases, with plans to advance it into phase III studies. The company is also preparing to file a new drug application for olanzapine. Overall, the FDA approval and strategic partnerships are likely to positively impact Tevas growth.
Product StagePartners
growth-positive
BofA Raises Teva Pharmaceutical (TEVA) PT to $24, Amid “Pivot to Growth” Strategy Execution
Teva Pharmaceutical Industries Limited has been identified as a promising stock under $100, with BofA raising its price target to $24 while maintaining a Buy rating. The company has achieved its 10th consecutive quarter of year-over-year revenue growth, driven by its Pivot to Growth strategy. Key innovative products like AUSTEDO, AJOVY, and UZEDY have shown significant revenue increases, prompting Teva to raise its 2025 revenue outlook. The company aims for a 30% operating profit margin by 2027. Despite Tevas potential, the article suggests that certain AI stocks may offer greater upside potential.
growth-positive
Evaluating Teva (NYSE:TEVA) Valuation After FDA Expands UZEDY Approval to Bipolar I Disorder
Teva Pharmaceutical Industries has received U.S. FDA approval for UZEDY, an extended-release injectable developed with Medincell, for treating adults with bipolar I disorder. This approval expands UZEDYs indication from its previous approval for schizophrenia. The recent FDA approval has contributed to a 22% increase in Tevas share price over the past three months, reinforcing confidence in the companys growth prospects. Teva is also focusing on launching biosimilars, with eight launches targeted through 2027, aiming to double biosimilar revenue. Despite the positive outlook, Teva faces challenges such as debt pressures and reliance on a few branded drugs. The companys fair value is estimated at $24.22, suggesting it is currently undervalued.
Product StageFDA approved/pending approval
growth-positive
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
Johnson & Johnson is set to report its third-quarter 2025 earnings on October 14, with expectations of a positive earnings surprise. The companys performance has been strong, consistently exceeding earnings expectations over the past four quarters. Key products such as Darzalex, Tremfya, and Erleada are expected to drive sales growth, while new drugs like Carvykti and Tecvayli are contributing to top-line growth. However, the Innovative Medicines segment faces challenges due to the launch of biosimilar versions of Stelara, impacting growth negatively. Despite this, the overall outlook remains positive, with a projected earnings beat.
growth-positive
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
Teva Pharmaceutical Industries Ltd has received FDA approval for UZEDY® (risperidone) extended-release injectable suspension for the treatment of bipolar I disorder in adults. This approval marks a significant advancement in addressing the needs of individuals with BD-I and schizophrenia. UZEDY is the first subcutaneous, long-acting formulation of risperidone using Medincells SteadyTeq™ technology. The approval is based on existing clinical data and Model-Informed Drug Development methodologies. This development underscores Tevas commitment to advancing neuroscience and providing innovative treatments for complex mental health conditions. Medincell is a partner in this endeavor.
FDA approved/pending approvalPartners
growth-positive
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Teva Pharmaceutical Industries Limited, a global pharmaceutical company based in Tel Aviv, Israel, is noted for its development, manufacturing, and marketing of branded and generic drugs, including biosimilars and over-the-counter products. The company plans to separate its Active Pharmaceutical Ingredients (API) unit into a standalone business. Teva holds a Zacks Rank #3 (Hold) with a Momentum Style Score of A and a VGM Score of B. Despite a slight recent decline, the stock has gained 15.1% over the past year. Analysts have revised earnings estimates upwards, and the Zacks Consensus Estimate for 2025 has increased. The article suggests considering TEVA for investment due to its solid rankings and earnings metrics.
growth-positive
Medincell: FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
Teva Pharmaceuticals, in collaboration with Medincell, has received FDA approval for UZEDY® (risperidone), an extended-release injectable suspension for the treatment of bipolar I disorder and schizophrenia in adults. This approval is a significant milestone in addressing the unmet needs of individuals with these conditions. UZEDY is the first subcutaneous, long-acting formulation of risperidone, utilizing Medincells proprietary SteadyTeq™ technology. The approval is based on existing clinical data and Model-Informed Drug Development methodologies. This development underscores Tevas commitment to advancing treatments in neuroscience and mental health.
FDA approved/pending approval
growth-negative
SoftBank, HSBC, Teva, Ferrari: Stocks Worldwide in Focus
HSBC has made an offer to take Hong Kong’s Hang Seng Bank private in a $13.6 billion deal, providing shareholders with a significant premium. Despite the attractive offer, HSBCs stock experienced a 5% decline in London trading. This acquisition move is part of HSBCs strategy to strengthen its presence in Asia, but the immediate market reaction has been negative, reflecting investor concerns or market conditions. The deal highlights HSBCs focus on expanding its influence in the Asian financial sector.
Acquisition
growth-positive
Overcoming past mistakes, generics powerhouse Teva embraces an innovative ‘mindset change’
Teva Pharmaceuticals, historically known for its generics, is undergoing a transformation towards innovative medicines. After a challenging period following the $40 billion acquisition of Allergan’s generics unit Actavis, Teva has focused on new drug development. Under the leadership of CEO Richard Francis and CMO Dr. Eric Hughes, the company has prioritized innovation, resulting in 10 consecutive quarters of growth. Key products like Austedo and Ajovy have contributed to this success. Tevas pipeline includes promising candidates like duvakitug, partnered with Sanofi, and other mid-stage drugs. The company is focusing on neuroscience and immunology, aiming to shorten development timelines and improve efficiency.
Product StagePartners
growth-positive
Teva (TEVA) Is Up 9.2% After New Schizophrenia Drug Data and Innovation Shift - What’s Changed
Teva Pharmaceutical Industries has announced positive clinical data for its schizophrenia treatment, Olanzapine LAI, and is making strides in its transition to higher-value, innovative medicines. The company is focusing on operational initiatives for cost savings by 2027 and aims to use 100% renewable electricity within a decade. Analysts are optimistic about Tevas expanding innovative medicines portfolio, which could positively influence its investment narrative. The FDA approval and US launch of a generic version of Saxenda are part of Tevas strategy to balance legacy generics with new product launches. Despite these advancements, risks related to price negotiations on existing branded drugs remain. Teva is projected to reach $17.8 billion in revenue by 2028, with a fair value estimate of $23.89 per share.
Product StageFDA approved/pending approval
growth-positive
Truist Securities Reaffirms Its Buy Rating for Teva Pharmaceutical Industries Limited (TEVA)
Teva Pharmaceutical Industries Ltd. is reaffirmed with a Buy rating by Truist Securities, maintaining a $25 price target. The company is focusing on expanding its innovative medicines division, with the launch of Olanzapine LAI as part of its strategy. Teva aims to transition towards higher-value treatments, focusing on innovation, debt reduction, and achieving $700 million in cost savings by 2027. Key drugs like Austedo and Ajovy are projected to reach significant peak sales. The article highlights Tevas growth potential, especially in its schizophrenia treatment franchise, and its strategic shift towards innovation and cost efficiency.
Product StageExpand
growth-positive
UBS Maintains its Buy Rating on Teva Pharmaceutical Industries Limited (TEVA); Raises Its Price Target to $26.00
Teva Pharmaceutical Industries Limited, a global developer and distributor of biopharmaceutical products, received a positive outlook from UBS, which maintained its Buy rating and increased the price target from $23.00 to $26.00. UBS also raised its 2030 sales estimate from $6.3 billion to $6.6 billion, factoring in potential income from Tevas new inhaler, DARI, expected to launch in 2028. Additionally, Medicares pricing for Austedo is expected to be clarified by November 30, with a projected 40% discount, less than the feared 60%. These developments contribute to a stronger outlook for Tevas branded business.
growth-positive
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
Amicus Therapeutics lead product, Galafold, is a major revenue driver, showing consistent sales growth. It is approved in multiple countries for treating Fabry disease. The company also markets Pombiliti + Opfolda for Pompe disease, which has shown significant sales growth. A licensing agreement with Teva Pharmaceuticals resolved a patent lawsuit, preventing Teva from selling a generic version of Galafold in the U.S. until 2037. While Amicus is heavily reliant on Galafold, the approval of Pombiliti + Opfolda presents new commercial opportunities. However, competition from companies like Sanofi and Takeda poses challenges.
Product StagePartners
growth-positive
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
Teva Pharmaceutical Industries Limited, a global pharmaceutical company based in Tel Aviv, Israel, is highlighted for its strong valuation fundamentals and impressive earnings. The company develops, manufactures, and markets branded and generic drugs, including biosimilars and over-the-counter products, as well as active pharmaceutical ingredients (APIs). Teva plans to separate its API unit into a standalone business through a sale. The company holds a Zacks Rank #3 (Hold) and has a Value Style Score of B, with shares trading at a forward P/E of 7.6X, compared to the industry average of 8.1X. Analysts have revised earnings estimates upwards, and the Zacks Consensus Estimate for 2025 has increased. Tevas strong financial metrics make it an attractive option for value investors.
growth-positive
Here's How Alvotech is Expanding its Portfolio Beyond Immunology
Alvotech is expanding its presence in the biosimilar market through a partnership-driven model, focusing on development and manufacturing while partners handle marketing and sales. This strategy has allowed Alvotech to mitigate risks and accelerate product launches. The company has seen significant revenue growth, driven by its immunology biosimilars marketed in the U.S. by Teva Pharmaceuticals and in Europe by Stada. Alvotech is also entering the ophthalmology space with its biosimilar Mynzepli, approved in the EU through a partnership with Advanz Pharma. The company is expanding its partnerships with Dr. Reddy’s Laboratories and Advanz Pharma to develop biosimilars in neurology and oncology, aiming to build a diverse, multi-therapeutic portfolio.
PartnersCustomersProduct Stage
growth-positive
Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025
Teva Pharmaceutical Industries Ltd, a leading biopharmaceutical company, announced it will release its third quarter 2025 financial results on November 5, 2025. The company will also conduct a conference call and live webcast on the same day to discuss the results. Teva, known for its innovative and generic medicines, is focused on expanding its pipeline of innovative and biosimilar medicines. The announcement is part of Tevas ongoing strategy to maintain its competitive edge and address patient needs globally. The company emphasizes its commitment to growth and organizational transformation, despite facing significant risks and uncertainties.
growth-neutral
Teva Releases Q3 2025 Aide Memoire
Teva Pharmaceutical Industries Ltd, a leading biopharmaceutical company, announced the availability of its Q3 2025 Aide Memoire on its website. This document is designed to assist in financial modeling of the companys quarterly results, based on prior results and managements commentary. Teva is known for its innovative work in neuroscience and immunology, as well as its strong generics business. The press release includes a cautionary note about forward-looking statements, highlighting potential risks and uncertainties that could affect future performance. The document is intended for investors and analysts interested in Tevas financial outlook.
growth-positive
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
Alvotech, a company in the biosimilar space, has adopted a partnership-based business model to expand its market reach while minimizing commercialization risks. Through collaborations with companies like Teva Pharmaceuticals and Dr. Reddy’s Laboratories, Alvotech has rapidly increased its product revenues, achieving a 200% year-over-year growth in the first half of 2025. The company has successfully launched biosimilars such as Simlandi and Selarsdi, and secured EU approval for Mynzepli. Alvotech is further expanding its portfolio by developing biosimilars in neurology and oncology through partnerships with Dr. Reddy’s and Advanz Pharma. Despite operating in a competitive market, Alvotechs strategic alliances and product approvals position it for continued growth.
PartnersCustomersProduct Stage
growth-positive
Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®
Medincell, a biopharmaceutical licensing company, has announced that Teva Canada Limited, a subsidiary of its partner Teva Pharmaceutical Industries Ltd., has received regulatory approval from Health Canada for risperidone LAI (Long-Acting Injectable) for treating schizophrenia in adults. This approval marks the third country, following the United States and South Korea, where the product is approved. The treatment utilizes Medincells proprietary BEPO® technology, which allows controlled drug delivery over extended periods. The FDA had previously approved the first treatment based on this technology in April 2023. Medincell collaborates with leading pharmaceutical companies to develop long-acting injectable treatments across various therapeutic areas.
Product StagePartners
growth-positive
J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?
Johnson & Johnson (J&J) has experienced a significant stock price increase, with shares up 17.7% over the past three months, adding nearly $63 billion in market capitalization. The companys Innovative Medicine unit is showing growth, with sales rising 2.4% in the first half of 2025. J&J expects continued growth driven by key products and new drugs. The MedTech segment also saw sales growth, driven by acquisitions and new product adoption. J&Js oncology sales are projected to exceed $50 billion by 2030. Recent FDA approvals for drugs like Inlexzo and acquisitions such as Intra-Cellular Therapies are contributing to J&Js positive outlook.
Product StageAcquisitionFDA approved/pending approval
growth-positive
Medincell: New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®
Medincell, in partnership with Teva, has successfully launched UZEDY®, a long-acting injectable treatment for schizophrenia, which has been approved in the U.S. since 2023. The product has shown significant benefits over Invega Sustenna®, including shorter hospital stays and cost savings. Healthcare practitioners have favored UZEDY® for its ease of administration and dosing characteristics. The data was presented at the 2025 Psych Congress, highlighting the products advantages in real-world settings. Medincell receives royalties and milestone payments from Teva, who leads the commercialization efforts.
Product StagePartnersFDA approved/pending approval
growth-positive
Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed
Medincell, in partnership with Teva, is advancing its investigational Olanzapine LAI for schizophrenia treatment. The Phase 3 SOLARIS trial showed no cases of PDSS, confirming the safety profile of the drug. Teva plans to submit a New Drug Application (NDA) in the US by Q4 2025. This development is part of Medincells collaboration with Teva, which also includes the FDA-approved UZEDY®. Medincells technology, SteadyTeq™, is used to ensure a controlled release of the drug. The successful trial results and upcoming NDA submission mark significant progress for Medincell, potentially enhancing treatment options for schizophrenia patients.
Product StagePartners
growth-positive
Teva Pharmaceutical Industries (NYSE:TEVA): Evaluating Valuation Potential After Recent Share Movement
Teva Pharmaceutical Industries has been gaining attention from investors due to its recent stock performance and potential undervaluation. Despite a slight retreat in shares over the past week, the company has seen an 8% increase in stock value over the past three months. Analysts suggest that Teva is trading below its fair value, with an optimistic outlook on future earnings recovery and market positioning. The company is focusing on accelerating the launch of biosimilars, aiming to double biosimilar revenue by 2027, which could offset challenges from traditional generics. However, Tevas heavy debt burden and reliance on key drugs pose risks to its growth outlook.
growth-positive
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Teva Pharmaceutical Industries Ltd announced new data from its schizophrenia medicines portfolio at the 2025 Psych Congress Annual Meeting. The SOLARIS Phase 3 trial showed no incidence of post-injection delirium/sedation syndrome (PDSS) in patients using olanzapine LAI (TEV-749), a long-acting injectable formulation. Additionally, UZEDY, an extended-release injectable suspension of risperidone, was found to be associated with shorter hospital stays compared to Invega Sustenna. These findings highlight Tevas commitment to developing innovative treatments for complex mental health conditions, potentially leading to improved patient outcomes and healthcare cost savings.
Product Stage
growth-positive
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Teva Pharmaceutical Industries Ltd presented data from a real-world survey of patients using AUSTEDO XR, a treatment for tardive dyskinesia (TD). The survey, involving 209 patients, revealed high satisfaction with the medication, with over 94% reporting movement improvement and over 89% expressing overall satisfaction. The survey also highlighted improvements in social and emotional well-being, with patients appreciating the ease of use and the ability to adjust doses. The data was presented at the 2025 Psych Congress Annual Meeting, emphasizing the positive impact of AUSTEDO XR on patients quality of life.
growth-positive
Roche strikes $3.5 billion deal for U.S.-Israeli biotech 89bio | CTech
Roche has agreed to acquire 89bio, a biotechnology company focused on treatments for advanced liver disease, in a deal valued at up to $3.5 billion. This acquisition positions Roche at the forefront of a new therapeutic frontier intersecting obesity and metabolic disorders. Founded in 2018, 89bio has rapidly advanced its lead drug candidate, pegozafermin, into late-stage trials for metabolic dysfunction-associated steatohepatitis (MASH). The acquisition highlights Roches strategy to expand beyond GLP-1 weight-loss drugs into related areas such as liver diseases. The deal includes an upfront payment of $2.4 billion, with potential milestone payments bringing the total to $3.5 billion.
Acquired-by
growth-positive
Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth
Alvotech, a biosimilar drugmaker, has adopted a partnership-driven commercial model, allowing it to focus on development and manufacturing while partners handle distribution. This strategy has led to a significant revenue increase, with product revenues surging over 200% in the first half of 2025. Key partnerships with companies like Teva Pharmaceuticals and Stada have been instrumental in marketing biosimilars such as Simlandi and Selarsdi in the U.S. and Europe. Alvotech is expanding into ophthalmology with its EU-approved biosimilar Mynzepli and plans to develop biosimilars in neurology and oncology. Despite underperforming in the stock market, the companys strategic alliances are expected to support sustained growth.
PartnersCustomersProduct Stage
growth-negative
J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why
Johnson & Johnsons immunology drug, Stelara, lost its patent exclusivity in the United States in 2025, leading to the launch of several biosimilar versions by companies like Amgen, Teva Pharmaceutical Industries/Alvotech, and Samsung Bioepis/Sandoz. This has significantly eroded Stelaras sales, which declined by 42.7% in the second quarter of 2025, impacting J&Js sales and profits. Despite this, J&J anticipates growth in its Innovative Medicine segment, driven by other key products and new drugs. The company expects to generate over $57 billion in sales in this segment in 2025, maintaining levels similar to 2024.
Product StageCustomers
growth-positive
Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
Medincell, a biopharmaceutical company based in Montpellier, France, is advancing its clinical-stage pipeline with the completion of the phase 3 SOLARIS trial for Olanzapine LAI, a long-acting injectable treatment for schizophrenia. The drug, developed in partnership with Teva Pharmaceuticals, utilizes Medincells BEPO® technology for controlled drug delivery. Teva plans to submit a New Drug Application (NDA) in Q4 2025. This follows the FDA approval of UZEDY®, another schizophrenia treatment using the same technology, in April 2023. Medincells innovative approach aims to improve medication adherence and effectiveness while reducing environmental impact.
Product StagePartners
How Is Deckers Outdoor Corporation's Stock Performance Compared to Other Consumer Discretionary Stocks?
The article provides instructions on how to customize chart settings and navigate through chart options. It explains how users can save their preferred chart setup as a template and switch market flags to access targeted data from different countries. Additionally, it guides users on how to access more chart options by right-clicking on the chart and using keyboard arrows to navigate through symbols.
growth-positive
Teva Pharmaceutical Industries (TEVA) Attains FDA’s Fast Track Designation for Emrusolmin
Teva Pharmaceutical Industries Limited has received Fast Track designation from the U.S. FDA for its investigational treatment, emrusolmin, targeting Multiple System Atrophy (MSA). The drug is currently in Phase 2 trials and has also been granted Orphan Drug designation. This development is part of a strategic collaboration with MODAG GmbH, a German biotech company. The article highlights the urgent need for new MSA treatments and positions Teva as a promising investment in the healthcare sector. However, it also suggests that certain AI stocks might offer better short-term gains.
Product StagePartners
growth-positive
Teva Pharmaceutical Industries Limited (TEVA)’s Emrusolmin Gains FDA Fast Track for Multiple System Atrophy
Teva Pharmaceutical Industries Limited is transitioning from a generics-focused company to a biopharmaceutical leader. The company is focusing on specialty products and biopharmaceutical innovation, with key products like Austedo and Uzedy expected to drive significant sales growth. Teva plans to release new products, including an ICS-SABA inhaler and olanzapine, and aims for a 30% operating margin by 2027. The companys investigational drug emrusolmin received FDA Fast Track designation for treating Multiple System Atrophy, highlighting its commitment to high-value therapies. Despite its potential, the article suggests that certain AI stocks may offer better investment opportunities.
Product StageFDA approved/pending approval
growth-positive
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
Teva Pharmaceutical Industries Ltd announced plans to present data from its completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting in San Diego. The company will also host a conference call for analysts and investors to discuss the data. Teva, a leading biopharmaceutical company, focuses on neuroscience and immunology, providing complex generic medicines and biosimilars worldwide. The announcement is part of Tevas strategy to expand its innovative and biosimilar medicines pipeline. The press release includes forward-looking statements, highlighting potential risks and uncertainties. Teva emphasizes its commitment to better health and innovation in the pharmaceutical industry.
Product Stage
growth-positive
J.P. Morgan Maintains a Buy on Teva Pharmaceutical (TEVA) With a $23 PT
Teva Pharmaceutical Industries Limited has received FDA approval for its generic version of Saxenda, a GLP-1 drug indicated for weight loss. This approval marks a significant milestone for Teva as it enters the growing market for weight loss therapies in the US. The company targets both adults with obesity and overweight-related medical issues, as well as pediatric patients. J.P. Morgan analyst Chris Schott has maintained a Buy rating on Teva, setting a price target of $23.00. Despite the positive outlook for Teva, the article suggests that certain AI stocks may offer better investment opportunities.
FDA approved/pending approval
growth-positive
Here’s Why Sound Shore Fund Added Teva Pharmaceutical Industries Limited (TEVA) in Q2
Sound Shore Management, an investment management firm, highlighted Teva Pharmaceutical Industries Limited in its second-quarter 2025 investor letter. Teva, headquartered in Tel Aviv, Israel, focuses on developing and distributing generic and biopharmaceutical products. Despite regulatory uncertainties affecting the healthcare sector, Sound Shore Management increased its position in Teva, citing confidence in the companys growth strategy and pipeline success. Tevas stock saw a 15.02% one-month return and a 10.22% gain over the past year. The companys revenue grew by 1% year-over-year to $4.2 billion in Q2 2025. Sound Shore Managements investment reflects a positive outlook on Tevas potential amidst market challenges.
Investment
growth-positive
Assessing the Valuation of Yue Yuen Industrial (SEHK:551) After Recent Volatility
Yue Yuen Industrial (Holdings) has experienced notable stock price fluctuations, drawing attention from investors. Despite a year-to-date decline of 21%, the company has shown resilience with an 11% gain over the past year and a 13% increase in the past three months. Over a longer period, the stock is up 53% over three years and 44% over five years. The companys P/E ratio of 7.2x suggests it is undervalued compared to industry peers, indicating potential for growth if profit levels are sustained or improved. While the company shows steady revenue and net income growth, risks remain due to inconsistent short-term returns and potential shifts in market sentiment.
growth-positive
Nifty clocks fifth session of gains led by IT on Infosys buyback, US rate cut hopes
Infosys led gains in Indias Nifty 50 index, which closed higher for the fifth consecutive session, driven by a 5% surge in Infosys shares following the announcement of a share buyback plan. The IT sector, which accounted for a significant portion of the days gains, benefited from expectations of a U.S. interest rate cut, which could boost technology spending in the U.S., a key market for Indian IT firms. The broader market also saw gains, with the Nifty 50 and BSE Sensex both rising by 0.39%. The anticipation of a Federal Reserve rate cut was fueled by weaker-than-expected U.S. job data.
growth-positive
BHP Xplor Opens Applications for 2026 Cohort, Offering Equity-Free Funding and Global Support
BHP Group Limited has announced the opening of applications for the 2026 cohort of its BHP Xplor accelerator program, which aims to transform the discovery of critical minerals. The program offers early-stage explorers up to USD $500,000 in equity-free funding, mentorship, and access to BHP’s global network. BHP Xplor has been successful in previous years, fostering partnerships and accelerating exploration projects. The program supports BHPs long-term growth by engaging with diverse exploration projects. Applications are open from September 8 to October 15, 2025.
Partners
growth-positive
Westin Desaru Coast Resort partners with CAYIN Technology for digital signage
CAYIN Technology has partnered with Westin Desaru Coast Resort in Johor, Malaysia, to enhance guest communication and operational efficiency through the implementation of its CMS-WS server and CAYIN Signage Player. This collaboration involves the use of digital signage to provide real-time updates across 14 Samsung displays in various areas of the resort. The project was executed in partnership with Hola Media, which provided integration services, including installation, design, staff training, and support. The system has improved communication, reduced staff workload, and enhanced the guest experience, preparing the resort for future digital expansion.
Partners
growth-positive
Is Now the Right Moment to Reassess PCCW Amid Strong 2025 Gains?
The article discusses the stock performance and valuation of PCCW, highlighting its impressive long-term gains despite recent short-term dips. PCCWs stock has increased significantly over the past year and longer periods, suggesting a growth-positive outlook. The company is currently undervalued based on common valuation methods, with a value score of 4 out of 6. The Discounted Cash Flow (DCF) model indicates that PCCW is trading at a 24.8% discount compared to its intrinsic value, suggesting potential for future growth. The article emphasizes the importance of valuation in investment decisions and provides insights into PCCWs financial projections.
growth-positive
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy
Teva Pharmaceutical Industries Ltd has received Fast Track designation from the U.S. FDA for its investigational treatment emrusolmin (TEV-56286) for Multiple System Atrophy (MSA), a rare neurodegenerative disorder. Emrusolmin, currently in Phase 2 trials, targets the alpha synuclein protein involved in MSA pathogenesis. The FDA had previously granted Orphan Drug designation to emrusolmin in 2022. This development is part of a strategic collaboration with MODAG GmbH, a German biotech company. The Fast Track designation aims to expedite the review process for drugs addressing serious conditions with unmet medical needs. Teva is committed to advancing treatments for neurological conditions, with emrusolmin representing a significant step forward.
Product StagePartners
growth-positive
Strauss Group (TASE:STRS): Assessing Valuation After Mixed Q2 Earnings and Sales Growth
Strauss Group has released its second quarter and half-year earnings, showing a rise in sales for both periods in 2025. Despite the increase in revenue, net income has decreased, indicating potential cost pressures or margin changes. The companys stock has risen by nearly 64% over the past year, though recent gains have slowed. Strauss Groups price-to-earnings ratio is slightly below the Asian Food industry average, suggesting it is valued in line with sector peers. The companys strong profit growth and above-average profit margin support its current valuation. However, potential risks include slowing net income growth or changes in consumer demand.
growth-negative
Does the Recent 24% Drop Signal an Opportunity in NICE for 2025?
NICE has experienced a significant decline in its stock price, with a 24.2% drop year-to-date and a 34% decrease over three years. This decline is partly attributed to broader market uncertainties, particularly in the tech sector, where rising interest rates have caused investors to shift away from growth stocks. Despite this, NICEs core business remains strong, and the company is considered undervalued based on several valuation measures. The Discounted Cash Flow (DCF) model suggests an intrinsic value of $841.39 per share, indicating a 43.8% potential upside from current trading levels. This presents an opportunity for patient investors, although market perception remains cautious.
growth-positive
Nikkiso Addresses Growing Ammonia-Handling Demand and Launches Next-Generation Pump at Gastech 2025
Nikkiso Clean Energy & Industrial Gases Group (Nikkiso CE&IG) announced the launch of a next-generation submerged ammonia pump at the Gastech Conference. This pump is designed to be the safest and most reliable in the industry, addressing common maintenance issues with its seal-less, maintenance-friendly, copper-free construction. The pump can deliver over 2,500m3 per hour and has a mean time between outages of over 16,000 hours. This launch is part of Nikkiso CE&IGs ongoing innovation in ammonia handling, with the company having decades of experience in this field. The pump is expected to meet growing demand for ammonia in various sectors, including power generation and shipping.
Product Stage
growth-positive
Is There Room for Growth in MMG After Its 29.5% Price Surge?
The article discusses the recent performance of MMGs stock, which has seen significant growth, with a 29.5% increase in the last month and a 168.0% return over the past year. The stocks performance is attributed to positive shifts in the broader market, particularly in commodities and base metals. Despite a slight dip of 0.9% last week, the overall sentiment remains optimistic. The article evaluates MMGs valuation using the Discounted Cash Flow (DCF) model, indicating that the stock is undervalued, trading at an 83.8% discount to its estimated intrinsic value of $33.04 per share. Analysts forecast ongoing growth in Free Cash Flow, projecting it to reach $3.21 billion by 2035.
growth-positive
Teva (NYSE:TEVA) Valuation in Focus After FDA Approval and U.S. Launch of Generic Saxenda
Teva Pharmaceutical Industries has received FDA approval and launched its generic version of Saxenda in the U.S., a move that could significantly enhance its growth prospects. This approval is a strategic step for Teva, potentially unlocking new growth avenues and strengthening its position in the competitive generic drug market. The companys stock has seen a recent uptick, reflecting optimism about its future performance. Tevas strategic focus on expanding its innovative branded products and a robust late-stage pipeline is expected to drive higher-margin growth. However, challenges such as debt constraints and price pressures on key drugs remain. Analysts consider Teva significantly undervalued, with a fair value estimate of $23.56.
FDA approved/pending approvalProduct StageCustomers
growth-positive
TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?
Teva Pharmaceutical Industries Limited has seen a 19.4% rise in its stock price over the past month, driven by its mixed second-quarter results announced on July 30. While the company missed sales estimates, it exceeded earnings expectations. The growth in sales of its branded drugs Austedo, Ajovy, and Uzedy has been a key factor, with Austedo sales projected to exceed $3 billion by 2030. Tevas partnership with Sanofi for the development of duvakitug, an anti-TL1A therapy, is also noteworthy. The company plans to advance its pipeline with new drug applications and further international launches.
Product StagePartners
growth-positive
Anti-Parkinson's Drugs Global Market Research Report 2025-2030 | $9.2 Bn Opportunities Driven by Increased Awareness in Emerging Countries and a Robust Pipeline of Innovations
The global anti-Parkinsons drugs market is projected to grow significantly from $6.1 billion in 2025 to $9.2 billion by 2030, with a CAGR of 8.6%. The market is driven by the approval of novel therapies, including AbbVies Vyalev, which received FDA approval in October 2024. This drug is the first subcutaneous 24-hour infusion of levodopa-based therapy, offering enhanced efficacy for advanced Parkinsons disease. The report highlights the high unmet need for disease-modifying therapies and the evolving treatment landscape with increased R&D activities. The market is segmented by drug class and region, with a focus on major countries across North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
FDA approved/pending approvalProduct Stage
growth-positive
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
Teva Pharmaceutical Industries Ltd, a leading biopharmaceutical company, announced that its President and CEO, Richard Francis, will present at two upcoming investor conferences in September 2025. These conferences include the Morgan Stanley 23rd Annual Global Healthcare Conference and the BofA Global Healthcare Conference. Teva is committed to innovating in neuroscience and immunology and providing complex generic medicines and biosimilars globally. The company is focused on expanding its innovative and biosimilar medicines pipeline and commercializing its portfolio profitably. The presentations may contain forward-looking statements, highlighting the companys growth strategy and potential risks. Teva emphasizes its dedication to addressing patients needs and achieving cost savings through organizational transformation.
growth-positive
Teva Pharmaceutical Industries (TEVA) Announces the FDA Approval and U.S. Launch of Generic Saxenda
Teva Pharmaceutical Industries Limited announced the FDA approval and U.S. launch of Generic Saxenda, a GLP-1 indicated for weight loss. This marks Tevas fifth first-to-market entry of a generic drug this year, enhancing its diverse complex generics portfolio. The Liraglutide injection is intended for adults with obesity or overweight-related medical issues and pediatric patients with obesity. This development is expected to positively impact Tevas growth, as it targets the rising demand for weight loss therapies in the U.S. market. The article also mentions the potential of AI stocks as investments, suggesting that some may offer greater upside potential.
FDA approved/pending approval
growth-positive
Did FDA Approval of Generic Saxenda Just Shift Teva's (TEVA) Investment Narrative?
Teva Pharmaceuticals announced in late August 2025 that it received FDA approval for its generic version of Saxenda® (liraglutide injection) and commenced its U.S. launch. This approval marks a significant expansion of Tevas generic drug portfolio, potentially capturing market share in the weight management segment. The FDA approval is expected to provide a short-term boost to generic revenues, although it does not address Tevas core challenges related to debt and limited generics growth. The company also received FDA approval for AJOVY for pediatric migraine, further expanding its market reach. Despite these positive developments, Tevas heavy debt burden remains a concern for investors.
Product StageFDA approved/pending approval
growth-positive
Teva Pharmaceutical Industries Limited (TEVA) Gains FDA Nod for Pediatric Migraine Drug AJOVY
Teva Pharmaceutical Industries Limited is experiencing strong momentum due to recent product innovations and strategic initiatives. The company received FDA approval for AJOVY, a pediatric migraine drug, expanding its reach in the pediatric market. Teva has reported its 10th consecutive quarter of growth, driven by key products like AUSTEDO, AJOVY, and UZEDY. The companys Pivot to Growth strategy aims for a 30% operating margin by 2027 and $700 million in net cost savings. Teva is also advancing its R&D pipeline with a focus on innovative specialty therapies, positioning itself for long-term growth.
Product StageFDA approved/pending approval
growth-positive
Teva brings first generic GLP-1 to US market with Saxenda copycat approval
Teva Pharmaceutical has received FDA approval for its generic version of Saxenda, a glucagon-like peptide-1 receptor agonist (GLP-1RA) used for weight loss. This marks the first generic GLP-1RA approved for weight loss in the US. Despite the rise of next-generation drugs like Wegovy and Zepbound, which have dominated sales, Tevas generic could capture a significant patient share due to its lower cost. Analysts suggest that while the generic may not impact the sales of more effective drugs, it could expand access to GLP-1RAs for patients who do not require high-efficacy treatments. The GLP-1RA market is projected to grow significantly in the coming years.
FDA approved/pending approval
growth-positive
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
Teva Pharmaceutical Industries Ltd has announced the FDA approval and U.S. launch of its generic version of Saxenda® (liraglutide injection), marking the first-ever generic GLP-1 product indicated for weight loss in the U.S. market. This development is part of Tevas Pivot to Growth Strategy, enhancing its complex generic medicine portfolio. The product is aimed at adults with obesity or overweight and pediatric patients aged 12-17 years with obesity. Saxenda® had annual sales of $165 million as of June 2025. The approval is a significant milestone for Teva, reinforcing its position as a leader in the generics market.
Product StageFDA approved/pending approval
Deckers Outdoor Stock: Is Wall Street Bullish or Bearish?
The provided text appears to be instructions or a guide on how to use chart settings and options, rather than an article about a specific company. It discusses how to save chart templates, switch market flags for targeted data, and access more chart options through an interactive menu. There is no mention of a specific company, investment, acquisition, or any other business-related event.
growth-positive
Deckers Outdoor (DECK) Sees 12% Rise in Share Price Over Past Week
Deckers Outdoor experienced a 12% increase in its share price over the past week, driven by product-related developments such as the launch of Tevas Autumn-Winter 2025 Collection and a collaboration with designer Sean Wotherspoon. These initiatives align with the companys strategy to expand its UGG and HOKA brands through product launches and market expansion. Despite potential risks like currency fluctuations, the companys long-term shareholder returns have been strong, though recent returns were less favorable compared to the US Luxury industry. The share price, currently at $116.73, remains below the analyst target of $129.28, suggesting potential for further growth.
Product StagePartners
growth-positive
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk
The FDA has approved the first-ever generic weight-loss drug, a knockoff of Novo Nordisks Saxenda, developed by Teva Pharmaceutical. This approval marks a significant milestone for Teva, as it allows them to enter the weight-loss drug market with a generic version, potentially increasing their market share and revenue. The approval is seen as a setback for Novo Nordisk, which previously held a strong position in the market with Saxenda. The introduction of a generic alternative is expected to make weight-loss treatments more accessible and affordable for consumers.
FDA approved/pending approval
growth-positive
J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?
Johnson & Johnson (J&J) has been experiencing a positive stock performance, with its stock trading above the 50-day and 200-day simple moving averages since mid-June 2025. This bullish trend, known as a golden cross, suggests potential for continued upward momentum. J&Js strengths lie in its diversified business model, operating in both medical devices and pharmaceuticals. The company separated its Consumer Health business into Kenvue, allowing it to focus on core areas. Despite challenges like the loss of exclusivity for Stelara, J&Js Innovative Medicine unit is showing growth, with expectations of significant sales in 2025 and beyond. The company anticipates oncology sales to exceed $50 billion by 2030.
growth-positive
Piper Sandler Reiterates a Buy Rating on Teva Pharmaceutical Industries (TEVA)
Teva Pharmaceutical Industries Limited is highlighted as a strong buy stock, with Piper Sandler analyst David Amsellem reiterating a Buy rating and setting a price target of $29.00. The company reported its fiscal Q2 2025 results, marking the tenth consecutive quarter of year-over-year revenue growth, with revenues reaching $4.2 billion. Teva is on track to achieve a 30% operating profit margin by 2027 as part of its Pivot to Growth Strategy. The company also reported a 47% year-over-year growth in free cash flow. Despite its potential, the article suggests that certain AI stocks may offer greater upside potential.
growth-positive
Deckers Outdoor (DECK): Assessing Valuation After New Teva Launches and Continued Earnings Momentum
Deckers Outdoor has been gaining attention due to successful product launches and consistent revenue and earnings growth. The company recently unveiled Tevas Autumn-Winter 2025 collection, featuring new designs and a collaboration with Sean Wotherspoon. Despite a 31% decline in stock price over the past year, Deckers has shown strong performance over a longer period. Analysts consider the stock undervalued, with potential growth driven by key brands like UGG and HOKA. However, risks such as supply chain issues and currency fluctuations could impact future growth. The stock is currently seen as an opportunity for value investors.
Product StageCustomers
growth-positive
Will Teva’s Designer Collaboration and New Collection Signal a Brand Evolution for Deckers (DECK)?
In August 2025, Deckers Outdoor announced the launch of Tevas Autumn-Winter 2025 footwear collection, featuring a designer collaboration with Sean Wotherspoon. This move aims to blend heritage design with modern performance, enhancing consumer interest and brand engagement in outdoor and fashion markets. While Tevas contribution to Deckers revenue is smaller compared to UGG and HOKA, the new launches signal a strategic push to diversify appeal and maintain brand heat. Deckers projects $6.5 billion in revenue and $1.1 billion in earnings by 2028, requiring an 8.5% annual growth rate. The company faces challenges in managing inventory and international expansion amid a potentially more promotional retail environment.
Product StageCustomers
growth-positive
CalPrivate Bank Appoints Angel Martinez to the CalPrivate Bank Board
Private Bancorp of America, Inc., the holding company for CalPrivate Bank, announced the appointment of Angel Martinez to the board of its subsidiary, CalPrivate Bank. Martinez brings over 45 years of experience in the footwear industry, having served as CEO and Chairman of Deckers Brands and as a founding executive of Reebok. His appointment is seen as a strategic move to enhance the banks growth and commitment to exceptional client service. CalPrivate Bank is recognized for its superior client solutions and has been ranked highly in customer service and financial performance. The bank operates in several locations and offers a range of banking services, catering to high-net-worth individuals and businesses.
Management Changes
growth-positive
[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
The article discusses a market research report by Custom Market Insights on the global Biologics and Biosimilars market. The report highlights the markets growth potential, with an expected increase from USD 478.83 billion in 2024 to USD 1,320.19 billion by 2034, at a CAGR of 10.42%. The growth is driven by the rising incidence of chronic diseases like cancer and diabetes, necessitating long-term treatments. The expiration of patents for major biologics has opened the market for biosimilars, offering cost-effective alternatives. The report also emphasizes advancements in biomanufacturing technologies that enhance production efficiency.
growth-positive
Latest Fed cut signals, pharma relief rally, Apple TV+ price hike
Apple has announced a 30% price increase for its Apple TV+ subscription service, raising the monthly cost to $12.99. This price hike is effective immediately and is part of a broader trend of adjustments in the market. The increase is seen as a growth-positive move for Apple, potentially boosting its revenue from the streaming service. Meanwhile, pharmaceutical stocks, including Teva, Pfizer, and Eli Lilly, experienced a positive impact following the announcement of a US-EU trade deal that imposed a 15% tariff on pharmaceutical goods, alleviating fears of much higher tariffs. Additionally, Walmart shares fell after a profit miss, despite raising its sales guidance for the year.
growth-negative
Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?
Johnson & Johnson is facing significant challenges in 2025 due to the expiration of its patent for Stelara, leading to the launch of biosimilars by companies like Amgen and Teva, which has substantially eroded Stelaras sales. The companys sales are further impacted by the Medicare Part D redesign under the Inflation Reduction Act, which is expected to negatively affect sales by approximately $2 billion. Additionally, J&J is embroiled in over 62,000 lawsuits related to its talc-based products, with its bankruptcy strategy to settle these lawsuits failing multiple times. These factors contribute to a negative growth outlook for the company.
CustomersProduct Stage
growth-positive
US-EU trade deal impacts on pharma industry more 'manageable' than expected
The recent trade deal between the US and the EU, which sets a 15% cap on import tariffs for pharmaceutical goods, has been positively received by the pharmaceutical industry. Stocks of major pharmaceutical companies like Pfizer, Eli Lilly, and Johnson & Johnson saw a slight increase following the announcement. The deal aims to equalize US drug costs with those in the EU by applying the higher of either the US MFN tariff rate or a 15% tariff on EU-manufactured drugs. Additionally, the US will enforce MFN pricing on generics and chemical precursors starting September 1. This is seen as a manageable change, with limited financial impact on the industry.
growth-positive
Teva Debuts Autumn Winter 2025 Collection Inspired By "For Playground Earth"
Teva, a division of Deckers Brands, has announced its Autumn-Winter 2025 collection, which is part of the brands For Playground Earth platform. The collection includes new styles designed for cold-weather trail and camp adventures, such as the Hurricane Daybreaker family and the updated Tirra Sport. These products aim to encourage outdoor exploration and connect with nature. The collection reflects Tevas commitment to innovation and outdoor play, offering functional performance footwear for various adventures. The new products will be available for purchase starting in early November.
Product Stage
growth-positive
Teva® and Sean Wotherspoon Reimagine Archival Icons, Bridging Street Style and Outdoor Adventure
Teva, a division of Deckers Brands, has announced a limited-edition collaboration with designer Sean Wotherspoon. The Teva x Sean Wotherspoon collection features a reimagined version of the Wraptor and Hurricane XLT2, incorporating bold designs and multi-terrain functionality. The collection, which includes recycled materials, aims to blend style with performance, encouraging outdoor exploration. This collaboration reflects Tevas commitment to innovation and design, leveraging its archives to create a future-ready product line. The collection launched globally on August 14, 2025.
Partners
growth-positive
Deckers Outdoor (DECK) Launches Teva x Sean Wotherspoon Collection Globally
Deckers Outdoor has experienced an 8% increase in share price over the last month, driven by recent product launches and collaborations. Notably, Tevas collaboration with Sean Wotherspoon and HOKAs Mafate 5 launch have contributed to this growth. These initiatives align with Deckers strategy to expand its global presence through innovative products and direct-to-consumer strategies, potentially driving revenue growth and enhancing brand recognition. Despite a strong long-term performance, the companys one-year return has lagged behind the US market and luxury industry, indicating potential short-term challenges. However, with revenue forecasts of $5.12 billion and earnings nearing $990 million, the company is positioned for future growth.
PartnersCustomers
growth-positive
PureTech forms respiratory spin-off Celea to advance deuterated pirfenidone
Celea Therapeutics, a new spin-off from PureTech Health, has been launched to advance the late-stage clinical development of deupirfenidone, a Phase III-ready candidate for idiopathic pulmonary fibrosis (IPF). Led by former Teva CEO Sven Dethlefs, Celea aims to develop deupirfenidone for multiple fibrotic and inflammatory lung conditions. The drug is a deuterated form of Esbriet, designed to overcome efficacy challenges due to toxicity at high doses. PureTech plans to discuss Phase IIb results with the FDA by the end of Q3 2025, with a Phase III trial initiation planned for the end of 2025. The IPF market is competitive, with existing drugs like Ofev and upcoming ones like nerandomalist and N-115.
Product StageManagement Changes
growth-positive
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabian Osteoporosis Drugs Market is projected to grow significantly, driven by an aging population, increasing osteoporosis rates, and favorable healthcare regulations. The market is expected to expand from $210.89 million in 2024 to $308.84 million by 2033, with a CAGR of 4.33% from 2025. While bisphosphonates remain popular due to cost-effectiveness, biologics are anticipated to grow rapidly. Government initiatives under Vision 2030 are enhancing local drug production and healthcare infrastructure, improving drug accessibility. However, challenges such as low adherence and rural access persist. Key players include Amgen, Eli Lilly, and Pfizer. The market is concentrated in urban areas, with rural regions facing limited access to experts and treatments.
growth-positive
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
PureTech Health plc has announced the launch of Celea Therapeutics, a new entity focused on developing therapies for serious respiratory diseases. The lead program, deupirfenidone (LYT-100), is a Phase 3-ready candidate targeting idiopathic pulmonary fibrosis (IPF). Sven Dethlefs, PhD, former CEO of Teva North America, has been appointed to lead Celea. His extensive experience in pharmaceutical leadership is expected to accelerate the programs advancement. The launch of Celea underscores PureTechs strategy to advance differentiated programs through focused and capital-efficient structures. The initiative is seen as a growth-positive move for PureTech, with the potential to set a new standard of care for IPF and other lung conditions.
Product StageManagement Changes
growth-positive
Following a 4.2% decline over last year, recent gains may please Teva Pharmaceutical Industries Limited (NYSE:TEVA) institutional owners
The article discusses the ownership structure of Teva Pharmaceutical Industries, highlighting that institutional investors hold a significant 78% stake in the company. This ownership implies that the companys stock price is sensitive to the trading actions of these institutions. The recent 4.3% increase in share price, following a year of 4.2% losses, is seen as a positive sign by institutional investors. The largest shareholders include Phoenix Investments & Finances Ltd, FMR LLC, and BlackRock, Inc. The article suggests that the board of Teva Pharmaceutical Industries will likely need to consider the preferences of these institutional investors due to their substantial ownership.
growth-positive
Vantage Drilling International Ltd. Announces Completion of the Sale of the Tungsten Explorer
Vantage Drilling International Ltd. has completed the sale of the Tungsten Explorer to TEVA Ship Charter LLC, a joint venture entity owned 25% by Vantage and 75% by TotalEnergies. Vantage will continue to manage the Tungsten Explorer for a ten-year term, with an option to extend for an additional five years. This sale aligns with previous announcements and strengthens Vantages partnership with TotalEnergies. The company, an offshore drilling contractor, focuses on contracting drilling units and providing management services globally. The completion of this sale is expected to foster a productive relationship with TotalEnergies.
PartnersAcquisition
growth-positive
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Teva Pharmaceutical Industries Limited is experiencing a positive transformation, driven by its Pivot to Growth strategy. The company has delivered its 10th consecutive quarter of growth, raising its 2025 revenue and EPS guidance. Key innovative drugs like Austedo, AJOVY, and UZEDY are leading revenue growth, with projections to increase from $2.3 billion in 2024 to over $5 billion by 2030. Tevas financial discipline is evident in its reduced net debt and improved credit ratings. Despite trading at a lower P/E ratio compared to industry averages, Tevas robust pipeline and strengthened balance sheet present a compelling investment opportunity. Risks include pricing pressures and high short interest, but the companys strategic initiatives suggest significant upside potential.
Product StageInvestment
growth-positive
Teva’s Ajovy becomes first migraine prevention drug approved for children
Teva has received FDA approval for a label expansion of its migraine prevention drug, Ajovy, to include children and adolescents aged 6 to 17 years. This makes Ajovy the first CGRP inhibitor approved for this age group, giving Teva a competitive edge over rivals like Amgen and Eli Lilly. Ajovy, which was initially approved for adults in 2018, is now available for a broader patient base, addressing a significant gap in pediatric migraine care. The drug demonstrated superior efficacy in a Phase III trial and is expected to boost Tevas sales, which reached $507 million last year.
FDA approved/pending approval
growth-positive
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
Teva Pharmaceutical Industries Ltd has received FDA approval for AJOVY, a single-dose injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more. This marks AJOVY as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention, expanding its use beyond adults since its initial U.S. approval in 2018. The approval represents a significant advancement in migraine treatment options for younger patients, addressing a critical gap in care and offering families a new option to manage this common neurological condition.
FDA approved/pending approval
growth-positive
Endocarditis Market Global and Regional Research Report 2025-2035 | AI and Molecular Diagnostics Set to Revolutionize Endocarditis Management
The article discusses the growing incidence of endocarditis, a heart infection, due to factors like healthcare-associated infections and intravenous drug use. Technological advancements, including AI-assisted echocardiography and minimally invasive procedures, are improving detection and patient outcomes. Despite challenges like early detection difficulties and antimicrobial resistance, the integration of AI and next-generation antibiotics is expected to redefine endocarditis management. North America leads the market, with significant growth in Asia-Pacific due to increased cardiovascular cases and healthcare investments. Key players like Pfizer and Teva Pharmaceutical are driving innovations in this sector.
growth-positive
According to "The Wall Street Journal," the average target price of 11 investment institutions covering Teva's stock is $24.29, a 57.9% premium on the current share price.
Teva Pharmaceutical Industries Ltd. reported its second quarter financial results, showing lower revenue but higher profit than expected. Despite a recent decline in stock price, investment institutions like Oppenheimer see this as a buying opportunity, citing Tevas strategic aims for 2027 and its potential for growth in branded drugs. The company plans to lay off 3,000 employees by 2027 to save $700 million. Teva is also developing a drug with Sanofi, expected to enter phase 3 clinical trials, potentially earning Teva $500 million. The sale of its active ingredients division could free up $1.5-2 billion.
LayoffsProduct StageCustomers
growth-negative
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
Teva Pharmaceutical Industries reported second-quarter 2025 adjusted earnings of 66 cents per share, surpassing the Zacks Consensus Estimate of 63 cents. However, revenues of $4.18 billion missed the estimate of $4.28 billion, remaining flat year over year. The revenue growth was hindered by lower generic drug sales, despite increased sales of branded drugs like Austedo, Ajovy, and Uzedy. Tevas exit from Japan contributed to the decline in generic sales. The company launched new biosimilars, Simlandi and Selarsdi, in partnership with Alvotech, and Epysqli with Samsung Bioepis. Despite these efforts, Tevas shares have decreased by 23.6% this year, compared to the industrys 9.8% decline.
Product StagePartnersCustomers
growth-positive
Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA
The article discusses the addition of the Multiple Sclerosis - Global Clinical Trials Review, 2025 report to ResearchAndMarkets.coms offerings. This report provides a comprehensive overview of the global landscape of clinical trials for Multiple Sclerosis, including data by region, phase, and sponsor. It highlights top drugs and trial trends, aiding in strategic decision-making and competitive advantage. The report is generated using a proprietary database and includes data from over 80 clinical trial registries and other sources. It aims to assist in formulating business strategies, identifying key locations for trials, and understanding global market opportunities.
Product Stage
growth-negative
Teva CEO on Tariffs, Generic Drugs Market, MFN Pricing
Teva Pharmaceuticals CEO, Richard Francis, discussed several challenges facing the company, including potential tariff pressures, the generic drugs market, and the implications of Most Favored Nation drug pricing. These factors could negatively impact the companys growth. The conversation took place on Bloomberg Markets with hosts Scarlet Fu and Katie Greifeld. The discussion highlighted the current market challenges and regulatory pressures that Teva Pharmaceutical is navigating.
growth-negative
Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics
Teva Pharmaceutical Industries Ltd. reported its financial results for the quarter ending June 2025, with revenue of $4.18 billion, slightly up by 0.3% from the previous year. However, this was a 2.47% miss compared to the Zacks Consensus Estimate of $4.28 billion. The EPS was $0.66, exceeding the consensus estimate of $0.63, marking a 4.76% surprise. The companys performance varied across different regions and product lines, with notable growth in the European market and a significant increase in AJOVY sales in the U.S. Despite some positive metrics, the overall financial performance was mixed, leading to a growth-negative impact.
growth-positive
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
Teva Pharmaceutical Industries Ltd is on track to achieve a 30% operating profit margin by 2027 as part of its Pivot to Growth Strategy. The company reported its 10th consecutive quarter of year-over-year revenue growth in Q2 2025, with revenues of $4.2 billion. Key products like AUSTEDO®, AJOVY®, and UZEDY® showed significant growth, contributing to an increased revenue outlook for 2025. The company also reported stable performance in its generics segment and strong growth in biosimilars, with plans for two new launches in the second half of 2025. Tevas transformation programs are expected to deliver significant cost savings, further supporting its growth objectives.
growth-positive
Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings
Teva Pharmaceutical reported better-than-expected second-quarter earnings, with revenue reaching $4.27 billion, surpassing analyst expectations. The company also narrowed its full-year profit outlook, expecting earnings per share between $2.50 and $2.65. Teva reaffirmed its 2025 revenue outlook, projecting between $16.8 billion and $17.2 billion. The stable performance in generic drug sales contributed to the positive earnings report.
growth-positive
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
Medincell, a biopharmaceutical company, is experiencing growth through its partnership with Teva Pharmaceuticals. Their product UZEDY®, a long-acting injectable for schizophrenia, has been commercialized in the U.S. since May 2023, generating $117 million in sales. Medincell receives royalties and is eligible for significant commercial milestones. Another product, a long-acting olanzapine injectable, completed Phase 3 trials with positive results and is preparing for an NDA submission in Q4 2025. Medincells BEPO® technology, used in UZEDY®, was FDA approved in April 2023. The company collaborates with leading pharmaceutical companies to enhance global health through innovative treatments.
Product StagePartnersFDA approved/pending approval
growth-positive
The Israeli pharmaceutical company beat the analysts on profit but missed on revenue in the second quarter of 2025.
Teva Pharmaceutical Industries Ltd. reported better-than-expected profits for the second quarter of 2025, with non-GAAP earnings per share at $0.66, surpassing analysts forecast of $0.62. Despite missing revenue expectations, Teva raised its annual net profit guidance for 2025. The company is executing a Pivot to Growth strategy, focusing on innovation, which has resulted in a 26% increase in key innovative products in local currency. Teva is also recycling debt by raising a $2.3 billion bond. However, the company plans to lay off 250-300 employees in Israel. The article highlights Tevas financial performance, innovative drug guidance, and debt management.
Layoffs
growth-positive
Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy
Teva Pharmaceutical Industries Ltd. reported its second-quarter 2025 financial results, showing a mixed performance. The company generated $4.20 billion in revenue, slightly below analyst expectations. The decline was attributed to weaker sales in its generic drug portfolio, particularly in the International Markets segment, and a drop in Copaxone sales. However, Tevas innovative drug offerings, including Austedo, Uzedy, and Ajovy, showed strong growth. Austedo sales increased by 19%, Uzedy sales more than doubled, and Ajovy sales rose by 31%. The biosimilars segment also showed robust growth, with plans to launch two new biosimilars in the second half of 2025. Tevas adjusted earnings per share surpassed expectations, and the gross profit margin improved, driven by higher-margin innovative products.
Product StageCustomers
growth-negative
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
Alvotech, a commercial-stage company specializing in biosimilar medicines, is set to announce its Q2 2025 earnings. The company is expected to report a loss per share of 26 cents and total revenues of $115.4 million. Alvotechs revenues come from product sales and licensing, with biosimilars Simlandi and Selarsdi being key products. Despite their launch, these products have yet to gain significant market traction. Alvotech is also developing other biosimilars in partnership with companies like Teva Pharmaceuticals, Advanz Pharma, and Dr. Reddy’s Laboratories. Regulatory filings for these products are under review in the US and EU. Year-to-date, Alvotechs shares have dropped by 26.5%, contrasting with the industrys slight growth.
Product StagePartnersFDA approved/pending approval
growth-negative
Austedo disappoints, while Uzedy and Ajovy drive upside in brand-name drugs.
Teva concluded the second quarter of 2025 with a revenue of $4.17 billion, slightly below analysts expectations. While sales of original medicines grew, the overall revenue was flat compared to the previous year. The companys gross profit margin improved, and adjusted earnings per share exceeded expectations. However, weaker-than-expected sales of Austedo, Tevas treatment for movement disorders, contributed to the revenue shortfall. In contrast, Ajovy and Uzedy performed well, with Uzedy showing significant growth. Teva plans to cut 3,000 jobs by 2027 as part of its restructuring efforts to improve profit margins. The company reaffirmed its full-year guidance and highlighted the momentum in its biosimilars division as a key growth area.
LayoffsCustomers
growth-positive
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics
Teva Pharmaceutical Industries Ltd. is projected to announce quarterly earnings of $0.63 per share, a 3.3% increase year over year, with revenues reaching $4.29 billion, up 3% from the previous year. Despite a 0.7% downward revision in EPS estimates over the last 30 days, analysts projections for key metrics such as Revenue- COPAXONE- Total and Geographic Revenue in various regions provide insights into the companys performance. Notably, Revenue- Other- Total is expected to see a significant increase of 144.4% from the prior year. These projections suggest a positive outlook for Tevas short-term stock performance.
growth-positive
This is the Most Dangerous Week for Investors in 20 Years
The article discusses the potential impact of proposed tariffs by the Trump administration on various industries, including pharmaceuticals, semiconductors, copper, steel, and lumber. The tariffs aim to repatriate manufacturing and reshape the global supply chain. Companies with significant U.S. production, like Eli Lilly, Thermo Fisher Scientific, Intel, and Micron Technology, could benefit from these changes. The tariffs could also boost domestic suppliers like Freeport-McMoRan and Cleveland-Cliffs. The article highlights the potential for a significant shift in the market landscape due to these tariffs, with August 1st being a critical date for implementation.
growth-negative
S&P 500 Gains and Losses Today: Deckers Stock Jumps as Global Footprint Grows; Intel Shares Sink
Intel reported an unexpected second-quarter loss, causing its shares to drop by 8.5%. Despite revenue exceeding forecasts, the profitability shortfall raised concerns about the companys turnaround plan under CEO Lip-Bu Tan. The plan includes layoffs and other cost-cutting measures. Additionally, Intel announced it would slow down the construction of its manufacturing facilities in Ohio and cancel previously announced projects in Germany and Poland. These developments indicate challenges in Intels efforts to improve its financial performance and operational efficiency.
Layoffs
growth-positive
Deckers Brands Reports First Quarter Fiscal Year 2026 Financial Results
Deckers Brands reported a strong financial performance for the first quarter of fiscal year 2026, with a 17% increase in revenue to $965 million and a 24% rise in diluted EPS to $0.93. The companys brands, HOKA and UGG, exceeded expectations, contributing to a 16.9% increase in net sales. Despite a decrease in domestic sales, international sales surged by 49.7%. The company maintains a robust cash position with $1.720 billion in cash and no outstanding borrowings. Deckers Brands remains confident in its long-term growth prospects despite global trade uncertainties.
growth-negative
Menora Mivtachim and Phoenix have become parties in interest in the Israeli pharmaceutical company.
Teva Pharmaceutical Industries Ltd. has seen two Israeli institutional investors, Menora Mivtachim and Phoenix Financial Ltd., each acquire a 5% stake in the company, with US asset manager Fidelity holding a 7.1% stake. Despite these investments, Tevas stock has fallen 26% since the beginning of the year. The company plans to lay off 250-300 employees in Israel as part of a streamlining plan to cut 8% of its workforce by 2027. Analysts expect a slight increase in revenue and EPS in the upcoming financial report. The companys market cap stands at $18.7 billion.
InvestmentLayoffs
growth-positive
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
Johnson & Johnson (J&J) reported strong second-quarter 2025 results, surpassing expectations in both revenue and earnings. Despite the loss of exclusivity for Stelara, J&Js Innovative Medicines unit and MedTech segment performed well, driven by strong sales of key drugs and new products. The company raised its sales and EPS guidance for the year, reflecting strong operational performance and favorable currency impacts. J&Js shares rose over 6% following the earnings announcement. The companys diversified business model, with operations in both medical devices and pharmaceuticals, continues to be a significant strength. In 2023, J&J separated its Consumer Health business into a new company, Kenvue, allowing it to focus on its core areas.
growth-positive
EdgeOne Medical Announces Appointment of Michael Denzer as VP, Client Relations to Further Elevate Product Innovation and Client Partnerships
EdgeOne Medical has appointed Michael Denzer as Vice President of Client Relations. Denzer brings over 30 years of experience in the development, commercialization, and lifecycle management of innovative packaging and combination products. His career includes roles at major pharmaceutical and biotech companies such as Schering-Plough, Bristol Myers Squibb, Amgen, and others. Denzers appointment is expected to enhance EdgeOne Medicals leadership team and further its mission to support innovative combination products that improve patient outcomes. EdgeOne Medical is a professional service organization focused on device development for combination products in the bio-pharmaceutical industry.
Management Changes
growth-negative
Trump Aims Tariff Double Whammy at Industries, Nations by Aug. 1
The article discusses President Donald Trumps plans to implement industry-specific tariffs alongside country-specific duties, aiming to reshape the USs global trade standing. A 50% duty on copper is expected to be announced soon, with potential tariffs on pharmaceuticals, semiconductors, lumber, chips, critical minerals, and drugs to follow. These tariffs, under Section 232 of the Trade Expansion Act, are justified on national security grounds. The European Union, Japan, and India are attempting to negotiate lower rates. The financial markets view Trumps tariff strategy as a negotiating tactic rather than a long-term economic threat.
growth-positive
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
Johnson & Johnson reported its second-quarter 2025 earnings, with earnings per share at $2.77, surpassing the Zacks Consensus Estimate of $2.66. Despite a 1.8% decline from the previous year, the companys reported earnings increased by 18.7% year-over-year. Sales reached $23.74 billion, exceeding the expected $22.80 billion, and reflecting a 5.8% rise from the previous year. The company, now focused on Pharmaceuticals and MedTech after separating its Consumer Health segment into Kenvue, saw significant growth in its Innovative Medicines segment, driven by key products like Darzalex and new drugs such as Carvykti and Tecvayli. The sales growth was slightly offset by competition from generics and biosimilars.
growth-positive
Deckers Brands Announces Conference Call to Review First Quarter Fiscal 2026 Earnings Results
Deckers Brands, a global leader in designing and distributing innovative footwear, apparel, and accessories, announced a conference call to review its first quarter fiscal 2026 results. The call is scheduled for July 24, 2025, and will be accessible on their investor relations website. Deckers Brands, known for its portfolio of brands including UGG, HOKA, Teva, Koolaburra, and AHNU, has a strong global presence with products sold in over 50 countries. The company has a history of building niche footwear brands into market leaders, attracting a loyal consumer base worldwide.
growth-positive
Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim’s Buy List
Neurocrine Biosciences Inc. (NASDAQ:NBIX) is highlighted as one of the best debt-free stocks to invest in. Guggenheim analyst Yatin Suneja reaffirmed a Buy rating on the stock, maintaining a price target of $165. The company is experiencing continued momentum with its product Ingrezza, expecting sales growth in Q2 and a stronger performance in the latter half of 2025. Management addressed concerns about pricing pressure from TEVAs Austedo under the Inflation Reduction Act but emphasized the long-term growth potential for VMAT2 inhibitors. Neurocrine Biosciences focuses on treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The article also mentions the potential of AI stocks, suggesting they may offer greater upside potential.
growth-positive
TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?
Teva Pharmaceutical Industries Limited has seen a 21.6% rise in its stock price over the past three months, driven by the successful launch of several biosimilars and high-value generics. The companys branded drugs, including Austedo, Uzedy, and Ajovy, are experiencing strong sales growth. Teva has implemented cost-cutting measures to improve operating profits and reduce debt. The company anticipates significant revenue growth from its branded products by 2030, with Austedo expected to generate over $2.5 billion annually by 2027. Teva has partnered with Sanofi to advance its anti-TL1A therapy, duvakitug, into phase III trials. The company continues to expand its market presence with new launches in Europe and international markets.
Product StagePartnersCustomers
Teva Pharmaceutical (TEVA) Just Flashed a Statistically Viable Signal for Bullish Traders
The article provides instructions on how to customize chart settings and navigate through chart options. It explains how to save chart setups as templates, switch market flags for targeted data, and access more chart options through the interactive chart menu. The article is focused on providing users with guidance on utilizing chart features effectively.
growth-positive
Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278
Teva Pharmaceutical Industries Limited has announced a collaboration with Shanghai Fosun Pharmaceutical Group Co., Ltd. to co-develop TEV-56278, an investigational anti-PD1-IL2 ATTENUKINE therapy. This partnership aims to accelerate clinical data generation for TEV-56278, which is currently in a Phase 1 study targeting various forms of cancer, including melanoma. Under the agreement, Fosun Pharma will have exclusive rights to develop, manufacture, and commercialize TEV-56278 in several Asian regions. This collaboration is expected to enhance Tevas growth prospects in the biopharmaceutical sector. Despite the positive outlook for Teva, the article suggests that certain AI stocks may offer better investment opportunities.
Product StagePartners
growth-positive
Teva’s Ajovy Shows Sustained Long-Term Efficacy in Migraine Prevention Trial
Teva Pharmaceutical announced the final results of its PEARL Phase IV trial for Ajovy, a migraine prevention drug. The trial demonstrated sustained long-term efficacy, with over 66% of episodic migraine patients and 51.6% of chronic migraine patients experiencing significant benefits for more than 24 months. The study also reported high injection adherence rates and consistent long-term tolerability and safety profiles. Teva develops and markets generic and biopharmaceutical products globally. While Teva is considered undervalued, the article suggests that certain AI stocks may offer greater investment potential.
Product Stage
Deckers Outdoor Corporation's Quarterly Earnings Preview: What You Need to Know
The article provides instructions on how to customize chart settings and navigate through chart options. It explains how to save chart setups as templates, switch market flags for targeted data, and access more chart options through an interactive menu. The article is focused on providing users with guidance on utilizing chart features effectively.
growth-positive
Teva Recognized Among TIME and Statista's 2025 World's Most Sustainable Companies
Teva Pharmaceutical has been recognized as one of the Worlds Most Sustainable Companies in 2025 by TIME and Statista. This accolade highlights Tevas commitment to sustainability, focusing on patient access, resilient operations, ethical governance, and climate action. The company was selected from over 5,000 global companies based on more than 20 key performance indicators, including carbon emissions reduction and renewable energy use. This recognition underscores Tevas efforts to integrate sustainability into its business operations, aiming to deliver long-term value for patients, communities, and the planet.
growth-negative
Jim Cramer on Deckers: “I’m Not Ready to Throw in the Towel”
Deckers Outdoor Corporation, known for its brands like UGG, HOKA, and Teva, has experienced a significant stock decline, being the biggest loser in the S&P 500 in the first half of the year. Despite this, Jim Cramer remains optimistic about the companys potential, citing the impressive growth of the HOKA brand. However, the article suggests that AI stocks might offer better investment opportunities due to their potential upside and lower risk. Deckers continues to offer a diverse range of footwear, apparel, and accessories, but the focus on AI stocks and economic factors like tariffs may influence investor decisions.
growth-positive
Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen solid returns of 112% over the past three years
Teva Pharmaceutical Industries Limited has seen its share price increase by 112% over the past three years, despite not being profitable in the last twelve months. The company has experienced a modest annual revenue growth of 3.6%, which some investors might find uninspiring given its lack of profitability. However, the stocks impressive annual growth rate of 29% suggests market optimism about its future potential. Shareholders have seen a 2.6% increase in the past year, which is below the market average, but the longer-term returns are more promising at around 8% annually over five years. The article suggests that Tevas stock performance might warrant further examination by potential investors.
neutral
Teva Releases Q2 2025 Aide Memoire
Teva Pharmaceutical Industries Ltd announced the availability of its Q2 2025 Aide Memoire on its website. The document is intended to assist in financial modeling based on Tevas prior results and managements commentary. Teva is a global biopharmaceutical leader with a commitment to delivering medicines worldwide, focusing on innovation and the production of generics and biologics. The press release includes cautionary notes regarding forward-looking statements, highlighting risks related to competition, indebtedness, and regulatory matters. No specific events like investments, acquisitions, or partnerships were mentioned in the article.
Neutral
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
Teva Pharmaceutical Industries Ltd announced that it will release its second quarter 2025 financial results on July 30, 2025. Following the release, a conference call and live webcast will be conducted. Teva is a global biopharmaceutical leader with a focus on delivering medicines worldwide, including generics and biologics. The company emphasizes its commitment to health and innovation. The press release includes cautionary notes regarding forward-looking statements, highlighting potential risks and uncertainties that could impact future performance. The company operates in 57 markets with 37,000 employees, aiming to address current and future patient needs.
growth-positive
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Teva Pharmaceutical Industries Limited is undergoing a strategic transformation known as its Pivot to Growth, aiming to reposition itself from a generics-focused company to one with a balanced portfolio emphasizing innovative drugs. The company targets over $5 billion in revenue from innovative drugs by 2030, with key areas in neuroscience, immunology, and respiratory treatments. Tevas innovative pipeline includes promising treatments like UZEDY for schizophrenia and AUSTEDO for Tardive Dyskinesia, with potential multi-billion-dollar sales. Despite a market cap of around $20 billion, Teva trades at a discount due to legacy concerns, but improved debt metrics and strong cash flow projections indicate financial health. The strategic shift is expected to drive long-term growth and re-rating.
Product StagePartners
growth-positive
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?
Stanley Druckenmiller, a billionaire investor, has made significant investments in three companies: DocuSign, Flutter Entertainment, and Teva Pharmaceutical, during the first quarter of 2025. DocuSign, a leader in electronic signature and contract lifecycle management solutions, saw a 16% decline in stock price in 2025 but remains up over 40% in the last 12 months. Druckenmillers family office initiated a new position in DocuSign, purchasing 1.07 million shares. Flutter Entertainment, a top online sports betting and gaming operator, experienced a stock price roller-coaster but saw a 1,985.5% increase in Druckenmillers stake. Teva Pharmaceutical, a major drugmaker, had a rough year but was Druckenmillers biggest purchase on a dollar basis, increasing his stake by 65.4%.
Investment
growth-positive
Teva reports final analysis of migraine prevention trial of Ajovy
Teva Pharmaceutical has announced the final results of the PEARL Phase IV trial for Ajovy, a monoclonal antibody used for migraine prevention. The trial demonstrated high injection adherence rates of nearly 90% and confirmed that primary and secondary endpoints were achieved. The study involved 1,140 subjects, and the data showed significant long-term benefits for both chronic and episodic migraine patients. The results support the continued clinical use of Ajovy, reaffirming its long-term effectiveness and safety profile. This positive outcome follows previous successful trials, including the Phase III SPACE trial for younger patients.
Product Stage
growth-positive
Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth
Teva Pharmaceutical Industries Limited, a multinational pharmaceutical company, has been identified as a top stock pick by billionaire Stan Druckenmiller, with significant growth potential. Goldman Sachs analysts have initiated coverage of Teva with a Buy rating and a price target of $24, citing the companys strengthening core business and growth opportunities in its branded drug segment. Key branded medications like Austedo, Uzedy, Ajovy, and LAI olanzapine are expected to drive substantial growth by 2027. While the generics sector shows modest growth, the introduction of five new biosimilars in the U.S. between 2025 and 2027 offers additional potential. However, the expiration of the gRevlimid settlement in 2026 may offset some of this growth.
growth-positive
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
Johnson & Johnson (J&J) has seen a 4.4% rise in its stock over six months, adding over $15 billion to its market value. Despite challenges like slowing MedTech sales, loss of exclusivity for Stelara, and talc lawsuits, J&Js strengths lie in its diversified business model and strong Innovative Medicine unit. The company has separated its Consumer Health business into Kenvue, allowing it to focus on pharmaceuticals and medical devices. J&J anticipates significant growth in its Innovative Medicine segment, driven by key products and new drug launches, with expectations of over $57 billion in sales by 2025.
Product StageAcquired-by
growth-positive
Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
Teva Pharmaceutical Industries Ltd announced the final analysis of the PEARL Phase 4 migraine prevention study, which was presented at the 11th Congress of the European Academy of Neurology in Helsinki. The study demonstrated that AJOVY (fremanezumab), an anti-CGRP monoclonal antibody, showed sustained effectiveness in reducing migraine frequency, duration, and severity over a two-year period. The study involved 1,140 patients, with high injection adherence and favorable safety and tolerability profiles. The findings underscore fremanezumabs role in migraine prevention and highlight the importance of real-world studies in shaping clinical practice.
growth-positive
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy
Teva Pharmaceutical has entered into a strategic collaboration with Fosun Pharmaceutical to co-develop TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. This partnership grants Fosun exclusive rights to develop, manufacture, and commercialize the therapy in China and select regions, while Teva retains rights elsewhere. The collaboration aims to leverage Fosuns oncology expertise and Tevas innovative drug development to broaden access to this novel cancer therapy. TEV-56278 is in early-stage studies for various cancers, including melanoma. No financial details were disclosed. Despite a 22.9% decline in Tevas shares year-to-date, the partnership is seen as a strategic move to enhance market presence and therapeutic reach.
Partners
growth-negative
Generic Drugmakers Resist Trump’s Calls for More U.S. Manufacturing
The article discusses the resistance of generic drugmakers to the Trump administrations calls for increased U.S. manufacturing. The companies argue that further domestic investment is too risky due to the low-margin and unpredictable nature of the business. This reluctance highlights the challenges faced by the industry in balancing cost-efficiency with political and economic pressures to localize production. The article suggests that the current business environment does not favor significant shifts in manufacturing strategies for these companies.
growth-positive
Teva to collaborate with Fosun Pharma for TEV-56278
Teva Pharmaceutical has entered into a collaboration with Shanghai Fosun Pharmaceutical to advance the global development of TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. This partnership aims to enhance clinical data generation for the treatment, which targets PD-1 + T cells and is designed to offer efficacy with low toxicity across various oncology indications. Fosun Pharma will have exclusive rights to develop, manufacture, and commercialize the therapy in specific Asian regions, while Teva retains rights elsewhere. The collaboration leverages Fosun Pharmas regional data and commercial capabilities, potentially accelerating the delivery of this therapy globally.
PartnersProduct Stage
growth-positive
Teva, Fosun Pharma partner to develop TEV-56278
Teva Pharmaceutical has entered a strategic partnership with Shanghai Fosun Pharmaceutical to develop TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. This collaboration grants Fosun Pharma exclusive rights to develop, manufacture, and commercialize the therapy in certain Asian regions, while Teva retains rights elsewhere. The partnership aims to accelerate clinical data generation and leverage Fosuns data globally. This move is seen as a significant step in the global development of TEV-56278, potentially offering high efficacy and low toxicity in oncology treatments.
Partners
growth-positive
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
Teva Pharmaceutical Industries Ltd has entered into a strategic partnership with Shanghai Fosun Pharmaceutical to develop TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy, currently in Phase 1 clinical trials for cancer treatment. This collaboration aims to accelerate clinical data generation, with Fosun Pharma gaining exclusive rights to develop, manufacture, and commercialize the therapy in several Asian regions. Teva retains rights for the rest of the world, allowing it to leverage data generated by Fosun Pharma. This partnership aligns with Tevas strategy to advance its innovative drug pipeline and improve oncology treatment outcomes.
PartnersProduct Stage
growth-positive
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters
The article discusses Stanley Druckenmillers investment strategy, highlighting his exit from Palantir Technologies, a leading AI company, and his increased investment in Teva Pharmaceutical Industries. Druckenmillers decision to sell Palantir shares is attributed to potential profit-taking, concerns over defense spending cuts, AI market volatility, and Palantirs high valuation. Meanwhile, Tevas stock has surged due to resolving opioid litigation, improving its balance sheet, and focusing on novel-drug development. Tevas turnaround, driven by CEO Richard Francis, positions it for growth, making it an attractive investment for Druckenmiller.
InvestmentCustomers
growth-negative
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris
The article discusses the challenges faced by generic drugmakers like Sandoz, Teva Pharmaceuticals, and Viatris due to pricing competition and potential pharmaceutical import tariffs proposed by the Trump administration. These policies aim to align U.S. drug prices with global benchmarks but could disrupt revenues and profitability for generic drugmakers, which operate on tighter margins compared to branded drugmakers. Despite these challenges, companies like Sandoz are positioned to navigate these headwinds through their global scale, diversified portfolios, and strategic focus on complex and branded generics. They are also implementing cost optimization strategies to improve margins.
growth-negative
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
The article discusses the challenges faced by generic drugmakers due to pricing competition, import tariffs, and the proposed most-favored-nation pricing model. These policies aim to align U.S. drug prices with global benchmarks but could disrupt revenues and profitability in the industry. While branded drugmakers are better positioned to withstand these pressures, generic drugmakers like Sandoz, Teva Pharmaceuticals, and Viatris are vulnerable due to tighter margins. However, these companies are leveraging their global scale, diversified portfolios, and strategic focus on complex generics to navigate these challenges. They are also implementing cost optimization strategies to improve margins and resource efficiency.
growth-positive
CrowdStrike and McDonald’s downgraded: Wall Street’s top analyst calls
Sarepta has been upgraded by Scotiabank to Outperform from Sector Perform with an unchanged price target of $80. Despite recent negative news, including a patient death and a downward revision of 2025 sales guidance, the firm believes these issues are already reflected in the share price. Scotiabank sees several important catalysts that could drive the stock higher, suggesting a favorable risk-reward scenario. This upgrade is part of a broader set of research calls that include both upgrades and downgrades for various companies.
growth-positive
Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am
Goldman Sachs has initiated coverage on U.S.-listed generic pharmaceutical companies, including Teva Pharmaceutical Industries, with a Buy rating. The bank cites improving fundamentals, strong free cash flow, and undemanding valuations as reasons for optimism. Tevas branded drug portfolio is highlighted as a key growth engine, supported by positive clinical updates and potential valuation upside. Despite macroeconomic risks and policy uncertainties, Goldman sees long-term potential in the sector as companies shift toward complex generics, biosimilars, and branded drugs. The analysts expect strong free cash flow to support debt reduction, capital return, and strategic acquisitions.
Product StageInvestment
growth-negative
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
Teva Pharmaceutical Industries Ltd announced the pricing and early acceptance results of its tender offers to purchase outstanding notes issued by its finance subsidiaries. The tender offers involve several series of notes with varying interest rates and maturity dates. The company has set tender caps for each pool of notes, representing the maximum aggregate purchase price for the notes. The early acceptance results indicate the principal amounts tendered and accepted for each series of notes, along with the proration factors and total consideration. This financial maneuver is part of Tevas strategy to manage its debt obligations effectively.
growth-positive
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
Teva Pharmaceutical Industries Ltd announced the early tender results for its previously announced tender offers for several series of notes issued by its finance subsidiaries. The company has increased the tender caps for its Pool 2 and Pool 3 Notes, raising the Pool 2 Tender Cap from $250 million to $350 million and the Pool 3 Tender Cap from $200 million to $400 million. The total maximum amount for the notes has been increased from $2.25 billion to $2.3 billion. These changes reflect Tevas strategic financial management and commitment to sustainability-linked financing.
growth-positive
Teva Pharmaceutical Industries Raises Pool Tender Offer, Reports Early Tender Results
Teva Pharmaceutical Industries has announced an increase in its pool tender offer and reported early tender results. This move is part of the companys strategy to manage its financial obligations and optimize its capital structure. The announcement led to a positive impact on the companys stock, reflecting investor confidence in Tevas financial maneuvers. The tender offer is part of a broader effort to strengthen the companys financial position and enhance shareholder value. The article suggests that Teva is actively engaging in financial strategies to support its growth and stability.
PIPE/PO
growth-positive
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
Teva Pharmaceutical Industries Ltd presented positive real-world clinical outcomes for UZEDY® (risperidone), an extended-release injectable suspension for schizophrenia treatment. The studies showed improved adherence, persistence rates, and reduced healthcare resource utilization compared to second-generation daily oral options. Additionally, Phase 3 SOLARIS data for TEV-749, a long-acting injectable formulation of olanzapine, showed no incidence of post-injection delirium/sedation syndrome (PDSS). These findings were presented at the 2025 Psych Congress Elevate Annual Meeting. The data suggest that UZEDY may help prevent relapse, reduce hospital visits, and lower healthcare costs, while TEV-749 could fill a critical gap in schizophrenia treatment.
Product StageCustomers
growth-positive
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
Teva Pharmaceutical Industries Ltd has announced findings from a study highlighting significant gaps in the diagnosis and treatment of tardive dyskinesia (TD) among residents in long-term care (LTC) facilities. The study revealed that more than half of LTC residents with TD do not receive standard care, with many being misdiagnosed with extrapyramidal syndrome. Teva is committed to advancing research to address these unmet needs and improve TD care. The study emphasizes the importance of accurate diagnosis and appropriate treatment, as many patients are either untreated or receive non-FDA approved treatments. Tevas efforts aim to raise awareness and improve care for TD patients in LTC settings.
growth-positive
Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target
Teva Pharmaceutical Industries Limited, an Israeli pharmaceutical company known for its generic drugs, received a Buy rating from Truist Securities with a price target of $25. The company is focusing on a dual strategy of high-margin branded products and generics, which is expected to support sustainable growth. Teva has launched a $700 million cost-cutting initiative to improve operational efficiency, including reducing headcount. This initiative aims to achieve a 30% operating margin by 2027. Recently, Moodys and Fitch upgraded Tevas corporate credit rating, reflecting its focus on debt and cost reduction. Despite the positive outlook, the article suggests that AI stocks may offer higher returns.
Layoffs
growth-positive
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
Teva Pharmaceutical Industries Ltd is accelerating its growth strategy to become a leading biopharmaceutical company. The company aims to exceed $5 billion in its innovative medicines franchise by 2030, driven by products like AUSTEDO, AJOVY, and UZEDY, along with a robust late-stage pipeline. Teva has completed Phase 1 of its strategy, achieving nine consecutive quarters of growth and generating over $2.3 billion in revenue from its innovative portfolio in 2024. The company plans to expand its LAI schizophrenia franchise and expects significant sales growth for its key products by 2027. Tevas strategic focus on innovation and transformation is set to deliver sustained shareholder value through 2030.
Product StageCustomers
growth-positive
Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408
Teva Pharmaceutical Industries Limited announced that its investigational drug, TEV-53408, has received Fast Track designation from the FDA for treating celiac disease in patients adhering to a gluten-free diet. TEV-53408 is an anti-IL-15 monoclonal antibody designed to inhibit interleukin-15, which is implicated in the immune response causing intestinal damage in celiac disease. The drug is currently in a Phase 2a clinical trial to assess its efficacy and safety. This designation highlights the promise of TEV-53408 and the urgent need for new therapeutic options for celiac disease. The Fast Track process aims to expedite the development and review of drugs addressing serious conditions and unmet medical needs.
Product Stage
growth-negative
Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead
The article discusses the investment activities of Stanley Druckenmillers Duquesne Family Office, highlighting its complete exit from Palo Alto Networks, a prominent stock-split stock, and increased investment in Teva Pharmaceutical Industries. Druckenmillers decision to sell Palo Alto Networks shares may be due to profit-taking and valuation concerns, despite the companys strong performance and AI-supported cybersecurity model. On the other hand, Teva Pharmaceuticals is seen as a promising investment due to its focus on novel-drug development, cost reduction, and resolution of opioid litigation issues. The article emphasizes the importance of 13F filings in understanding market trends.
Customers
growth-positive
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate
Teva Pharmaceutical Industries Limited, in collaboration with Biolojic Design Ltd., has initiated IND-enabling studies for BD9, a dual-specific multibody targeting TSLP and IL-13 for treating TH2-driven inflammatory diseases like asthma and atopic dermatitis. Teva holds an exclusive license to develop BD9 globally, while Biolojic will receive regulatory and commercial milestone payments. Additionally, the FDA has granted Fast Track designation to Tevas anti-IL-15 antibody, TEV-53408, for celiac disease treatment. This designation aims to expedite the development of drugs addressing serious conditions. Tevas innovative pipeline, primarily in neuroscience and immunology, is progressing well. Shares of Teva rose by 4.4% following the announcement, although they have declined by 19.6% year-to-date.
Product StagePartners
growth-positive
Why Is Teva Stock Trading Higher On Tuesday?
Teva Pharmaceutical Industries Ltd has initiated IND-enabling studies for BD9, a dual-specific multibody targeting TSLP and IL-13, in collaboration with Biolojic Design Ltd. This marks a significant step towards developing treatments for TH2-driven inflammatory diseases like atopic dermatitis and asthma. Teva holds an exclusive license to develop BD9 globally and will make milestone payments to Biolojic. Additionally, the FDA approved Teva and Alvotechs Selarsdi as interchangeable with Johnson & Johnsons Stelara. Teva also resolved patent litigation with Axsome Therapeutics over Auvelity. These developments, along with a recent stock price increase, indicate positive growth momentum for Teva.
Product StagePartnersFDA approved/pending approval
growth-positive
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
Teva Pharmaceutical Industries Ltd announced that the FDA has granted Fast Track designation for its investigational drug TEV-53408, an anti-IL-15 antibody, for the treatment of celiac disease. This designation is intended to expedite the development and review process for drugs addressing serious conditions with unmet medical needs. TEV-53408 is currently in a Phase 2a trial to evaluate its efficacy and safety in adults with celiac disease. This development highlights Tevas commitment to innovation and its efforts to provide new treatment options for chronic autoimmune diseases. The Fast Track designation is a positive step towards addressing the needs of patients with celiac disease, who currently have limited treatment options.
Product Stage
growth-positive
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
Teva Pharmaceutical Industries Ltd has initiated IND-enabling studies for BD9, a dual-specific multibody targeting TSLP and IL-13, in collaboration with Biolojic Design Ltd. This development is part of Tevas strategy to enhance its innovative pipeline and address unmet medical needs in TH2-driven inflammatory diseases such as atopic dermatitis and asthma. The collaboration leverages Biolojics Multibody Platform, which uses computational biology and AI to design multifunctional antibodies. The initiation of these studies marks a significant milestone in Tevas efforts to bring transformative therapies to underserved patient populations, demonstrating a commitment to innovation and improved health outcomes.
PartnersProduct Stage
growth-positive
TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?
Teva Pharmaceutical Industries Limiteds stock rose by 12.9% in a month following its first-quarter 2025 results announcement on May 7. The company reported mixed results, beating earnings estimates but missing sales expectations. Teva adjusted its 2025 sales guidance and EPS range, citing minimal impact from U.S. tariffs due to its substantial U.S. manufacturing footprint. The company reaffirmed its 2027 targets, aiming for a 30% adjusted operating margin through cost savings and branded drug growth. Teva anticipates $700 million in net cost savings by 2027. The market share of its branded drugs, Austedo and Ajovy, continues to grow, with significant sales increases in 2024 and the first quarter of 2025. The positive outlook on tariffs and earnings has impressed investors, contributing to the stocks recent rise.
Customers
growth-positive
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
Teva Pharmaceutical Industries Ltd. announced that its executive management team will present at two upcoming investor conferences in June 2025. The conferences include the Jefferies Global Healthcare Conference and the Goldman Sachs 46th Annual Global Healthcare Conference. Teva is a global pharmaceutical leader, focusing on innovation and delivering medicines worldwide. The company is committed to expanding its innovative and biosimilar medicines pipeline and commercializing its portfolio. The article highlights Tevas strategic focus on growth and innovation, as well as its commitment to addressing patient needs. The presentations may contain forward-looking statements, which are subject to risks and uncertainties.
growth-positive
Regulatory Shake-Up Led to the Sell Off in Teva Pharmaceutical Industries Limited (TEVA)
Sound Shore Management, an investment firm, highlighted Teva Pharmaceutical Industries Limited in its Q1 2025 investor letter. Despite regulatory challenges impacting the healthcare sector, Tevas focus on execution and pipeline development under new leadership has led to improved margins and positive clinical trial results. The company, which specializes in generic and specialty drugs, reported a 2% revenue increase to $3.9 billion in Q1 2025. Tevas stock, which closed at $16.96 with a market cap of $19.45 billion, saw a one-month return of 14.06%. Sound Shore Management added to its position in Teva due to its attractive valuation and potential for growth.
Management ChangesProduct Stage
growth-positive
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
Teva Pharmaceutical Industries Ltd. announced an increase in the maximum tender amount of its tender offer from $2.0 billion to approximately $2.25 billion. The company is offering to purchase various senior notes, including sustainability-linked notes, with increased pool tender caps for certain notes. This move is part of Tevas strategy to manage its debt effectively. Additionally, Teva successfully priced a concurrent offering of approximately $2.3 billion in senior notes, which was an upsize from the initially announced $2.0 billion. The settlement of these notes is expected around May 28, 2025, and will satisfy the financing condition for the tender offer.
PIPE/PO
growth-positive
Teva Pharmaceutical Industries (NYSE:TEVA) Upsizes Senior Notes Offering to US$2.3 Billion
Teva Pharmaceutical Industries has recently upsized its senior notes offering to approximately $2.3 billion, a strategic move aimed at managing its debt obligations. This financial maneuver, part of Tevas broader Pivot to Growth strategy, has contributed to a 23% increase in its share price over the past month. The companys financial recovery is further highlighted by a net income shift to $214 million in its first-quarter results, boosting investor confidence. Analysts expect a 2.6% annual revenue growth and a move to profitability over the next three years. Despite underperforming the US Pharmaceuticals industry over the past year, Tevas strategic steps are seen as fortifying its market position, with a potential 30.4% increase in share price.
PIPE/PO
growth-positive
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
Teva Pharmaceutical Industries Ltd has received a credit rating upgrade from Fitch Ratings, moving from BB to BB+ with a stable outlook. This upgrade is attributed to Tevas efforts in reducing debt, improving financial flexibility, and expected continuous revenue growth from its products AUSTEDO and AJOVY, as well as its biosimilar pipeline. The company is also focusing on optimizing external spend and modernizing its organization to enhance operating margins. This marks the second consecutive upgrade for Teva, following a recent upgrade from Moody’s. The upgrades are seen as endorsements of Tevas Pivot to Growth strategy and its commitment to financial discipline and operational efficiency.
growth-positive
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
Teva Pharmaceutical Industries Ltd announced the successful upsizing and pricing of its senior notes offering, raising approximately $2.3 billion. The offering was increased from the initially planned $2 billion. The proceeds will be used to fund tender offers for various senior notes, pay related fees, and potentially repay outstanding debt. The notes, issued by Tevas subsidiaries, are unsecured senior obligations guaranteed by Teva. The settlement is expected around May 28, 2025, and will satisfy the financing condition for the tender offer. The offering was made under an automatic shelf registration statement filed with the SEC.
PIPE/PO
growth-positive
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
Teva Pharmaceutical Industries Ltd announced its intention to issue $2 billion in senior notes through its special purpose finance subsidiaries. The proceeds from this offering will be used to fund tender offers for existing notes and repay outstanding debt. The offering is subject to market conditions and will be made under an effective automatic shelf registration statement filed with the SEC. The notes will be unsecured senior obligations and guaranteed by Teva. The offering involves several financial institutions, including BNP Paribas, BofA Securities, HSBC, Intesa Sanpaolo, and J.P. Morgan. This move is seen as growth-positive for Teva as it aims to manage its debt effectively.
PIPE/PO
growth-negative
The Israeli pharmaceutical company's debt at the end of the first quarter of 2025 was $16.7 billion, after the company repaid $1.4 billion in debt during the quarter.
Teva Pharmaceutical Industries Ltd. is managing its substantial debt, which stood at $16.7 billion at the end of Q1 2025, by recycling $2 billion in debt to repay bondholders. The company plans to lay off 3,000 employees and has received FDA approval for a biosimilar. Moodys recently upgraded Tevas debt rating from Ba2 to Ba1, approaching investment grade. Tevas debt largely stems from its $40 billion acquisition of Actavis in 2016, which has not met expectations. The company is addressing upcoming debt maturities in 2026 and 2027 through these financial maneuvers.
LayoffsFDA approval
growth-positive
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
Teva Pharmaceutical Industries Ltd announced the commencement of tender offers to purchase up to $2 billion of various series of notes issued by its finance subsidiaries. The initiative aims to manage and optimize Tevas debt capital structure and extend the maturity profile of its debt. The company plans to fund these offers with proceeds from a concurrent financing transaction and cash on hand. This strategic move is expected to be growth-positive as it focuses on improving financial stability and sustainability. The offers are subject to terms and conditions outlined in the Offer to Purchase document.
growth-positive
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
Teva Pharmaceutical Industries Ltd announced that Moodys Investor Services has upgraded its corporate credit rating from Ba2 to Ba1 with a stable outlook. This upgrade reflects Tevas significant global scale, growth in branded franchises, stabilization of its generics business, and focus on debt reduction and resolving legal liabilities. The improved credit rating is expected to lower Tevas cost of debt and enhance its access to a broader investor base. The company continues to execute its Pivot to Growth strategy, focusing on expanding its innovative and biosimilar medicines pipeline and sustaining its generic medicines portfolio.
growth-positive
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Teva Pharmaceutical Industries Limited is experiencing a significant transformation, marked by its ninth consecutive quarter of revenue growth. The company reported a 2% year-over-year revenue increase to $3.89 billion and an adjusted EPS of $0.52, surpassing expectations. Under CEO Richard Francis, Teva is shifting towards innovation, with products like Austedo, Ajovy, and Uzedy showing substantial growth. The company is also focusing on cost-cutting, aiming to reduce costs by $700 million by 2027, partly through AI adoption and an 8% reduction in global headcount. Tevas strategy includes expanding its generics pipeline and maintaining financial discipline to reduce its net debt-to-EBITDA ratio. The article presents Teva as a compelling investment opportunity with potential upside.
Product StageLayoffs
growth-positive
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Teva Pharmaceutical Industries Limited, headquartered in Tel Aviv, Israel, is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs. The company plans to separate its API unit into a standalone business through a sale. Teva holds a Zacks Rank #3 (Hold) with a Value Style Score of A and a VGM Score of B. The companys shares are trading at a forward P/E of 6.6X, which is lower than the industry average. Analysts have revised their earnings estimates upwards, and the Zacks Consensus Estimate has increased to $2.56 per share for fiscal 2025. The article suggests that investors should consider Teva for their portfolios due to its solid rankings and valuation metrics.
growth-positive
Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying
The article discusses the performance of Teva Pharmaceutical Industries Limited in the context of small-cap healthcare stocks that hedge funds are buying. The U.S. healthcare sector has shown strong performance in 2025, rebounding from previous years of weak performance. As inflation eases, the sector is expected to benefit from a more favorable economic environment, with lower inflation and interest rates enhancing growth and profitability. The healthcare market is projected to grow significantly, with digital transformation and innovation in biosimilars and specialty drugs driving this growth. However, tariffs remain a challenge, potentially increasing costs for drugs and medical devices.
growth-positive
Teva's 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
Teva Pharmaceutical Industries Ltd. has made significant progress in its sustainability efforts, as detailed in its 2024 Healthy Future Report. The company surpassed its target of reducing absolute scope 1 and 2 greenhouse gas emissions by achieving a 29% reduction from 2019 levels, ahead of its 2025 goal. Teva also launched two new programs to improve global access to medicines, bringing the total to nine programs, surpassing its target of eight by 2025. These initiatives have resulted in substantial savings for healthcare systems and have strengthened health systems and capacity building. Additionally, Teva has improved its sustainability scores from rating organizations and has ensured responsible sourcing practices through rigorous supplier evaluations.
growth-positive
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
Teva Pharmaceutical Industries experienced a significant boost in its share price, rising nearly 6%, following a recommendation upgrade from JPMorgan Chase analyst Chris Schott. Schott raised his rating from neutral to overweight, citing Tevas cost-cutting measures and promising branded products as key factors. The companys $700 million cost-cutting initiative is expected to help achieve a 30% operating margin by 2027, while branded drugs like Austedo, Olanzapine, and Duvakitug are anticipated to drive future growth. Analysts forecast a steady increase in revenue and net income over the coming years, reinforcing a positive outlook for Teva.
growth-negative
Teva's Bold $700M Gamble: Will It Be Enough to Rescue Its Plummeting Stock?
JP Morgan analysts have upgraded Teva Pharmaceuticals stock to Overweight, raising the price target to $23, following Tevas announcement of a $700 million cost-cutting program. This initiative aims to offset the anticipated revenue drop from gRevlimid while investing in its pipeline. Despite a 20% stock drop year-to-date, some analysts see potential for Teva to achieve its 30% operating margin target by 2027. However, skepticism remains about Tevas ability to execute its cost-cutting plan effectively. The market is reassessing the stocks potential upside, but Tevas ability to meet margin targets without sacrificing growth remains uncertain.
Product StageInvestment
growth-positive
Teva Pharmaceutical Industries Limited (TEVA): Among Billionaire Larry Robbins’ Stock Picks with Huge Upside Potential
The article discusses Larry Robbins, a prominent hedge fund manager, and his firm Glenview Capital Management. The firm has shown significant growth, with its flagship fund performing well in 2024. Robbins has diversified his investments away from a heavy concentration in healthcare stocks, expanding into the tech sector and other industries. Teva Pharmaceutical Industries Limited is highlighted as one of Robbins stock picks with significant upside potential. Glenview Capital Management manages $5.6 billion in assets and has a strong focus on straightforward investment strategies. The firms recent performance indicates a positive outlook for its investments, including Teva.
growth-positive
TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up
Teva Pharmaceutical Industries reported first-quarter 2025 adjusted earnings of 52 cents per share, surpassing the Zacks Consensus Estimate. Revenues for the quarter were $3.89 billion, slightly below expectations but up 2% from the previous year. The growth was driven by increased sales of generic and branded drugs, including Austedo, Ajovy, and Uzedy. Tevas biosimilar portfolio, featuring products like Simlandi and Selarsdi, is expanding under strategic partnerships with Alvotech and Samsung Bioepis. The company plans to launch additional biosimilars between 2025 and 2027, pending FDA approval. The strategic partnerships and product launches indicate a positive growth trajectory for Teva.
Product StagePartnersCustomers
growth-positive
Why Teva Pharmaceutical Industries Limited (TEVA) Skyrocketed On Wednesday
Teva Pharmaceutical Industries Limited saw its stock price rise by 9.18% on Wednesday, closing at $17.60 per share. This increase was driven by the companys strong earnings performance, marking its ninth consecutive quarter of impressive revenue growth. Teva reported a 2% increase in revenues for the first quarter of the year, reaching $3.89 billion, largely due to contributions from its US operations and generic product sales. The company also swung to a net income of $214 million, compared to a $139 million net loss the previous year. Tevas outlook remains optimistic, with expectations of minimal impact from US tariffs and projected revenues between $16.8 billion and $17.2 billion for 2025.
CustomersPartners
growth-positive
Teva Pharmaceutical Industries (NYSE:TEVA) Settles Class-Action Lawsuit For US$2 Million
Teva Pharmaceutical Industries recently agreed to a $2.25 million settlement in a class-action lawsuit concerning Effexor XR®. This legal resolution, while not directly impacting the companys product lines or operations, contributed to a 26% increase in Tevas stock price over the past month. The settlement, combined with a positive market environment, bolstered investor confidence. Despite negative earnings, Tevas stock has outperformed the US market and the pharmaceuticals industry over the past year, suggesting potential for sustained growth. However, future revenue and earnings improvements are crucial for aligning with optimistic forecasts.
growth-positive
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2025 Earnings Call Highlights: Strong Growth in ...
Teva Pharmaceutical Industries Ltd reported a 5% increase in revenue to $3.9 billion, marking its ninth consecutive quarter of growth. The company is transitioning from a generics powerhouse to a leading biopharmaceutical company, with strong performance from innovative brands like AUSTEDO, AJOVY, and UZEDY. Tevas biosimilar business is expanding with new product launches in the US. Despite challenges such as potential US tariffs and a revenue cliff from Generic Revlimid in 2026, Teva is focused on achieving a 30% operating margin by 2027 through cost optimization and strategic capital allocation. The company faces increased net debt due to cash distribution related to the Japan business closure.
Product StageCustomers
growth-positive
Teva Pharmaceutical Industries First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Teva Pharmaceutical Industries reported a revenue of US$3.89 billion, marking a 1.9% increase from the previous quarter. The company achieved a net income of US$214.0 million, a significant improvement from a US$139.0 million loss in the prior quarter. The profit margin rose to 5.5%, and earnings per share (EPS) increased to US$0.19. Despite missing revenue estimates by 2.4%, EPS exceeded expectations. The companys shares have risen by 13% over the past week. Revenue is projected to grow at an average of 3.5% annually over the next three years, compared to an 8.3% growth forecast for the US pharmaceuticals industry.
growth-positive
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
Teva Pharmaceutical Industries Ltd announced it will host an Innovation & Strategy Day on May 29, 2025, in New York. The event will focus on the acceleration phase of its strategy and portfolio priorities, emphasizing growth and innovation. Tevas President and CEO, Richard Francis, along with other executives, will provide updates on the companys strategic direction. The event is invitation-only for in-person attendance, but a live webcast will be available for analysts and institutional investors. Teva is a global biopharmaceutical leader, committed to delivering medicines worldwide, with a focus on generics and biologics. The announcement includes forward-looking statements subject to risks and uncertainties.
growth-negative
Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say
Teva Pharmaceutical Industries Ltd. reported a revenue of $3.89 billion for the quarter ended March 2025, marking a 1.9% year-over-year increase. However, this was a 1.92% shortfall from the Zacks Consensus Estimate of $3.97 billion. The companys EPS was $0.52, exceeding the consensus estimate of $0.47 by 10.64%. Despite some positive earnings surprises, the overall financial performance was mixed, with several geographic and product-specific revenues falling short of analyst expectations. The U.S. market showed a 10.7% year-over-year growth, while other regions and product lines experienced declines. This mixed performance suggests a growth-negative impact on the company.
growth-positive
Teva Pharm first-quarter profit rise tops estimates
Teva Pharmaceutical Industries, the worlds largest generic drugmaker, reported a stronger-than-expected rise in first-quarter profit, driven by robust sales of its branded drugs for migraines, Huntingtons disease, and schizophrenia. The company earned 52 cents per diluted share, excluding one-time items, surpassing analysts expectations of 46 cents per share. Revenue increased by 2% to $3.89 billion, slightly below the forecasted $3.99 billion. Despite confirmed U.S. tariffs, Teva anticipates minimal financial impact. The results indicate a positive financial performance for the Israel-based company.
growth-positive
Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says
Teva, a pharmaceutical company, reported first-quarter earnings that exceeded expectations and subsequently raised its full-year guidance. The companys CEO stated that Teva would increase the prices of its generic drugs if tariffs are imposed by the Trump administration. This announcement comes as part of Tevas strategy to navigate potential economic challenges posed by international trade policies. The companys strong earnings performance and optimistic guidance suggest a positive growth outlook, despite the potential for increased drug prices due to tariff implications.
growth-positive
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
Teva Pharmaceutical Industries Ltd reported a strong financial performance for Q1 2025, with revenues of $3.9 billion, marking a 5% increase. The company is on track to achieve a 30% operating profit margin by 2027 as part of its Pivot to Growth Strategy. Key products like AUSTEDO® and AJOVY® showed significant revenue growth, and the generics business expanded across all regions. Teva is preparing for a Phase 3 initiation of Duvakitug (Anti-TL1A) and an FDA NDA submission for olanzapine LAI in H2 2025. The company aims to transform into a modern biopharmaceutical entity, targeting $700 million in net savings. The financial outlook for 2025 has been revised upwards, excluding the impact of the Japan BV divestiture.
Product StageCustomers
growth-positive
Why Teva Pharmaceutical Stock Is Soaring Today
Teva Pharmaceuticals shares surged by 9.2% following the release of strong Q1 earnings and an upward revision of its full-year profit guidance. Despite missing revenue expectations, the company reported an adjusted EPS of $0.52, surpassing Wall Streets target. The companys margins improved, driven by higher-margin specialty drugs like Austedo, which saw a 39% increase in revenue. Teva raised its fiscal 2025 EPS guidance, signaling confidence in its growth strategy. CEO Richard Francis highlighted the companys focus on innovative growth and operational efficiency as part of its Pivot to Growth Strategy.
Product StageCustomers
growth-positive
Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter Report
Tevas stock experienced a surge following the companys announcement of an increased profit outlook for 2025, despite a mixed first-quarter report and a reduction in its sales forecast. The positive reaction in the stock market indicates investor confidence in Tevas future profitability, even as the company adjusts its sales expectations. This development highlights the significance of profit guidance in influencing market perceptions and stock performance.
growth-positive
FDA approves Selarsdi injection as interchangeable with Stelara
Teva Pharmaceuticals and Alvotech have announced that the FDA has approved their biosimilar, Selarsdi (ustekinumab-aekn), as interchangeable with the reference biologic Stelara. This approval allows Selarsdi to be used for treating conditions such as psoriatic arthritis, plaque psoriasis, ulcerative colitis, and Crohn’s disease. The companies have developed two biosimilars that have gained US regulatory approval with interchangeability. Alvotech developed and produces Selarsdi, and the strategic partnership with Teva, initiated in 2020, focuses on the commercialization of biosimilar products. The partnership expanded in 2023 to include additional biosimilars. The approval is a significant step for Teva and Alvotech in establishing a leadership position in the biosimilars market.
Product StagePartners
growth-positive
Q1 2025 Corcept Therapeutics Inc Earnings Call
Corcept Therapeutics Inc reported its financial results for the first quarter of 2025, showing revenue of $157.2 million, up from $146.8 million the previous year. The company is experiencing rapid growth in its patient base, driven by increased screening and treatment for hypercortisolism. Despite challenges with pharmacy operations and a transition to authorized generic tablets, Corcept remains confident in its growth prospects. The company plans to expand its sales force and anticipates significant revenue from its new medication, Relacorilant, expected to generate $3 billion to $5 billion annually. The company is focused on educating physicians and patients about hypercortisolism.
CustomersProduct Stage
growth-negative
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q1 Earnings
Teva Pharmaceutical Industries Ltd. is expected to report quarterly earnings of $0.47 per share, a 2.1% decline from the previous year. However, revenues are forecasted to increase by 3.9% to $3.97 billion. Analysts have revised the consensus EPS estimate upwards by 1.6% over the past 30 days. The report highlights various revenue projections, including a 14.2% decline in COPAXONE revenue and a 10% decrease in API sales to third parties. Despite these declines, the companys U.S. geographic revenue is expected to rise by 8.5%. The report suggests a mixed outlook for Teva, with some areas showing growth while others face declines.
growth-positive
Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy?
Teva Pharmaceutical Industries Limited, a global pharmaceutical company headquartered in Tel Aviv, Israel, is recognized for its development, manufacturing, and marketing of branded and generic drugs, including biosimilars and over-the-counter products. The company plans to separate its Active Pharmaceutical Ingredients (API) unit into a standalone business through a sale. Teva is currently rated as a Zacks Rank #3 (Hold) stock, with a Momentum Style Score of B and a VGM Score of A. The stock has shown significant growth, with shares up 8.9% over the past week and 17.3% over the past four weeks. Analysts have revised their earnings estimates higher for fiscal 2025, indicating a positive outlook for the company.
growth-positive
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
Teva Pharmaceutical Industries Ltd, in partnership with Alvotech, has received FDA approval for SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara®. This approval, effective April 30, 2025, allows SELARSDI to be used for treating conditions such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. The approval is expected to enhance patient access to affordable treatment options and reduce healthcare costs. Tevas launch of SELARSDI and another biosimilar, EPYSQLI, positions the company for growth in the biosimilars market. Alvotech is also expanding its portfolio with additional biosimilar candidates under FDA review.
Product StagePartners
growth-positive
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Teva Pharmaceutical Industries Limited, headquartered in Tel Aviv, Israel, is a global pharmaceutical company involved in developing, manufacturing, and marketing branded and generic drugs, including biosimilars and over-the-counter products. The company plans to separate its Active Pharmaceutical Ingredients (API) unit into a standalone business. Teva has a strong Value Style Score of A and a VGM Score of A, with a Zacks Rank #3 (Hold) rating. The companys shares are trading at a forward earnings multiple of 5.8X, and analysts have revised their earnings estimates upwards for fiscal 2025. The Zacks Consensus Estimate has increased to $2.55 per share. Tevas impressive earnings and valuation fundamentals make it a strong candidate for investors.
growth-positive
Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now
The article discusses the impact of President Trumps tariff policy on the stock market, highlighting the volatility it has caused. Despite the uncertainty, it presents a golden opportunity for long-term investors to buy stocks at attractive prices. Verizon Communications is identified as a strong investment due to its stable cash flow from wireless and broadband services, and its expansion into 5G technology. The article also mentions Teva Pharmaceutical Industries and Mastercard as other promising investment opportunities. Teva is recovering from past challenges and focusing on novel-drug development, while Mastercard benefits from its global payment processing operations.
growth-negative
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals
The article discusses the challenges faced by generic drugmakers, including Dr. Reddy’s Laboratories, Sandoz, and Teva Pharmaceuticals, due to potential tariffs on pharmaceutical imports announced by Trump. These tariffs could impact profitability as these companies rely on overseas production. In response, these companies are focusing on being the first to market their generic drugs to gain market exclusivity and are implementing cost optimization strategies to improve margins. The generic drug industry is characterized by stiff competition and thin margins, with companies relying on the loss of patent exclusivity of branded drugs to apply for FDA approval of generic versions.
growth-negative
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes
The pharmaceutical industry is facing uncertainty due to potential tariffs on pharmaceutical imports announced by Trump, which could impact generic drugmakers like Dr. Reddy’s Laboratories, Sandoz, and Teva Pharmaceuticals. These companies, which operate on tight margins, may see further profitability squeezes if tariffs are implemented. In response, they are focusing on being the first to market their generic drugs to gain temporary market exclusivity and are implementing cost optimization strategies to improve margins. The generic drugs industry is characterized by competition and thin margins, with companies relying on the loss of patent exclusivity of branded drugs to introduce cheaper generic versions.
growth-positive
5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility
The article discusses the investment strategies of prominent asset managers during a period of stock market volatility. It highlights investments in companies like Philip Morris International, Teva Pharmaceutical Industries, Sirius XM Holdings, Elevance Health, and American Tower. Teva Pharmaceutical Industries, in particular, has seen significant investment from Stanley Druckenmiller, who purchased over 7.5 million shares. The company is focusing on novel-drug development, which offers higher margins compared to generic drugs. Tevas financial flexibility has improved significantly, reducing its net debt from $35 billion to $14.5 billion. The article emphasizes the defensive nature of healthcare stocks and the strategic shift towards higher-margin products.
Investment
growth-positive
Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn
The article discusses the positioning of Teva Pharmaceutical Industries Limited among top healthcare stocks recommended by billionaire David Einhorn. Amidst a market downturn triggered by trade war fears and inflation concerns, healthcare stocks are seen as a defensive investment. Despite a general decline in equity markets, healthcare stocks have shown resilience, with a smaller decline compared to the S&P 500. The article highlights the potential of healthcare stocks to perform well in recessionary conditions, as demand for healthcare services remains stable. Teva Pharmaceutical is positioned as a favorable investment in this context.
growth-positive
Teva Pharmaceutical Industries (NYSE:TEVA) Pops As FDA Expands AJOVY'S Use For Pediatric Migraine Prevention
Teva Pharmaceutical Industries has received FDA acceptance for its supplemental Biologics License Application to expand the use of AJOVY® for preventing migraines in pediatric patients. This development is seen as a positive step that could enhance market potential and revenue growth, particularly in the pediatric segment. Despite this, Tevas share price has declined by 11% over the past week, aligning with a broader market downturn. However, analysts remain optimistic about Tevas future, forecasting profitability over the next three years and noting that the stock trades at a discount to the consensus price target. The article highlights Tevas resilience compared to broader market trends.
Product Stage
growth-positive
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Teva Pharmaceutical Industries Limited is experiencing a positive shift, with a focus on structural improvement and operational discipline. Despite past underperformance and litigation issues, the company is poised for growth, driven by a robust CNS-focused branded portfolio and a promising pipeline. Teva plans a $750 million cost optimization program to counter the expected revenue loss from Revlimids exclusivity expiration. The company projects significant financial growth, with revenue expected to rise to $17.3 billion in 2025 and EBIT margins climbing to 31.4% by 2029. The resolution of litigation risk and a favorable product mix shift further support Tevas potential for re-rating, with an estimated intrinsic value of $36.51.
Product StageCustomersInvestment
growth-positive
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
Teva Pharmaceutical Industries Ltd, in partnership with Samsung Bioepis Co., Ltd., has launched EPYSQLI® (eculizumab-aagh) in the U.S. market. This biosimilar to Soliris® is intended for treating rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. EPYSQLI is offered at a 30% discount compared to the reference product, making it a cost-effective option for patients. The strategic partnership, formed in January 2025, aims to expand access to affordable treatment options for rare disease patients, leveraging Tevas commercialization capabilities. The launch is expected to positively impact Tevas growth by expanding its biosimilars portfolio and enhancing its market presence in the U.S.
Product StagePartners
growth-positive
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
Teva Pharmaceutical Industries Ltd announced that the FDA has accepted its supplemental Biologics License Application for AJOVY, aiming to expand its indication for preventing episodic migraines in children and adolescents. If approved, AJOVY would become the first CGRP antagonist for both adult and pediatric migraine prevention, addressing a significant unmet need. The application is based on positive Phase 3 trial results showing AJOVYs efficacy and safety in reducing migraine days in pediatric patients. AJOVY is already approved for adult migraine prevention in the U.S., Europe, and other markets. This development highlights Tevas commitment to expanding access to innovative treatments for diverse patient populations.
Product Stage
growth-positive
Teva announces presentation of survey study on TEV-‘749
Teva Pharmaceuticals announced positive feedback from a survey study related to their Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study for TEV-‘749. The survey, presented at the 2025 Congress of the Schizophrenia International Research Society, showed high satisfaction rates among patients, nurses, and physicians regarding the treatments initiation regimen, monthly dosing schedule, and dosing options. This feedback is seen as encouraging for the treatment of schizophrenia, a complex mental health condition. The article also mentions FDA acceptance of a supplemental New Drug Application (sNDA) for another Teva product, Uzedy, in partnership with Medincell. Overall, the developments are seen as positive for Tevas growth prospects.
Product Stage
growth-negative
Is Teva Pharmaceutical Industries (TEVA) the Most Undervalued Healthcare Stock to Buy According to Analysts?
The article discusses the impact of tariffs on the healthcare industry, with a focus on Teva Pharmaceutical Industries Limited. As healthcare spending in the US rises, tariffs on Chinese goods and services could further complicate the market. China plays a crucial role in contract production and research for US healthcare companies, making it difficult to move operations back to the US due to infrastructure limitations. The article highlights the challenges faced by healthcare companies like Teva in managing costs and operations amid these tariffs, which could negatively impact growth.
growth-positive
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
Teva Pharmaceutical Industries Ltd announced positive feedback from the Phase 3 SOLARIS trial evaluating TEV-749, a long-acting injectable formulation of olanzapine for schizophrenia treatment. The survey showed high satisfaction rates among patients, nurses, and physicians regarding the initiation regimen, dosing schedule, and overall experience with TEV-749. The data were presented at the 2025 Congress of the Schizophrenia International Research Society. Tevas commitment to advancing schizophrenia treatment is evident through its innovative drug delivery technology, aiming to address Post-Injection Delirium/Sedation Syndrome (PDSS) risks. This development highlights Tevas focus on patient-centric research and treatment optimization.
Product Stage
growth-negative
These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now
Teva Pharmaceutical has experienced a 27% decline in its stock price in early 2025, primarily due to disappointing guidance for the year, despite slightly beating revenue and earnings expectations in its fourth-quarter report. The company is in a return to growth phase, aiming to accelerate growth from 2025 to 2027 by focusing on generics, expanding margins, and launching innovative products. Despite the current downturn, Tevas low valuation suggests potential upside if management achieves its goals. The article also discusses the performance of Block and Nextdoor, highlighting challenges and opportunities for each.
growth-negative
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
Teva Pharmaceutical Industries Ltd announced that it will release its first quarter 2025 financial results on May 7, 2025. A conference call and live webcast will follow the release. The company, a global leader in biopharmaceuticals, is committed to delivering medicines worldwide, focusing on generics and biologics. The press release includes forward-looking statements, highlighting risks such as market competition, significant indebtedness, and regulatory issues. These factors could impact Tevas future performance, as outlined in their Annual Report. The company advises caution regarding these statements, emphasizing the uncertainties involved.
growth-positive
Teva Releases Q1 2025 Aide Memoire
Teva Pharmaceutical Industries Ltd announced the availability of its Q1 2025 Aide Memoire, aimed at assisting in the financial modeling of its quarterly results. The document reflects Tevas prior results and managements outlook, and will be provided quarterly. Teva, a global biopharmaceutical leader, is committed to delivering medicines worldwide, with a focus on generics and biologics. The company emphasizes its dedication to advancing health and addressing patient needs. The press release contains forward-looking statements, highlighting potential risks and uncertainties that could impact future performance.
growth-negative
Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks
The article discusses Stanley Druckenmillers strategic shift at Duquesne Family Office, where he has sold off significant holdings in AI giants Palantir and Nvidia due to valuation concerns and potential market bubble risks. Instead, Druckenmiller is investing in turnaround stocks like Philip Morris International, Warner Bros. Discovery, and Teva Pharmaceutical Industries. These companies are seen as having strong potential for recovery and growth due to strategic changes and market positioning. The article highlights Druckenmillers focus on short-term price dislocations and his preference for companies with strong competitive advantages and potential for long-term growth.
Investment
growth-negative
Was Jim Cramer Right About Teva Pharmaceutical Industries (TEVA)?
The article discusses the performance of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the context of stocks mentioned by Jim Cramer a year ago. Cramer advises monitoring the Federal Reserve meeting and earnings reports, emphasizing the importance of the housing market in preventing a recession. He warns of potential new tariffs on imported vehicles, which could impact the market. The article also highlights the influence of the White House and Federal Reserve actions on market direction. The performance of 23 stocks, including Teva, is analyzed based on hedge fund sentiment and market performance over the past year.
growth-positive
Teva Pharmaceutical Stock Scores RS Rating Upgrade
Teva Pharmaceutical has received an upgrade in its IBD Relative Strength Rating, indicating an improvement in its stock price performance. This upgrade is a positive signal for the company, suggesting that its stock is performing better relative to other stocks. The article does not mention any new partnerships, acquisitions, or investments, nor does it discuss any changes in management or layoffs. The focus is primarily on the stock performance and the upgrade in the rating, which is likely to have a growth-positive impact on the companys market perception.
growth-positive
Teva Pharmaceutical Industries (NYSE:TEVA) Sees 14% Stock Price Rise With FDA Acceptance Of New Drug Application
Teva Pharmaceutical Industries experienced a 14% increase in stock price, driven by recent regulatory achievements, including the FDAs acceptance of a Supplemental New Drug Application for UZEDY. The company is also focusing on biosimilars, such as AVT06, to expand its therapeutic portfolio. Despite broader market declines, Tevas advancements have fostered investor optimism. The company resolved significant legal challenges in 2023, including a $225 million fine for price-fixing and a $750 million settlement with the Israel Tax Authority. These resolutions have allowed Teva to refocus on its core businesses. A partnership with Alvotech for U.S. commercialization of biosimilars further supports its growth strategy.
Product StagePartnersFDA approved/pending approval
growth-positive
Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma
Teva Hong Kong has formed a strategic partnership with Kerry Pharma, a subsidiary of Kerry Logistics Network Ltd, to enhance its pharmaceutical distribution system in Hong Kong, Macau, and the Greater Bay Area. This collaboration aims to improve the stability and efficiency of Tevas medicine supply chain by leveraging Kerry Pharmas extensive logistics capabilities. The partnership will establish a distribution network covering over 3,000 delivery points, including hospitals and pharmacies, ensuring operational efficiency and swift market responsiveness. This initiative aligns with Tevas global Pivot to Growth strategy, focusing on improving patient access to medicines and promoting medical integration and innovation in the region.
Partners
growth-negative
Teva debuts global campaign encouraging people to get outside
Teva, a sport sandal footwear brand, has launched a new campaign called For Playground Earth to revitalize its brand and encourage outdoor exploration. Despite the parent company Deckers overall sales growth, Tevas sales have declined by 6% in the third quarter. The campaign aims to attract a new generation of customers by introducing new hiking, trail running, and water shoes. Teva has also established the Bureau of Adventure to involve ambassadors and athletes in testing new products. The company is focusing on its performance roots to expand its customer base. Recent changes at Deckers include appointing Stefano Caroti as CEO and selling the Sanuk brand.
CustomersManagement Changes
growth-positive
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
Teva Pharmaceutical Industries Ltd announced that its President and CEO, Richard Francis, will present at two upcoming investor conferences in March 2025. These conferences are the Barclays 27th Annual Global Healthcare Conference and the Leerink Partners Global Healthcare Conference. Teva is a global pharmaceutical leader known for its commitment to delivering medicines worldwide, including generics and biologics. The company is focused on expanding its innovative and biosimilar medicines pipeline as part of its Pivot to Growth strategy. The article also includes a cautionary note regarding forward-looking statements, highlighting potential risks and uncertainties that could affect future results.
growth-positive
Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025
Axsome Therapeutics, Inc. has seen significant stock growth in 2025, driven by a settlement with Teva Pharmaceuticals over patent litigation for AUVELITY, a treatment for major depressive disorder. This settlement prevents Teva from launching a generic version until at least 2038. Additionally, the FDA approved SYMBRAVO for treating migraines, further boosting the companys prospects. Positive Phase 3 clinical trials for Alzheimers and narcolepsy treatments also contribute to the companys growth. The stocks consensus price target suggests a 30.81% upside. Hedge funds have shown interest in Axsome, with 44 holders in Q4 2024.
Product StageCustomersFDA approved/pending approval
growth-positive
Is Teva Pharmaceuticals Industries Limited (TEVA) the Best Weight Loss Drug Stock to Buy According to Analysts?
The article discusses the potential growth opportunities for Teva Pharmaceuticals Industries Limited in the weight-loss drug market. With the global obesity epidemic, there is a significant demand for innovative weight-loss medications that do not require strict diets or exercise. The market for obesity drugs is expected to grow substantially, with predictions of reaching $105 billion by 2030. Semaglutide, a leading GLP-1 agonist, is highlighted as a major player in this market, with a significant portion of new prescriptions. The article suggests that the increasing demand for obesity medications will benefit the biotech industry, including companies like Teva Pharmaceuticals.
growth-positive
Teva targets schizophrenia to build on innovative medicines growth
Teva Pharmaceuticals is making strides in the schizophrenia treatment space with its drug Uzedy, which has achieved higher-than-expected revenue and received FDA approval. Uzedy, developed using technology licensed from Medincell, offers a long-acting subcutaneous form of risperidone, improving patient adherence. Teva is also advancing TEV-749, a long-acting form of olanzapine, which has shown positive late-stage results. The companys Pivot to Growth strategy, focusing on generics, biosimilars, branded drugs, and innovative medicines, has led to a 6% revenue increase. Tevas innovative medicines portfolio, including Austedo, is thriving, and the company is evaluating TEV-749s potential market impact. The stigma around schizophrenia highlights the importance of long-acting treatments.
Product StageFDA approvedPartners
growth-positive
Is Teva Pharmaceutical Industries Limited (TEVA) the Best Low Price Pharma Stock to Invest In Right Now?
The article discusses the position of Teva Pharmaceutical Industries Limited among other pharmaceutical stocks, highlighting the growth potential in the pharmaceutical industry. The global pharmaceutical manufacturing market is expected to grow significantly, driven by advancements in medical technology and the development of new treatments. The use of AI in drug development is seen as a game-changer, potentially reducing costs and accelerating processes. The article also notes the growing interest in GLP-1 medications for weight loss and other health issues, with companies like Roche investing heavily in this area. Teva is positioned to benefit from these industry trends.
growth-positive
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd, in collaboration with Direct Relief and the National Association of Free and Charitable Clinics (NAFC), announced a $2 million funding initiative as part of a $4 million commitment to expand mental health services across 10 states. This initiative, known as Community Routes, aims to address mental health needs in underserved communities by providing grants to clinics in Alabama, Mississippi, and Texas. The program has already impacted over 63,000 beneficiaries and trained more than 2,800 community members. The latest funding cycle focuses on integrating behavioral health services into clinical operations, emphasizing evidence-based screening tools and treatment protocols. This initiative highlights Tevas commitment to improving mental health care access and resilience in communities.
InvestmentPartners
growth-positive
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
Teva Pharmaceuticals, in partnership with Medincell, announced that the supplemental New Drug Application (sNDA) for UZEDY, an extended-release injectable suspension for the maintenance treatment of bipolar I disorder (BP-I) in adults, has been accepted for filing by the U.S. FDA. UZEDY is already approved in the U.S. for treating schizophrenia in adults. The acceptance of the sNDA filing is based on existing clinical data and previous FDA findings on risperidone formulations. Teva will lead the regulatory process and potential commercialization, while Medincell will receive royalties on net sales. This development highlights the potential of UZEDY as a long-acting treatment for BP-I, addressing unmet medical needs in the CNS field.
FDA approved/pending approvalPartners
growth-neutral
Teva Pharmaceutical Industries Limited (TEVA): Among Bourgeon Capital’s Top Stock Picks
The article discusses Bourgeon Capital Management LLC, an investment advisory firm, and its investment strategies, focusing on Teva Pharmaceutical Industries Limited among other stocks. Founded by John Aniblo Zaro, Bourgeon Capital specializes in actively managed accounts with a portfolio value of nearly $535.55 million by the end of December 2024. The firm is known for personalized investment strategies aimed at managing risk and achieving long-term growth. Zaros extensive background in investment management includes roles at Morgan Stanley Smith Barney LLC and J.P. Morgan Investment Management. Bourgeon Capital emphasizes a client-centric approach to wealth management, fostering strong relationships through strategic financial guidance.
growth-negative
Richard Francis said that the question is no longer whether Teva will survive but whether it can grow more.
Teva Pharmaceutical Industries Ltd. has faced a challenging market reaction following the release of its 2024 financial results, which led to a $6 billion reduction in its market capitalization. Despite positive financial outcomes, the companys profit guidance for 2025 disappointed investors. CEO Richard Francis, who took over in 2023, emphasizes a strategic focus on growth, particularly in branded drugs, and highlights eight consecutive quarters of growth. Teva is working on expanding its product portfolio, including the development of Duvakitug with Sanofi for ulcerative colitis and Crohns disease. The company is also addressing its debt, with $8.1 billion maturing in the next two years, and has filed a shelf prospectus for potential equity or debt issuance.
Management ChangesProduct Stage
growth-positive
Axsome secures top drug’s future with Teva patent settlement
Axsome Therapeutics announced a patent settlement with Teva Pharmaceuticals on February 10, 2025, which will prevent Tevas generic version of Axsomes top drug, Auvelity, from entering the U.S. market until at least 2038. This settlement is seen as a significant positive for Axsome, as it ensures continued market exclusivity for Auvelity, a major revenue driver for the company. The agreement also resolves ongoing litigation between the two companies and will be submitted for review by the Federal Trade Commission and the Department of Justice. The news led to a 23% increase in Axsomes share price, adding over $1 billion to its market value.
PartnersCustomers
growth-positive
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Axsome Therapeutics has resolved its patent litigation with Teva Pharmaceuticals over its depression drug, Auvelity. The settlement allows Teva to sell a generic version of Auvelity starting in 2038 or 2039, depending on pediatric exclusivity. Axsomes Auvelity is approved for major depressive disorder in the U.S. and has shown significant sales growth. The company also recently received FDA approval for Symbravo, a treatment for migraines. Analysts view Axsome positively, with William Blair naming it a top pick for 2025 and Needham maintaining a $133 price target. Axsome is seen as a potential acquisition target, especially after Johnson & Johnsons recent acquisition in the sector.
Product StageCustomersFDA approved/pending approval
growth-negative
The Israeli pharmaceutical company's debt fell to $17.8 billion at the end of 2024, down from $19.8 billion at the end of the 2023.
Teva Pharmaceutical Industries Ltd. has filed a shelf prospectus with the US SEC to potentially issue various securities, including ADSs and debt securities. The company aims to use any raised funds for general business purposes, working capital, and debt repayments. Tevas debt decreased to $17.8 billion by the end of 2024, aided by debt payments and favorable exchange rate fluctuations. Despite this, the company faces significant debt repayments in the coming years. Teva has not raised capital since its acquisition of Actavis in 2016, which contributed to its current debt situation. The article was published on February 9, 2025.
PIPE/PO
growth-positive
Israeli pharmaceutical giant eyes stock offering as part of its recovery plan.
Teva, an Israeli pharmaceutical company, is preparing for a stock offering as part of its recovery plan after a decade of financial crises. The company has filed a shelf prospectus with the SEC, indicating its intent to raise capital or debt over time. This move comes after Teva incurred significant debt from a failed acquisition in 2015. Despite repaying a substantial portion of this debt, Teva still owes $14.5 billion. Under CEO Richard Francis, the company is shifting its focus from operational efficiency to growth, resulting in improved business performance and credit ratings. Tevas stock has surged by 80% in 2024, and the company expects revenue growth and increased profitability.
PIPE/PO
growth-negative
Teva Pharmaceutical Industries Full Year 2024 Earnings: EPS Misses Expectations
Teva Pharmaceutical Industries reported a revenue of US$16.5 billion, marking a 4.4% increase from FY 2023. However, the company faced a significant net loss of US$1.64 billion, which widened by 193% compared to the previous fiscal year. The earnings per share (EPS) also deteriorated to a loss of US$1.45 per share from US$0.50 in FY 2023. Despite revenue being in line with analyst estimates, EPS missed expectations significantly. The companys shares have decreased by 3.1% over the past week. Looking forward, Tevas revenue is expected to grow at an average rate of 3.6% annually over the next three years, which is below the 8.6% growth forecast for the US Pharmaceuticals industry.
growth-negative
The company's 2025 guidance sent its share price tumbling, but analysts stress its investment in its innovative pipeline and debt reduction.
Teva Pharmaceutical Industries experienced a significant drop in its share price following the release of its quarterly and annual financials, which included guidance for 2025. The companys share price fell by 13.9% in one day and continued to decline, resulting in a market cap loss of over $4 billion. Despite the negative market reaction, analysts remain optimistic about Tevas long-term prospects due to its investment in innovative products and debt reduction efforts. The company is focusing on R&D and promoting original drugs like Austedo and Ajovy. Analysts from Bank of America, Piper Sandler, and Jefferies have maintained positive ratings, citing the companys attractive valuation and potential for growth.
Product StageInvestment
growth-positive
Teva Pharmaceutical Industries Ltd (TEVA) Q4 2024 Earnings Call Highlights: Strong Revenue ...
Teva Pharmaceutical Industries Ltd reported a 9% increase in revenue for 2024, reaching $16.5 billion, with strong performance across its innovative, generics, and API businesses. AUSTEDO and AJOVY sales showed significant growth, contributing to the companys consistent performance and progress in its Pivot to Growth strategy. Despite a GAAP operating loss in Q4 2024 due to a goodwill impairment charge, Tevas credit ratings improved, reflecting enhanced growth prospects. The company faces potential challenges from the Inflation Reduction Act and aims to grow EBITDA through strategic investments, including a partnership with Sanofi for the duvakitug program.
Product StagePartners
growth-positive
This Drug Stock Sits On A Strong Earnings Foundation As It Tests New Entry
The article discusses the strong earnings performance of TEVA, a pharmaceutical company, over the past 12 months. This performance has led to significant gains in its stock value, and the company is now testing a new buy point. The article highlights the positive financial foundation of TEVA, which is contributing to its growth potential in the market. Despite the fluctuations in stock prices, TEVAs robust earnings are seen as a positive indicator for investors considering entering the market.
growth-negative
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
Teva Pharmaceutical Industries reported a decline in adjusted earnings for the fourth quarter of 2024, with earnings per share at 71 cents, slightly above estimates but down 29% year over year. Revenues also fell by 5% compared to the previous year, mainly due to the absence of a $500 million upfront payment from Sanofi for a collaboration agreement. Despite this, the company saw growth in generic and branded drug sales, including Austedo, Ajovy, and Uzedy. Tevas biosimilar pipeline is progressing, with recent approvals and launches, and an FDA decision expected in 2025 for a new biosimilar candidate.
Product StagePartnersCustomers
growth-negative
Despite a strong 80% gain in 2024, Teva’s stock dropped after the company revealed disappointing profitability and cash flow forecasts.
Teva experienced an 80% stock gain in 2024, but its stock dropped by 14% after releasing a disappointing 2025 forecast. Under CEO Richard Francis, Teva is shifting focus to developing originator drugs, which are costly but potentially more profitable than generics. The company is still recovering from its $40 billion Actavis acquisition, with a net debt of $14.5 billion. Teva plans to increase R&D and marketing expenses to accelerate drug development, with promising drugs like Uzedy and Austedo showing growth. However, profitability and cash flow forecasts remain weak, impacting investor confidence. Tevas revenue for 2024 was $16.5 billion, with a 6% growth, but future growth is expected to be single-digit.
Product StageManagement ChangesCustomers
growth-negative
Why Teva Pharmaceuticals (TEVA) Crashed on Wednesday?
Teva Pharmaceutical Industries Limited experienced a significant decline in its stock price, dropping by 13.89% to $18.54, following the announcement of disappointing earnings guidance for 2025. Despite a 3.8% increase in revenues to $16.5 billion, driven by strong sales in medications for migraines, Huntington’s disease, and schizophrenia, the companys projected earnings per share fell short of analyst expectations. Teva remains committed to its Pivot to Growth strategy, focusing on generic medications and resuming R&D efforts in key drugs for ulcerative colitis and Crohn’s disease. The companys stock was among the worst performers on Wednesday, highlighting investor concerns over its future earnings potential.
Product StageCustomers
growth-negative
Teva Stock Dives 14%. 'We're Victims Of Our Own Success,' Says CEO.
Tevas stock dropped by 14% following the announcement of a decline in fourth-quarter revenue. The CEO attributed the downturn to the companys previous successes, suggesting that high expectations may have led to the negative market reaction. The article highlights the financial challenges Teva is facing despite its past achievements. This decline in stock value indicates a growth-negative impact on the company, as investors reacted unfavorably to the revenue report.
growth-negative
Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.
Teva ended 2024 with better-than-expected financial results, reporting $16.5 billion in revenue and adjusted earnings of $2.49 per share. However, the company provided a lower-than-expected forecast for 2025, projecting adjusted earnings of $2.35–2.65 per share and revenue of $16.8–17.4 billion. This outlook is below market expectations, leading to a growth-negative impact. Austedo is expected to be a key growth driver with projected revenue of $1.9–2.0 billion, while Ajovy and Uzedy are also anticipated to contribute to revenue growth. Despite the disappointing forecast, Tevas CEO Richard Francis highlighted the companys progress in generics and innovative products, as well as new product launches.
growth-positive
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
Teva Pharmaceutical Industries Ltd reported a successful year in 2024, with revenues reaching $16.5 billion, marking a 6% increase in local currency terms compared to 2023. The companys key products, AUSTEDO® and AJOVY®, exceeded revenue expectations, and its generics business saw significant growth across various markets. Tevas biosimilar pipeline is expanding, with 18 assets, including a biosimilar to Prolia® under regulatory review. The company announced positive Phase 2B results for its anti-TL1A asset, Duvakitug, and plans to initiate Phase 3 trials in 2025. Tevas partnership with Sanofi is expected to contribute to its growth strategy. The companys outlook for 2025 includes revenues of $16.8 - $17.4 billion and continued focus on its growth strategy.
Product StagePartnersCustomers
growth-negative
Teva Pharmaceutical Industries (TEVA) Reports Q4 Earnings: What Key Metrics Have to Say
Teva Pharmaceutical Industries Ltd. reported a revenue of $4.23 billion for the quarter ended December 2024, marking a 5.1% decline year-over-year. The earnings per share (EPS) for the same period was $0.71, down from $1.00 a year ago. Despite the decline, the revenue and EPS figures surpassed the Zacks Consensus Estimates, with revenue exceeding by 3.13% and EPS by 1.43%. The companys performance varied across different geographic regions and product categories, with notable changes in revenue from Europe and international markets. However, the U.S. market saw significant declines in certain product categories. Overall, the financial results indicate a challenging period for Teva, with mixed performance across its product lines and regions.
growth-positive
VF Corp, Corning, Teva: Trending stocks
The article discusses the latest earnings reports from Wall Street, highlighting VF Corps strong fiscal third-quarter results, which exceeded expectations on both the top and bottom lines. The apparel company also raised its full-year 2025 free cash flow forecast to $440 million, leading to a rise in its stock. Corning reported an 18% growth in core sales for its fiscal fourth quarter, driven by the successful integration of generative AI products. In contrast, Teva Pharmaceuticals stock fell due to its 2025 full-year adjusted EBITDA guidance falling short of expectations.
growth-negative
Why Teva Pharmaceutical Stock Is Sinking Today
Teva Pharmaceutical Industries experienced a significant drop in its stock price, falling by 13.5% following its earnings report. Despite reporting a revenue increase to $16.5 billion for fiscal year 2024, slightly exceeding expectations, the companys guidance for 2025 disappointed investors. The forecasted earnings per share (EPS) for 2025 was lower than expected, contributing to the negative market reaction. Teva is currently focusing on its Pivot to Growth strategy, which includes reorganization efforts, a focus on generics, and advancing its research and development pipeline. The company has promising drugs in later stages of trials, but success is not guaranteed.
Product Stage
growth-positive
Trump Media's Truth.Fi, T-Mobile, Teva: Market Minute
Trump Media & Technology is expanding into the financial services market, which has positively impacted its stock. The company has secured funding of up to $250 million, with Charles Schwab acting as the custodian. This expansion is expected to drive growth for the company. Meanwhile, T-Mobile has issued strong guidance based on its fourth-quarter earnings, expecting to add 5.5 to 6 million new paid subscribers by 2025. In contrast, Teva Pharmaceuticals stock is under pressure due to a softer-than-expected outlook. The article provides a snapshot of the latest market movements and company updates.
InvestmentExpand
growth-negative
The Israeli pharmaceuticals company reported strong fourth quarter results but its 2025 outlook did not meet expectations.
Teva Pharmaceutical Industries Ltd. reported strong financial results for the fourth quarter and full year 2024, with revenue and earnings surpassing expectations. However, the companys 2025 outlook disappointed analysts, leading to a nearly 10% drop in share price. Despite this, 2024 was a transformative year for Teva, marked by growth in its generics and innovative products, and significant progress in its early-stage pipeline, including positive Phase 2b results for the duvakitug asset. Teva plans to advance to Phase 3 trials for duvakitug in collaboration with Sanofi. The companys market cap reached $25 billion, making it Israels most valuable company.
Product StagePartners
growth-positive
Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript
Teva Pharmaceutical Industries reported strong financial performance for 2024, driven by its Pivot to Growth strategy. The company achieved significant growth across its innovative, generics, and API businesses, with key products like AUSTEDO, AJOVY, and UZEDY showing impressive sales increases. Tevas partnership with Sanofi, which included a $500 million upfront payment, contributed positively to its revenue. The company is focused on expanding its innovative pipeline, with several late-stage products in development. Teva aims to continue its growth trajectory into 2025, with plans to launch new biosimilars and improve operational efficiency.
Product StageCustomersPartnersInvestment
growth-positive
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
Alvotech, a global biotech company, announced that the FDA has accepted its Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®. This marks the first U.S. BLA filing acceptance for a biosimilar candidate to golimumab. The FDA review is expected to conclude in the fourth quarter of 2025. Alvotechs strategic partnership with Teva Pharmaceuticals, which began in 2020, focuses on the commercialization of biosimilars in the U.S. Alvotech handles development and manufacturing, while Teva manages commercialization. The partnership has expanded to include nine products. Recent clinical studies have shown positive results for AVT05, indicating its potential as a cost-effective treatment for inflammatory conditions.
Product StagePartners
growth-negative
FDA adds boxed warning to multiple sclerosis drugs after anaphylaxis cases
The FDA has issued a new boxed warning for glatiramer acetate, marketed as Copaxone by Teva Pharmaceutical and Glatopa by Sandoz, due to a rare but serious risk of anaphylaxis. This follows reports of six patient deaths and 82 cases of severe allergic reactions worldwide since 1996. The warning highlights the need for healthcare professionals to educate patients on recognizing symptoms of anaphylaxis. Neither Teva nor Sandoz has commented on the warning. Additionally, Teva was fined €462.6m by the European Commission for patent protection violations related to Copaxone.
growth-negative
Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, has announced the selection of 15 additional drugs for price negotiations under Medicare Part D. This is part of the Inflation Reduction Act, with negotiations set to occur in 2025 and new prices effective in 2027. Novo Nordisks drugs, including Ozempic, Rybelsus, and Wegovy, are among those selected. Companies have until February 28 to decide on participation in the negotiations. This development could impact the revenue of the involved pharmaceutical companies due to potential price reductions.
growth-negative
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations
The Centers for Medicare and Medicaid Services (CMS) announced a new list of 15 drugs under Medicare Part D for price negotiations, including Novo Nordisks GLP-1 drugs like Ozempic and Wegovy. This announcement led to a 4% drop in Novo Nordisks stock price. The negotiation aims to improve drug affordability for Medicare enrollees, as part of the Inflation Reduction Act. The inclusion of Novos drugs was anticipated and could affect market dynamics, particularly impacting Eli Lillys competitive portfolio. The future of this negotiation list is uncertain with the incoming Trump administration, which may alter the process.
growth-negative
Update: Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks
Novo Nordisks drugs, Ozempic and Wegovy, have been selected for US Medicare price negotiations. This development is part of a broader effort to reduce drug costs for Medicare beneficiaries. The inclusion of these drugs in price talks could potentially impact Novo Nordisks revenue and market strategy, as it may lead to reduced prices and profit margins. The article also mentions responses from other pharmaceutical companies like Bristol-Myers Squibb and Boehringer Ingelheim, indicating a wider industry impact. This move is seen as a significant step in the US governments efforts to control healthcare costs.
growth-positive
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook
Amicus Therapeutics announced preliminary total revenues for Q4 and full-year 2024, driven by sales of Galafold and Pombiliti + Opfolda. Despite a 31.6% decline in shares over the past year, the company projects revenue growth of 17%-24% for 2025. Galafold and Pombiliti + Opfolda are expected to see significant revenue increases, with the latter projected to grow by 65%-85%. Amicus aims for positive GAAP net income in H2 2025 and anticipates exceeding $1 billion in sales by 2028. A licensing agreement with Teva Pharmaceuticals resolved a patent lawsuit, preventing Teva from selling a generic version of Galafold until 2037. Preliminary 2024 revenues were $528.5 million, a 32% increase year over year.
CustomersPartners
growth-positive
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
Teva Pharmaceutical Industries Ltd has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of FYB203, a biosimilar candidate to Eylea, in Europe (excluding Italy) and Israel. This partnership enhances Tevas biosimilars portfolio, aligning with its Pivot to Growth strategy. The collaboration leverages Tevas extensive distribution network and Formycons expertise in biosimilar development. Klinge holds the exclusive global commercialization rights to FYB203 and will receive milestone payments and a portion of the products revenue. This agreement builds on the successful commercialization of Formycons ranibizumab biosimilar in Europe, further strengthening Tevas commitment to expanding access to innovative medicines.
Partners
growth-positive
How Teva Pharmaceuticals is thinking about Trump's return: CEO
Teva Pharmaceuticals is preparing for the potential impact of the Trump administrations return to the White House. CEO Richard Francis discussed the companys strategy, emphasizing that Teva has not made any changes to its operations ahead of Trumps second inauguration. The company is waiting to see how Trumps policy promises will unfold. Teva is a significant player in the U.S. healthcare system, being the largest supplier of generic medicines in the country. The CEO highlighted the companys strong performance over the past year and its focus on innovation. The article also mentions Tevas advancements in generic obesity drugs and potential merger and acquisition activities.
growth-positive
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Teva Pharmaceutical Industries Ltd and Samsung Bioepis Co., Ltd. have entered into a strategic partnership to develop, license, and commercialize EPYSQLI® (eculizumab-aagh), a biosimilar to Soliris®, in the U.S. This collaboration aims to broaden treatment options for patients with rare diseases such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG). Samsung Bioepis will handle development and manufacturing, while Teva will manage commercialization. This partnership aligns with Tevas Pivot to Growth strategy and enhances its biosimilar portfolio, potentially increasing access to affordable treatments for rare disease patients.
Partners
growth-positive
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Catalyst Pharmaceuticals shares rose by 16.7% following a settlement agreement with Teva Pharmaceuticals regarding the Firdapse patent litigation. The settlement prevents Teva from marketing a generic version of Firdapse in the U.S. before February 25, 2035, protecting Catalysts market share for its primary revenue-generating drug. Firdapse is approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS) in adults and pediatric patients in the U.S., EU, and Japan. The settlement is a significant win for Catalyst, as Firdapse accounts for 65% of its net product sales. Catalyst also markets Fycompa for epilepsy and Agamree for Duchenne muscular dystrophy, providing additional revenue streams.
Product StageCustomers
growth-negative
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
Neumora Therapeutics experienced a significant setback as its lead pipeline candidate, navacaprant, failed in a late-stage study for major depressive disorder (MDD). The phase III KOASTAL-1 study did not meet its primary endpoint, showing no significant improvement over placebo in alleviating depression symptoms. This failure led to a drop in Neumoras shares. Meanwhile, Hoth Therapeutics reported positive interim results from a phase IIa study of HT-001, aimed at addressing skin toxicities in cancer patients. This positive data led to a surge in Hoths shares. Additionally, Catalyst Pharmaceuticals and its licensor, SERB, reached a settlement with Teva Pharmaceuticals regarding a patent litigation issue.
Product Stage
growth-positive
US analysts list Teva, Wix in 2025 top picks
The article discusses the positive outlook for Teva Pharmaceutical Industries Ltd. and Wix.com Ltd. Bank of America has raised Tevas price target to $26 per share, citing its strong product pipeline and plans to sell its active ingredients division, which could accelerate de-leveraging. Tevas collaboration with Sanofi on a drug for inflammatory bowel disease, which is entering Phase 3, also contributes to the positive sentiment. Meanwhile, Cantor Fitzgerald has raised Wixs price target to $260 per share, highlighting its strong product roadmap and potential for acquisition. Both companies have shown significant stock price increases in 2024, with Teva rising 111% and Wix 74%.
Product StagePartners
growth-positive
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Catalyst Pharmaceuticals Inc. has reached a settlement agreement with Teva Pharmaceuticals, resolving a patent litigation issue over Tevas attempt to market a generic version of Firdapse before the expiration of Catalysts patents. As part of the agreement, Teva will not market its generic version in the U.S. before February 25, 2035, unless specific conditions occur. This settlement ends ongoing litigation between Catalyst and Teva, as well as other defendants like Hetero and Lupin. The FDA recently approved an increased dosage for Firdapse, which is used to treat Lambert-Eaton myasthenic syndrome (LEMS). Catalyst reported a 19.7% increase in Firdapse revenues in the third quarter of 2024, projecting full-year revenues between $300 million and $310 million.
CustomersFDA approved/pending approval
growth-negative
Sector Update: Health Care Stocks Advance Late Afternoon
The article discusses the performance of health care stocks, highlighting a late afternoon rise in the NYSE Health Care Index by 0.6%. However, TEVAs stock experienced a decline of 7.07% on the same day. The article is part of a premium news service offered by MT Newswires, which requires a Silver or Gold subscription to access. The focus is on stock market movements and the impact on specific companies within the health care sector.
growth-positive
IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
Catalyst has entered into a significant agreement with Teva, a generic drug manufacturer, which will prevent Teva from producing a generic version of Catalysts drug, Firdapse, until 2035. This deal is expected to be beneficial for Catalyst as it secures the exclusivity of Firdapse in the market for an extended period, potentially leading to sustained revenue growth. The partnership with Teva is a strategic move to protect Catalysts market share and intellectual property.
Partners
growth-negative
Why Teva Pharmaceuticals Industries Ltd. (TEVA) Crashed Yesterday
Teva Pharmaceuticals Industries Ltd. experienced a decline in its stock price, falling 3.34% to $21.3 per share, as investors awaited further developments on its schizophrenia treatment, Tev’749. Despite showing statistical improvement in symptoms during its Phase III trial, concerns were raised about the drugs twice-daily dosing schedule. Meanwhile, Teva made progress with its Duvakitug drug, developed in partnership with Sanofi, which met primary goals for treating ulcerative colitis and Crohn’s disease. This partnership aims to achieve blockbuster status for the drug, potentially generating $1 billion in annual sales. The article also suggests that AI stocks may offer better investment returns than Teva.
Product StagePartners
growth-positive
Teva Pharmaceutical Industries Ltd (TEVA) Ends Trading Week Defying Market Bloodbath
Teva Pharmaceutical Industries Ltd saw its shares rise by 0.66% to $22.77, defying a bearish market trend. This growth was driven by positive news regarding its drug Duvakitug, developed in partnership with Sanofi, which met primary goals for treating ulcerative colitis and Crohn’s disease. The partnership, announced last year, aims to develop treatments for inflammatory bowel disease, with expectations of achieving blockbuster status and generating at least $1 billion in annual sales. Despite the market downturn, Tevas shares have surged by 113% year-to-date, reaching a new 52-week high. Analysts note that Tevas valuation is currently at overbought levels.
Partners
growth-positive
Why Teva Pharmaceuticals Industries (TEVA) Skyrocketed?
Teva Pharmaceuticals Industries Ltd. experienced a significant stock price increase of 33.79% last week, closing at $22.09. This growth was driven by the successful development of their drug, Duvakitug, in collaboration with Sanofi, which met its primary goals for treating ulcerative colitis and Crohn’s disease. Despite losing a bid against Amneal Pharmaceuticals and having to remove incorrect patents for an inhaler product, the positive news about Duvakitug overshadowed these setbacks. The collaboration with Sanofi aims to achieve blockbuster status for the drug, potentially generating at least $1 billion in annual sales. Teva ranked third among the top gainers of the week, highlighting its potential as a promising investment.
CustomersPartners
growth-positive
Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2025
Stanley Druckenmillers Duquesne Family Office has shifted its investment strategy by selling shares of AI giants Nvidia and Palantir, opting instead to invest in Teva Pharmaceutical Industries. This move comes as AI stocks have seen significant gains, prompting concerns about valuation and potential market bubbles. In contrast, Teva has shown promising growth, with shares up 112% for the year, driven by strategic shifts towards brand-name therapies and resolving opioid litigation. The company has reduced its debt and improved financial flexibility, making it an attractive investment. Duquesnes investment in Teva reflects confidence in its turnaround and growth potential.
Investment
growth-positive
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Teva Pharmaceutical Industries Ltd announced that its President and CEO, Richard Francis, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The presentation will focus on Tevas strategic initiatives, including its Pivot to Growth strategy aimed at expanding its innovative and biosimilar medicines pipeline. Teva, a global leader in pharmaceuticals, is committed to improving health outcomes through its generics expertise and innovation. The company operates in 58 markets with approximately 37,000 employees. The announcement highlights Tevas focus on innovation and strategic growth, positioning it positively in the competitive pharmaceutical landscape. The event is expected to provide insights into Tevas future plans and strategies.
growth-positive
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Teva Pharmaceutical Industries Limited is experiencing a positive growth trajectory, driven by its leadership in the emerging anti-TL1A drug class. The companys experimental drug, duvakitug, has shown promising results in treating ulcerative colitis and Crohn’s disease, positioning Teva as a leader in this space. Strategic partnerships, such as Sanofis $1.5 billion collaboration, underscore the drugs market potential. Tevas financial discipline, including plans to reduce net debt and streamline operations, further strengthens its investment case. Despite being undervalued, Teva is poised for significant growth, with revenue and EBIT expected to rise substantially by 2028. Key upcoming catalysts include the full data presentation for duvakitug and the anticipated API business divestiture.
Partners
growth-positive
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
This week, Pfizer issued its financial guidance for 2025, projecting revenues between $61.0 billion and $64.0 billion, with operational growth expected to be flat to 5% from the midpoint of 2024 guidance. Adjusted earnings are anticipated to grow 10%-18% year over year. Sanofi and Tevas phase IIb study on their IBD candidate, duvakitug, met its primary endpoints, showing promise for treating ulcerative colitis and Crohns disease. Merck entered a licensing deal with Hansoh Pharma for an obesity candidate, marking its entry into the obesity market. Merck will pay $112 million upfront, with potential milestone payments up to $1.9 billion. AbbVie announced an acquisition in the immunology space.
growth-positive
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
Teva Pharmaceutical Industries Ltd, a global leader in pharmaceuticals, announced it will release its fourth quarter and full year 2024 financial results on January 29, 2025. The company will also provide its financial guidance for 2025. A conference call and live webcast will follow the release, allowing participants to engage with the companys leadership. Teva, known for its generics expertise and innovation, employs around 37,000 people across 58 markets, focusing on improving health outcomes globally. The announcement includes cautionary notes regarding forward-looking statements, emphasizing potential risks and uncertainties that could affect future performance.
growth-positive
My Top 10 Portfolio Holdings for 2025
The article discusses a diversified investment strategy focusing on a mix of growth and value stocks, with a particular emphasis on Teva Pharmaceutical Industries. Teva is highlighted as a top holding due to its strategic shift from low-margin generic drugs to higher-margin brand-name therapies, which is expected to drive revenue and profit growth. The company has also settled opioid litigation and significantly reduced its net debt. Other companies mentioned include SSR Mining, Meta Platforms, Bark, Lovesac, PayPal Holdings, Bank of America, Pinterest, PubMatic, and First Majestic Silver, each with unique growth prospects and challenges. The article outlines the authors investment philosophy and expectations for these holdings in 2025.
CustomersPartners
growth-positive
Teva price target raised to $28 from $26 at UBS
UBS analyst Ashwani Verma has raised the price target for Teva Pharmaceuticals to $28 from $26, maintaining a Buy rating on the shares. This decision follows the positive results from Phase 2 duvakitug data, which exceeded expectations. UBS anticipates further upside for Tevas stock, despite its already strong performance, and suggests that the company is under-owned among long-only investors. UBS expects this to change by 2025 as Teva accelerates its brand transition and reduces its debt. The article also mentions other analysts raising their price targets for Teva, indicating a positive outlook for the company.
growth-positive
Fed decision looms, Nvidia looks to rebound: Yahoo Finance
Nvidia shares are poised for a rebound after experiencing recent pressure, as the company’s Blackwell chip has been named Yahoo Finances product of the year. This recognition is expected to have a positive impact on Nvidias growth. The article also mentions the anticipation surrounding the Federal Reserves latest interest rate decision, which is set to be announced at 2 p.m. ET. Other companies trending on Yahoo Finance include Teva Pharmaceutical Industries, Pfizer, and Nissan. The article lists several key guests scheduled to appear on Yahoo Finance, including Frances Donald, Jay Woods, Adam Sullivan, Mozelle Thompson, and Lawrence Yun.
growth-positive
Trending tickers: Pfizer, Micron, Nissan, Teva and National Grid
Pharmaceuticals giant Pfizer saw its shares rise nearly 5% after issuing an optimistic full-year outlook for 2025, projecting revenue between $61bn and $64bn and adjusted earnings per share of $2.80 to $3. The company also reaffirmed its 2024 guidance and announced $4bn in net operating expense savings through 2024, with an additional $500m expected in 2025. CEO Dr. Albert Bourla emphasized efforts to improve gross margin performance through manufacturing optimization. Meanwhile, US chipmaker Micron reported strong revenue forecasts and secured a $6.1bn subsidy from the US Department of Commerce for semiconductor manufacturing, aiming to significantly increase US memory manufacturing capacity. Additionally, carmaker Nissans shares surged on news of potential merger talks with Honda and Mitsubishi to enhance competitiveness in the EV market.
growth-positive
Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength?
Teva Pharmaceutical Industries Ltd. experienced a significant 26.5% increase in its stock price, closing at $20.88, following positive results from a mid-stage study of its experimental anti-TL1A therapy, duvakitug, for Ulcerative Colitis and Crohns disease. The drug is being developed in collaboration with Sanofi. Despite the positive trial results, the company is expected to report a year-over-year decline in earnings and revenue in its upcoming quarterly report. The consensus EPS estimate has been revised 0.9% lower over the last 30 days. The stock carries a Zacks Rank #3 (Hold), indicating a neutral outlook. The article also mentions Doctor Reddys Laboratories, another company in the same industry.
CustomersPartners
growth-positive
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Sanofi and Teva Pharmaceuticals announced positive results from their phase IIb RELIEVE UCCD study on the anti-TL1A therapy, duvakitug, for treating Ulcerative Colitis and Crohns disease. The study met its primary endpoints, showing significant clinical remission and endoscopic response compared to placebo. Following these results, Sanofi and Teva plan to initiate a late-stage study. The announcement led to a significant rise in the stock prices of both companies, with Tevas shares reaching a six-year high. Sanofi had previously in-licensed joint development and commercialization rights from Teva, paying $500 million upfront and agreeing to up to $1 billion in milestone payments. The companies will share development costs and profits, with Teva leading commercialization in Europe and Sanofi in North America and other regions.
PartnersInvestment
growth-positive
Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial
Sanofi and Teva Pharmaceuticals have announced positive results from their Phase IIb RELIEVE UCCD study, which evaluated the monoclonal antibody duvakitug for treating moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). The study met its primary endpoints, with significant proportions of subjects achieving clinical remission and endoscopic response. The therapy was well-tolerated, with no major safety concerns. Sanofi and Teva will share development costs and profits in major markets, with a royalty arrangement for other markets. These results suggest that duvakitug could become a significant treatment option for IBD patients. The studys success is a promising development for both companies, potentially enhancing their positions in the IBD treatment market.
Partners
growth-negative
Jim Cramer on Teva Pharmaceutical Industries (TEVA): A Game-Changer for Intractable Disease Treatments?
The article discusses Jim Cramers views on Teva Pharmaceutical Industries Limited amidst broader economic concerns. As the Federal Reserve continues interest rate cuts, inflation remains a key concern, potentially influenced by tariffs from the incoming Trump Administration. Cramer suggests that if tariffs are implemented, the Consumer Price Index (CPI) could rise, affecting the Feds rate decisions. He emphasizes the need to focus on the President-elects actions rather than future Fed decisions. Cramer also highlights the U.S. workforce shortage and the need for immigration reform to fill jobs. Additionally, he comments on Trumps criticism of healthcare benefit managers, suggesting Americans overpay due to middlemen. The article implies a growth-negative impact on Teva due to these economic uncertainties.
growth-positive
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
Teva Pharmaceutical Industries Ltd. and Sanofi SA saw their stocks rise after their Phase 2b RELIEVE UCCD study met primary endpoints for treating ulcerative colitis and Crohn’s disease with the monoclonal antibody duvakitug. The study showed significant clinical remission and endoscopic response rates compared to placebo. The treatment was well tolerated with no significant safety concerns. This positive outcome has likely contributed to the increase in stock prices for both companies, with Tevas stock rising by 20.40% and Sanofis by 4.07%. Detailed results are expected to be presented at a scientific forum in 2025.
growth-positive
Teva, Cloudflare, Sanofi: Trending Tickers
Cloudflares shares have risen following an upgrade from Stifel analysts, who changed their rating from Hold to Buy. The upgrade is attributed to Cloudflares industry leadership, strong sales performance, and momentum in artificial intelligence. Additionally, Teva Pharmaceutical Industries and Sanofi have seen gains due to promising data for their experimental drug for inflammatory bowel disease. This analysis was discussed on Yahoo Finances platform, highlighting the top trending tickers. The article provides insights into the latest market actions and trends.
growth-positive
Teva, Sanofi Say Inflammatory Bowel Disease Drug Study Meets Primary Endpoints
Teva Pharmaceutical Industries, in partnership with Sanofi, announced that their study on a drug for inflammatory bowel disease has met its primary endpoints. This development is seen as a positive step for both companies, potentially leading to new treatment options for patients. The announcement led to a significant increase in Tevas stock price, indicating a growth-positive impact. The collaboration with Sanofi highlights the importance of partnerships in advancing pharmaceutical research and development. The article also briefly mentions Nvidias Blackwell chip as a leading product in the AI revolution, although this is not directly related to Teva or Sanofis announcement.
Partners
growth-positive
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
Teva Pharmaceutical Industries Ltd, in collaboration with Sanofi, announced positive results from the Phase 2b RELIEVE UCCD study for treating ulcerative colitis (UC) and Crohn’s disease (CD) using duvakitug, a monoclonal antibody targeting TL1A. The study met its primary endpoints, showing significant clinical remission and endoscopic response rates in patients compared to placebo. The treatment was well-tolerated with no significant safety concerns. These results bolster Tevas reputation in developing innovative treatments and pave the way for Phase 3 trials, pending regulatory discussions. The collaboration with Sanofi highlights a strong partnership in advancing treatment for inflammatory bowel disease.
Partners
Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug
growth-positive
Update: Teva, Sanofi Shares Jump as Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease
Teva Pharmaceuticals and Sanofi have seen a significant increase in their stock prices following the successful completion of a Phase 2B study for Duvakitug, a treatment for inflammatory bowel disease (IBD). The study met its primary endpoints, leading to a 26.47% rise in Tevas stock and a 6.65% increase in Sanofis stock. This positive outcome highlights the potential of Duvakitug in treating IBD, positioning both companies favorably in the pharmaceutical market. The news has generated considerable interest among investors and stakeholders, reflecting optimism about the future prospects of the drug and its impact on the companies growth trajectories.
growth-positive
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
Teva and Sanofi have reported strong trial results for their IBD treatment, Duvakitug. The treatment was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events. As a result, Tevas stock soared, and Sanofi also saw gains. The positive trial results are expected to have a growth-positive impact on both companies.
growth-positive
Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations
Teva Pharmaceutical and Sanofi have announced promising results from Phase 2b trials of their drug duvakitug, which showed a 47.8% remission rate in Crohns disease patients at high doses. This success has led to a significant increase in Tevas stock price by 19% and a 4% rise for Sanofi. The drug is positioned to capture a substantial share of the $28 billion inflammatory bowel disease market. Sanofi has invested $500 million upfront in this partnership, with an additional $1 billion in milestones, including $600 million for Phase 3 trials. Both companies will share costs and profits, with Sanofi focusing on the U.S. and Asia, and Teva on Europe and Israel. Phase 3 trials are planned for 2025, with a commercial launch expected by the end of the decade.
Partners
growth-positive
Teva Stock Soars on Early Bowel Disease Drug Data
Teva, in collaboration with its partner Sanofi, announced promising early data for their bowel disease drug, duvakitug. The study showed that 47.8% of patients with ulcerative colitis who received a high dose of the drug experienced clinical remission, compared to 20.5% who received a placebo. This positive data has led to a significant increase in Tevas stock price, indicating a growth-positive impact for the company. The partnership with Sanofi is crucial in the development and potential success of this drug.
Partners
growth-positive
Teva and Sanofi jump on experimental bowel disease drug success
Teva Pharmaceutical Industries and Sanofi have seen a rise in their stock prices following promising results from a trial of their experimental drug for inflammatory bowel disease. Tevas shares increased by more than 25% during Tuesdays session, contributing to the stock more than doubling year-to-date. This positive development has been analyzed by Julie Hyman and Josh Lipton, who provide insights into the pharmaceutical companies stock movements. The article highlights the impact of the trial results on the companies market performance.
growth-positive
Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
Teva Pharmaceuticals and Sanofi reported positive results from a Phase 2b trial of their drug, duvakitug, for treating ulcerative colitis and Crohns disease. The trial showed significant clinical remission rates in patients compared to those receiving a placebo. Following the announcement, both companies U.S.-traded stocks saw significant gains, with Tevas shares reaching their highest level in six years. The companies plan to initiate a Phase 3 trial pending discussions with regulators and aim to present detailed results at a scientific forum in 2025. The positive trial results suggest that duvakitug could be a promising treatment option for these conditions.
growth-positive
Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients
Teva Pharmaceutical Industries Ltd has launched a new patient access program in partnership with Direct Relief to provide two generic inhaler products to uninsured patients in the United States. The program aims to address the unmet need for affordable inhalers in underserved communities by donating generic versions of AirDuo RespiClick and ProAir HFA inhalers to Direct Relief. These inhalers will be distributed through free and charitable clinics to ensure that uninsured patients can access necessary respiratory treatments. The initiative will run for a minimum of three years, with Teva also making a cash donation to support the programs administration. This partnership highlights Tevas commitment to enhancing patient access to affordable medicines.
Partners
growth-positive
Teva reports positive outcomes from episodic migraine trial in young patients
Teva Pharmaceutical Industries has announced positive results from its Phase III SPACE trial of Ajovy (fremanezumab) for preventing episodic migraines in children aged six to 17. The trial, which was placebo-controlled and involved 237 subjects, showed a statistically significant reduction in migraine frequency over 12 weeks compared to placebo. The safety profile was consistent with that observed in adults, and the therapy was well tolerated with no significant safety signals. The study also highlighted a higher response rate in pediatric subjects compared to placebo, with benefits observed across different age groups and genders. Teva plans to further explore the long-term safety and effects of the therapy in children with chronic migraine.
growth-positive
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
Teva Pharmaceutical Industries Ltd. has entered into an agreement with JKI Co., Ltd., established by J-Will Partners Co., Ltd., to divest its Teva-Takeda business venture in Japan. This move aligns with Tevas Pivot to Growth strategy, allowing the company to focus on innovative medicines in the Japanese market. The divestment is expected to be completed by April 1, 2025, subject to regulatory approvals. All employees of the business venture in Japan will remain employed under the terms of the agreement. This strategic divestment is seen as a positive step for Teva, enabling it to concentrate on its core innovative business while ensuring the continued delivery of affordable medicines in Japan.
Acquired-by
growth-positive
Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
Teva Pharmaceutical Industries Ltd presented positive data from its Phase 3 SPACE study on AJOVY® (fremanezumab) at the European Headache Congress in December 2024. The study evaluated the efficacy and safety of AJOVY® for preventing episodic migraines in children and adolescents aged 6-17 years. Results showed a significant reduction in monthly migraine and headache days compared to placebo, with a favorable safety profile consistent with adult studies. This milestone offers a promising treatment option for young patients with limited alternatives. The trial involved 237 participants and demonstrated significant efficacy across different age and sex subgroups.
growth-negative
TEVA Stock Down 10% in a Month: Should You Buy the Dip?
Teva Pharmaceutical Industries Limiteds stock has declined by 10% over the past month despite reporting strong third-quarter results. The company exceeded earnings and sales estimates and slightly raised its guidance, but investors were not impressed, leading to a stock decline. Teva, the largest generic drug company, is experiencing market share growth for its drugs Austedo and Ajovy, with significant revenue expectations in the coming years. The company has launched new formulations and expanded its market presence. Teva has partnered with Sanofi for the development of its anti-TL1A therapy, TEV-48574. Despite limited new complex generic approvals in recent years, Teva has launched several in 2024 and plans more in 2025, aiming to maintain its strong position in the generics market.
CustomersPartners
growth-positive
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
Teva Pharmaceutical Industries Ltd announced that its President and CEO, Richard Francis, along with Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer, will present at the 7th Annual Evercore ISI HealthCONx Conference on December 5, 2024. The presentation will focus on Tevas strategic initiatives, including its Pivot to Growth strategy, which aims to expand its innovative and biosimilar medicines pipeline. The company is committed to leveraging its generics expertise and innovation to improve health outcomes globally. Tevas management will discuss the companys current market position, challenges, and future growth prospects. The event will be webcast live, with an archived version available later. The announcement reflects Tevas ongoing efforts to engage with investors and stakeholders, highlighting its strategic direction and commitment to innovation.
growth-positive
Teva Pharmaceutical (TEVA): The Global Leader in Affordable Medicine Under $25
The article discusses the impact of Donald Trumps 2024 presidential election victory on various sectors, including the financial, cryptocurrency, and energy sectors. The Dow Jones Industrial Average, Nasdaq, and S&P 500 reached record highs, with the financial sector seeing significant gains due to expectations of reduced regulations and lower taxes under Trumps administration. The cryptocurrency market, particularly Bitcoin, also experienced a surge, with predictions of further growth. However, the clean energy sector faced challenges, with projects being put on hold due to uncertainty about future policies. Despite these challenges, the transition to cleaner energy sources is expected to continue, driven by customer and investor demand. The article also mentions Teva Pharmaceutical Industries Limited as a stock under $25 to consider for investment.
growth-positive
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Teva Pharmaceutical Industries Limited demonstrated a strong performance in Q3 2024, achieving a 15% year-over-year revenue increase to $4.3 billion and a 17% rise in adjusted EBITDA to $1.3 billion. The companys innovative product portfolio, including AUSTEDO and AJOVY, contributed significantly to this growth. Teva raised its full-year revenue guidance to $16.1 - $16.5 billion and EPS guidance to $2.40 - $2.50. The company also reported impressive free cash flow of $922 million, which helped reduce its net debt-to-EBITDA ratio to 3x. Tevas R&D pipeline is progressing well, with promising developments in its biosimilars portfolio. The company is positioned for continued momentum into Q4, driven by cost optimization and a favorable revenue mix.
growth-positive
Teva to Present at the Jefferies London Healthcare Conference
Teva Pharmaceutical Industries Ltd. announced that its President and CEO, Richard Francis, will present at the Jefferies London Healthcare Conference on November 19, 2024. The presentation will focus on Tevas strategic initiatives, including its Pivot to Growth strategy, which aims to expand its innovative and biosimilar medicines pipeline. Teva is a global leader in pharmaceuticals, with a strong emphasis on generics and innovation. The company employs approximately 37,000 people across 58 markets. The presentation will be available via a live webcast on Tevas Investor Relations website, with an archived version accessible within 24 hours. The announcement underscores Tevas commitment to advancing healthcare and maintaining its competitive edge in the pharmaceutical industry.
growth-positive
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
The article discusses Teva Pharmaceutical Industries (TEVA), highlighting its strong position as a value stock according to Zacks Investment Research. TEVA currently holds a Zacks Rank of #2 (Buy) and an A grade for Value, with favorable valuation metrics such as a Forward P/E ratio of 6.43 and a P/B ratio of 3.01. These metrics suggest that TEVA is undervalued compared to its industry averages, making it an attractive option for value investors. The article emphasizes the importance of value investing and how TEVAs current metrics and earnings outlook position it as a strong candidate in this category.
growth-positive
Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ...
Teva Pharmaceutical Industries Ltd reported a 15% increase in revenues, reaching $4.3 billion for Q3 2024. The companys innovative products, including AUSTEDO, AJOVY, and UZEDY, showed strong growth, contributing to a positive financial outlook. Tevas global generics business also saw a 17% increase, with significant contributions from all regions. Despite strong performance, the company recorded a GAAP operating loss of $51 million due to goodwill impairment charges and higher legal settlements. Legal challenges, including a $350 million provision related to an antitrust investigation, and foreign exchange rate impacts have posed challenges. However, Tevas financial guidance for the full year has been raised, reflecting confidence in its key products.
Customers
growth-positive
TEVA Stock Down 7% Despite Q3 Earnings & Sales Beat, Guidance Increase
Teva Pharmaceutical Industries reported strong third-quarter 2024 results, with adjusted earnings of 69 cents per share surpassing estimates and rising 15% year over year. Revenues reached $4.33 billion, exceeding expectations and growing 13% on a reported basis. The growth was driven by increased sales of generic products and branded drugs like Austedo, Ajovy, and Uzedy. The U.S. segment saw a 17% revenue increase, largely due to generic drug sales. Tevas biosimilar pipeline, developed in partnership with Alvotech, is progressing well, with recent approvals and launches. The company continues to expand its presence in the generic and biosimilar markets, contributing to its positive growth outlook.
CustomersPartners
growth-positive
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
Amicus Therapeutics reported a strong third-quarter 2024 performance, with adjusted earnings of 10 cents per share, surpassing the Zacks Consensus Estimate of 8 cents. The company achieved a 37% year-over-year revenue increase, totaling $141.5 million, driven by sales of Galafold and the newly approved Pombiliti + Opfolda. Despite the positive financial results, Amicus shares fell by 4.3% on November 6, 2024, and have declined 20.8% year-to-date. The company updated its full-year 2024 revenue growth guidance to 30%-32%, reflecting strong demand and expansion into new markets. As of September 30, 2024, Amicus had $249.8 million in cash and marketable securities.
Customers
growth-positive
Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter Report
Teva Pharmaceuticals stock saw a significant increase following the release of its third-quarter report, which exceeded expectations in both sales and profit. This positive financial performance has been well-received by investors, signaling a potential buy opportunity. The report highlights Tevas strong market position and effective business strategies, contributing to its growth trajectory.
growth-positive
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
Teva Pharmaceutical Industries Ltd. reported a strong financial performance for Q3 2024, with revenues reaching $4.3 billion, marking a 15% increase in local currency terms compared to Q3 2023. The companys innovative portfolio and generics business contributed significantly to this growth. Key products like AUSTEDO®, AJOVY®, and UZEDY® showed substantial revenue increases. Tevas biosimilar candidate to Prolia® has been accepted for review by the U.S. FDA and EMA, and the company plans to divest Teva api by the first half of 2025. The company raised its full-year 2024 business outlook, reflecting confidence in its growth strategy. The report highlights Tevas continued execution of its Pivot to Growth Strategy.
growth-positive
Teva's Explosive Q3 Results: Pivot to Growth Strategy Shocks Investors with Record Revenue Surge
Teva Pharmaceuticals reported impressive growth in its Q3 2024 financial results, with a 13% increase in revenue, reaching $4.3 billion. The companys U.S. generics sales exceeded $1 billion, and key therapies like Austedo and Uzedy contributed significantly to the growth. Despite posting a net loss due to impairment charges and legal settlements, Teva raised its 2024 financial outlook, projecting revenue up to $16.5 billion and adjusted EPS of $2.50. The companys strategic focus on generics and new treatments is paying off, with a robust development pipeline and strong execution across core therapies. Tevas strengthened guidance and expanding cash flow indicate a promising growth trajectory, making it an attractive option for investors seeking growth and resilience.
growth-positive
Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript
Teva Pharmaceutical Industries held its Q3 2024 earnings call, reporting a 15% increase in revenue to $4.3 billion, driven by strong performance in its innovative and generics portfolios. The company highlighted growth in key products like AUSTEDO, AJOVY, and UZEDY, and discussed its strategic focus on innovation and biosimilars. Tevas CEO, Richard Francis, emphasized the companys Pivot to Growth strategy, which aims to deliver sustainable growth through innovation and operational excellence. The company also announced an increase in its full-year revenue guidance and discussed progress in its pipeline, including biosimilars and innovative treatments. Tevas financial outlook remains strong, with improvements in gross margins and free cash flow.
CustomersPartners
growth-positive
Teva Pharmaceutical Industries (TEVA) Reports Q3 Earnings: What Key Metrics Have to Say
Teva Pharmaceutical Industries Ltd. reported a significant financial performance for the quarter ending September 2024, with a revenue of $4.33 billion, marking a 12.5% year-over-year increase. The earnings per share (EPS) stood at $0.69, surpassing the previous years $0.60. Both revenue and EPS exceeded the Zacks Consensus Estimates, with surprises of +6.12% and +6.15%, respectively. The companys performance was analyzed across various geographic and product segments, showing notable growth in the United States and international markets. Despite some declines in specific product revenues, the overall financial results indicate a positive growth trajectory for Teva, as it continues to outperform analyst expectations.
growth-positive
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
The article discusses the upcoming third-quarter 2024 earnings reports for several large biotech and generic drug companies, including Novo Nordisk. The Medical sector has seen a positive trend, with many companies beating earnings and revenue estimates. Novo Nordisk is expected to report a positive earnings surprise, driven by strong demand for its semaglutide products, such as Ozempic and Wegovy. The companys earnings are projected at 90 cents per share, with revenues estimated at $10.68 billion. Novo Nordisks performance has been mixed in the past quarters, but it holds a Zacks Rank #3, indicating a likely positive outcome for the upcoming report on November 6.
growth-positive
Teva Pharmaceutical Industries (TEVA) Upgraded to Strong Buy: What Does It Mean for the Stock?
Teva Pharmaceutical Industries Ltd. has been upgraded to a Zacks Rank #1 (Strong Buy) due to an upward trend in earnings estimates. This upgrade is a positive indicator of the companys earnings outlook, which could favorably impact its stock price. The Zacks rating system, which focuses on changes in earnings estimates, is highly regarded for its ability to predict near-term stock price movements. The upgrade suggests an improvement in Tevas underlying business, potentially leading to higher stock prices as institutional investors adjust their valuation models based on these revised earnings estimates.
growth-negative
EC fines Teva $502m over multiple sclerosis treatment Copaxone practices
The European Commission (EC) has fined Teva Pharmaceuticals Industries €462.6 million ($502 million) for delaying competition to its multiple sclerosis treatment, Copaxone. The fine is the first of its kind for dual practices, which include extending patent protection and spreading misleading information about rival products. The EC found that Teva misused patent procedures and orchestrated a campaign to discredit competing medicines, affecting markets in several EU countries. Teva disputes the ECs findings and plans to appeal, maintaining its commitment to the multiple sclerosis community.
growth-positive
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)
Teva Pharmaceuticals presented findings from six schizophrenia studies at the Psych Congress 2024, showcasing its commitment to innovation in neuroscience. The data revealed that the TEV-749 drug delivery technology resulted in no occurrences of Post-Injection Delirium/Sedation Syndrome (PDSS) events. The Phase 3 SOLARIS trial demonstrated significant improvements in social functioning and quality of life for patients with schizophrenia. Additionally, real-world analyses of UZEDY, a subcutaneous long-acting injectable, showed high adherence rates in adults with schizophrenia facing treatment barriers. These findings highlight the potential benefits of TEV-749 and UZEDY in improving patient outcomes. The studies were presented at the Psych Congress 2024 held from October 29 to November 2, 2024, in Boston, MA.
growth-positive
Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Teva Pharmaceutical Industries Ltd. is expected to report quarterly earnings of $0.65 per share, an 8.3% increase from the previous year, with revenues forecasted at $4.08 billion, marking a 6% year-over-year growth. Analysts have adjusted the consensus EPS estimate upward by 0.3% over the past 30 days, indicating a positive reassessment of the companys performance. Key metrics include a significant decline in Revenue- COPAXONE- Total and Revenue- Other- Total, while Geographic Revenue- International Markets and Geographic Revenue- United States- AUSTEDO show substantial growth. The report highlights the importance of earnings estimate revisions in predicting stock performance, with analysts providing detailed projections for Tevas various revenue streams.
growth-positive
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
Teva Pharmaceuticals announced interim results from the Phase 4 IMPACT-TD Registry study, which evaluates the effects of tardive dyskinesia (TD) on patients with psychotic and mood disorders. The study highlights the significant burden of TD on quality of life and reveals differences in diagnosis rates between patients with psychotic disorders and those with mood disorders. The findings, presented at the Psych Congress 2024, show real-world treatment patterns with AUSTEDO XR and AUSTEDO tablets. Teva aims to improve patient outcomes and address mental health equity gaps through continued research and innovation.
growth-negative
Teva Statement on European Commission Decision; Company to Appeal
Teva Pharmaceuticals is challenging a decision by the European Commission regarding its practices related to COPAXONE, a treatment for multiple sclerosis. The company disagrees with the Commissions legal theories, which it considers extreme and unsupported by facts. Teva plans to appeal the decision and is prepared to defend its position. Despite the setback, Teva remains committed to supporting the MS community and maintaining ethical business practices. The company has been cooperating with the European Commission since 2019 and emphasizes its role as a partner to Europe and its healthcare systems.
growth-negative
EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug
The European Commission has fined Israeli generic drugmaker Teva over 460 million euros ($500 million) for misusing the patent system to extend protection for its multiple sclerosis drug, Copaxone. Teva conducted a disparagement campaign against Synthon, the only other company with an authorized drug in Europe containing the same active ingredient, glatiramer acetate. The campaign aimed to delay Synthons market entry by spreading misleading information about the safety and efficacy of its product. This action potentially prevented significant cost savings for European countries, as Synthons drug could be up to 80% cheaper than Copaxone. Teva has been ordered to pay the fine and refrain from similar practices in the future. Previously, Teva settled price-fixing charges in the U.S. for $225 million.
growth-negative
Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns
Teva Pharmaceutical has been fined 462.6 million euros by the European Union for allegedly abusing its market position, potentially delaying competitors from entering the multiple sclerosis market. This significant fine highlights regulatory concerns over competition practices within the pharmaceutical industry. The EUs decision underscores the importance of fair competition and the consequences of market dominance abuse. This financial penalty is likely to impact Tevas financial standing and market perception negatively.
growth-positive
Investors in Teva Pharmaceutical Industries (NYSE:TEVA) have seen impressive returns of 120% over the past year
Teva Pharmaceutical Industries Limited has seen its stock price more than double in a year, rising by 120%, despite not being profitable in the last twelve months. The companys revenue grew by 8.5% over the past year, which is relatively modest for a company not making profits. The impressive stock performance suggests that the market may be considering factors beyond revenue growth. Shareholders have enjoyed a total return of 120% over the past year, indicating positive sentiment around the company. The article suggests that the business might be improving over time, although it highlights the need for more substantial growth to justify the stock price increase.
growth-positive
Wall Street Analysts Predict a 25.1% Upside in Teva Pharmaceutical Industries (TEVA): Here's What You Should Know
Shares of Teva Pharmaceutical Industries Ltd. have increased by 2.9% over the past four weeks, closing at $18.25. Analysts have set a mean price target of $22.83, indicating a potential upside of 25.1%. The price targets range from $18 to $26, with a standard deviation of $2.79, suggesting a moderate level of agreement among analysts. While analysts price targets are often questioned for their accuracy, the consensus on Tevas potential for better-than-expected earnings adds to the positive outlook. The article highlights the importance of considering multiple factors, beyond just price targets, when making investment decisions. Analysts price targets can be influenced by business incentives, but a low standard deviation in targets suggests a high degree of agreement on the stocks potential movement.
growth-positive
Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More
Amicus announced a licensing agreement with Teva Pharmaceuticals, resolving a patent lawsuit over the generic version of Amicuss drug Galafold. The agreement allows Teva to sell its generic version in the U.S. starting January 30, 2037, subject to FDA approval and customary conditions. This settlement ends ongoing litigation between Amicus and Teva, although litigation continues against Aurobindo Pharma and Lupin. The announcement positively impacted Amicus, which is ranked as a strong buy by Zacks. Meanwhile, Gilead Sciences and Merck reported positive results from a phase II study on an investigational HIV treatment, planning to advance to phase III studies.
Partners
growth-positive
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
The article discusses Teva Pharmaceutical Industries (TEVA), highlighting its strong position as a value stock. TEVA currently holds a Zacks Rank of #2 (Buy) and a Value grade of A, indicating it is undervalued compared to its industry peers. Key valuation metrics such as P/E, P/B, and P/S ratios suggest that TEVA is trading at a lower price relative to its earnings, book value, and sales, respectively. The companys P/E ratio is 6.79, compared to the industry average of 10.22, and its P/B ratio is 3.14, compared to the industry average of 3.98. These metrics, along with a positive earnings outlook, make TEVA an attractive option for value investors.
growth-positive
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?
Teva Pharmaceutical Industries Ltd., a member of the Medical sector, has shown strong performance this year, outperforming its sector with a 76.1% return since the start of the calendar year. The company holds a Zacks Rank of #2 (Buy), indicating a positive earnings outlook. Over the past 90 days, the Zacks Consensus Estimate for TEVAs full-year earnings has increased by 0.6%, reflecting improved analyst sentiment. In comparison, the Medical sector has gained an average of 6.6%, and the Medical - Generic Drugs industry, to which Teva belongs, has gained about 19.2%. Investors are advised to keep an eye on Teva and Addus HomeCare, another strong performer in the Medical sector.
growth-positive
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Teva Pharmaceutical Industries Ltd, in partnership with Alvotech, announced that the FDA has approved SELARSDI, a biosimilar to Stelara, for intravenous infusion in a new presentation. This approval expands SELARSDIs indications to include treatment for Crohn’s disease and ulcerative colitis, aligning it with the reference product Stelara. The U.S. launch is anticipated in Q1 2025. This development marks a significant milestone in Teva’s strategy to increase access to biosimilars in the U.S. The partnership with Alvotech, which began in 2020, now includes nine biosimilar products. Teva handles commercialization in the U.S., leveraging its extensive sales and marketing infrastructure. The approval is expected to positively impact Tevas growth by expanding its biosimilar portfolio.
Partners
growth-positive
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Teva Pharmaceutical Industries Limited is navigating through significant challenges such as legal issues, pricing pressures, and regulatory difficulties. Despite these setbacks, there is cautious optimism for its long-term growth. The company is focusing on expanding its portfolio of branded products, with Austedo expected to reach $2.5 billion in sales by 2027. Tevas venture into long-acting injectables and its pipeline in immunology and inflammation, supported by partnerships like the one with Sanofi, represent promising opportunities. The generics business remains stable and contributes to debt reduction, allowing reinvestment into its branded portfolio. However, risks such as litigation related to the opioid crisis and regulatory uncertainties persist.
Partners
growth-positive
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
Amicus Therapeutics has entered into a licensing agreement with Teva Pharmaceuticals, resolving a patent lawsuit related to Amicus drug Galafold. The agreement allows Teva to sell a generic version of Galafold in the U.S. starting in 2037, pending FDA approval. This settlement led to a 14% increase in Amicus stock price. Galafold, a key growth driver for Amicus, has shown strong sales performance, prompting the company to raise its revenue guidance for 2024. Additionally, Amicus newly approved drug for Pompe disease, Pombiliti + Opfolda, is expected to contribute significantly to future revenues. The agreement with Teva ends ongoing litigation between the two companies, though litigation continues with Aurobindo Pharma.
Partners
growth-positive
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?
Amicus Therapeutics experienced a 14% increase in its stock price, closing at $11.97, following the announcement of a licensing agreement with Teva Pharmaceuticals. This agreement resolves a patent lawsuit related to Tevas attempt to sell a generic version of Amicuss Galafold before patent expiration. The deal allows Teva to sell the generic version in the U.S. from January 30, 2037, pending FDA approval. Amicus is expected to report quarterly earnings of $0.08 per share, a 214.3% increase year-over-year, with revenues projected at $133.91 million, up 29.4% from the previous year. The positive trend in earnings estimates suggests potential further stock price appreciation. Amicus holds a Zacks Rank #2 (Buy).
Partners
growth-positive
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
Amicus Therapeutics has reached a settlement with Teva Pharmaceuticals regarding a patent lawsuit over a generic version of its drug, Galafold, used to treat Fabry disease. The agreement allows Teva to market its generic version in the U.S. starting January 30, 2037, pending FDA approval. This settlement resolves ongoing litigation between the two companies, although litigation continues against Aurobindo. The resolution of this lawsuit is seen as a positive development for Amicus, as it removes a significant legal hurdle. The announcement led to a 12.4% increase in Amicuss stock price. The agreement is part of a broader strategy to protect Amicuss intellectual property while allowing for future market competition.
Partners
growth-negative
Update: Teva Pharmaceutical to Pay $450 Million to Settle Anti-Kickback Allegations
Teva Pharmaceutical has agreed to pay $450 million to settle allegations related to anti-kickback practices. This settlement is part of ongoing legal issues faced by the company, which could impact its financial standing and reputation. The settlement aims to resolve claims that Teva engaged in unlawful practices to promote its products. This development is likely to have a negative impact on the companys growth prospects as it deals with the financial and reputational fallout from these allegations.
growth-negative
Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes
Teva Pharmaceuticals Industries Ltd has agreed to a $450 million settlement with the U.S. government to resolve allegations of violating the Anti-Kickback Statute and the False Claims Act. The settlement addresses claims that Teva engaged in unlawful kickback schemes affecting Medicare and drug pricing. The resolution includes $225 million in criminal penalties previously paid by Teva USA as part of a deferred prosecution agreement with the Department of Justice. The allegations involve Teva covering Medicare copays for the drug Copaxone and conspiring with other manufacturers to fix prices of generic drugs. This settlement is part of a broader initiative against pharmaceutical industry price-fixing and kickbacks.
growth-negative
Settlement with the Department of Justice addresses price hikes from $17,000 to $85,000 per year for the multiple sclerosis drug.
Teva, an Israeli pharmaceutical company, has agreed to a $450 million settlement with the U.S. Department of Justice over allegations of inflating the price of its multiple sclerosis drug, Copaxone. The drugs price increased from $17,000 to $85,000 per year between 2006 and 2017. The settlement resolves accusations that Teva used charitable organizations to subsidize the drugs cost, with the remaining amount billed to government programs like Medicare. Teva will pay the settlement over six years without admitting guilt. This settlement is part of a broader legal challenge involving Teva and other pharmaceutical companies, with the original lawsuit filed in 2020 seeking $10 billion in damages. The settlement marks the resolution of another significant legal issue for Teva, following its involvement in opioid litigation.
growth-negative
Teva Pharmaceuticals to Pay $450 Million to Settle Kickback Allegations
Teva Pharmaceuticals has agreed to pay $450 million to settle allegations of submitting false claims and violating federal laws prohibiting kickbacks. The allegations suggest that Teva engaged in practices to generate federal healthcare business or induce patient referrals improperly. This settlement is a significant financial hit to the company and highlights ongoing legal challenges. The resolution of these allegations may help Teva avoid further legal complications, but the financial impact is substantial.
growth-negative
Teva to pay $450 million to resolve US kickback, price-fixing cases
Teva Pharmaceutical Industries Ltd has agreed to pay $450 million to settle allegations of using charities to pay kickbacks to boost sales of its multiple sclerosis drug Copaxone and conspiring to fix prices for generic drugs. The settlements, announced by the U.S. Department of Justice, include $425 million to resolve a lawsuit filed in Boston in 2020 and a separate $25 million civil settlement for price-fixing claims. Teva did not admit wrongdoing and will pay the amount over six years. The lawsuit alleged that Teva paid over $350 million to charitable foundations to cover co-payments for Copaxone, violating the Anti-Kickback Statute. The drugs price increased significantly during this period, generating substantial revenue for Teva.
growth-positive
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2024 Earnings Call Highlights: Strong Revenue ...
Teva Pharmaceutical Industries Ltd reported a strong financial performance in Q2 2024, with an 11% increase in revenue to $4.2 billion. The company raised its full-year guidance for revenue, EBITDA, and EPS due to strong performance, particularly in AUSTEDO, which saw a 32% revenue increase. Teva launched SIMLANDI, a biosimilar Humira, and received FDA approval for a biosimilar of Stelara, with a planned launch in February 2025. Despite a GAAP net loss of $846 million and a decrease in free cash flow to $324 million, the company remains optimistic about its innovative pipeline and future growth. The TAPI business is undergoing a divestment process, and there is uncertainty regarding the impact of the Inflation Reduction Act on AUSTEDOs future revenue.
growth-positive
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
Teva Pharmaceutical Industries Ltd. announced that the FDA and EMA have accepted applications for TVB-009P, a biosimilar candidate to Prolia (denosumab), aimed at treating osteoporosis in postmenopausal women. This marks Tevas first internally developed biosimilar submitted to the U.S. FDA, supported by comprehensive clinical data. The decision from both agencies is expected in the second half of 2025. Tevas robust biosimilar portfolio includes 7 approved biosimilars and 16 in the pipeline, across therapeutic areas like oncology and immunology. The acceptance of TVB-009P underscores Tevas commitment to expanding global access to affordable biosimilars, leveraging its generics expertise and successful biologics track record. The company aims to enhance its portfolio and offer more affordable treatment options, addressing the high osteoporosis risk among postmenopausal women.
Customers
growth-positive
Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?
Teva Pharmaceutical Industries Ltd. (TEVA) has shown impressive performance in the Medical sector, significantly outperforming its peers with a year-to-date gain of about 67.5%, compared to the sectors average of 7.5%. The company is currently ranked #2 (Buy) by Zacks, indicating strong analyst sentiment and an improving earnings outlook. Teva is part of the Medical - Generic Drugs industry, which has gained an average of 16.7% this year. The article also mentions Adaptive Biotechnologies, another strong performer in the Medical sector. Investors are advised to keep an eye on both companies for potential continued strong performance.
growth-positive
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
The article discusses Teva Pharmaceutical Industries (TEVA) as a strong candidate for value investors, highlighting its favorable valuation metrics. TEVA holds a Zacks Rank of #2 (Buy) and a Value grade of A, with a P/E ratio of 6.53, which is lower than the industry average of 10.10. The stocks P/B ratio is 3, also below the industry average of 3.94. Additionally, TEVAs P/S ratio is 1.22, compared to the industrys average of 2.8. These metrics suggest that TEVA is currently undervalued, making it an attractive option for value investors. The article emphasizes the strength of TEVAs earnings outlook, positioning it as one of the markets strongest value stocks.
growth-positive
Teva and mAbxience partner to develop biosimilar candidate for oncology
Teva Pharmaceuticals International and mAbxience have entered into a global licensing agreement to develop an oncology biosimilar. This marks their second collaboration, reinforcing their partnership. Teva will handle regulatory approvals and market launch in Europe and the US, while mAbxience will focus on development and manufacturing using its facilities in Spain and Argentina. The agreement aligns with mAbxiences global expansion strategy and Tevas aim to grow its biosimilar portfolio through strategic partnerships. This collaboration is expected to enhance healthcare accessibility and innovation. Additionally, Teva settled an $80 million lawsuit with Baltimore over its role in the opioid crisis in September 2024.
Partners
growth-positive
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
Teva Pharmaceutical Industries Ltd and mAbxience have expanded their strategic partnership through a new global licensing agreement to develop an anti PD-1 oncology biosimilar candidate. This marks their second agreement, reinforcing their collaboration that began in April 2024. The partnership aligns with Tevas Pivot to Growth strategy, enhancing its biosimilar portfolio and focusing on providing cost-effective, high-quality treatments. Under the agreement, mAbxience will lead the development and production, while Teva will handle regulatory approvals and commercialization. The collaboration aims to improve access to critical oncology treatments globally. This partnership is a testament to both companies commitment to innovation and accessibility in healthcare.
Partners
growth-positive
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
Teva Pharmaceutical Industries Ltd announced the launch of the first and only generic version of Sandostatin® LAR Depot in the United States. This launch is significant as it showcases Tevas expertise in complex generic formulations and reinforces its position as a leading generics powerhouse. The generic drug, octreotide acetate for injectable suspension, is indicated for the treatment of acromegaly and severe diarrhea associated with carcinoid syndrome. The original Sandostatin® LAR Depot had annual sales of $826 million as of July 2024. This launch is expected to provide patients with a new treatment option and bring value to healthcare systems.
Customers
growth-positive
Why Are Analysts Bullish On Teva Pharmaceutical Industries Limited (TEVA) Right Now?
Teva Pharmaceutical Industries Limited (NYSE:TEVA) has shown strong financial performance in Q2 2024, with revenue increasing by 11% year-over-year to $4.2 billion and non-GAAP EPS surpassing expectations at $0.61. The company is held by 68 hedge funds, up from 58 in the previous quarter, indicating growing institutional interest. Key products like AUSTEDO and AJOVY have shown significant revenue growth, and the generics segment saw a 14% increase. Tevas strategic focus on growth engines, innovation, and generics has led to raised full-year guidance for revenue, EBITDA, and EPS. The company is well-positioned for sustained value delivery to shareholders.
CustomersInvestment
growth-neutral
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
Teva Pharmaceutical Industries Ltd. announced that it will release its financial results for the third quarter of 2024 on November 6, 2024. The company will also conduct a conference call and live webcast on the same day to discuss the results. Teva is a global pharmaceutical leader with a strong focus on generics and innovation. The press release includes a cautionary note regarding forward-looking statements, highlighting various risks and uncertainties. No new partnerships, acquisitions, or investments were mentioned in the announcement.
growth-positive
Invesco EQV European Equity Fund Bolsters Position in Teva Pharmaceutical with a 1. ...
Invesco EQV European Equity Fund, a mutual fund under Invesco Ltd., has disclosed its N-PORT filing for Q3 2024. The fund, which targets high-growth opportunities in European markets, has made significant investments by adding four new stocks, including Teva Pharmaceutical Industries Ltd, Edenred SE, and Arkema SA. It also increased its stakes in seven stocks, notably BAE Systems PLC and London Stock Exchange Group PLC, while reducing its position in 23 stocks, including FinecoBank SpA and Schneider Electric SE. The portfolio now includes 56 stocks, with top holdings in Novo Nordisk AS, Investor AB, and RELX PLC.
Investment
growth-positive
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
Teva Pharmaceutical Industries Ltd. announced that its open-label extension (OLE) study showed long-term improvement in Tardive Dyskinesia (TD) symptoms with deutetrabenazine treatment over three years in European patients. The study, presented at the European College of Neuropsychopharmacology Congress in Milan, revealed that deutetrabenazine was well tolerated and provided sustained symptom improvement. This positive outcome supports deutetrabenazine as an effective treatment option for TD, a condition with high unmet medical needs in Europe. The studys success is expected to enhance Tevas market position and treatment offerings.
Customers
growth-positive
Teva touts safety profile of once monthly schizophrenia therapy
Teva Pharmaceuticals has released new safety data from its Phase III SOLARIS trial and a Phase I study of its extended-release subcutaneous olanzapine, TEV-‘749. The data showed no cases of post-injection delirium/sedation syndrome (PDSS), a serious side effect that has limited the use of long-acting olanzapine. The SOLARIS study met its primary endpoint by showing improvement in schizophrenia symptoms and also met its secondary endpoint by improving clinical global impression severity. The results were presented at the Annual European College of Neuropsychopharmacology Congress in Milan. The positive safety data is expected to boost Tevas market presence, with projected annual sales of $145 million by 2034 in the US.
Customers
growth-positive
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
Teva Pharmaceutical Industries Ltd. presented new data at the 37th Annual European College of Neuropsychopharmacology Congress, demonstrating the effectiveness of switching to UZEDY, an extended-release injectable suspension for treating schizophrenia. The data showed that switching to UZEDY from once-monthly RBP-7000 resulted in comparable pharmacokinetic properties. The ADVANCE survey highlighted key reasons for patients accepting long-acting injectable treatments, including symptom improvement and ease of use. This reinforces Tevas commitment to providing optimal treatment options for schizophrenia patients. The event took place in Milan, Italy, from September 21-24, 2024.
Customers
growth-positive
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
Teva Pharmaceutical Industries Ltd. announced positive results from its Phase 3 SOLARIS trial evaluating TEV-749, a subcutaneous long-acting injectable (LAI) treatment for schizophrenia. The study showed significant improvements in the Positive and Negative Syndrome Scale (PANSS) total score, Clinical Global Impression-Severity (CGI-S) scale, and Personal and Social Performance (PSP) scale compared to placebo. Importantly, no incidences of Post-Injection Delirium/Sedation Syndrome (PDSS) were observed. These findings were presented at the 37th Annual European College of Neuropsychopharmacology (ECNP) Congress. The results suggest that TEV-749 could become a significant treatment option for schizophrenia, addressing unmet needs and potentially improving patient outcomes.
Customers
growth-neutral
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is favoured by institutional owners who hold 68% of the company
The article discusses the ownership structure of Teva Pharmaceutical Industries, highlighting that institutional investors hold 68% of the companys shares. The top 25 shareholders own 47% of the company, with Phoenix Investments & Finances Ltd, BlackRock, Inc., and FMR LLC being the largest shareholders. Insider ownership is under 1%, but insiders hold shares worth $124 million. The general public holds a 32% stake. The article suggests that institutional ownership can significantly influence the companys stock price and provides insights into the potential future performance based on analyst forecasts.
growth-positive
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?
Teva Pharmaceutical Industries Limited has seen a significant rise in its stock, outperforming the industry, sector, and S&P 500. The company, known for its generic and branded drugs, has faced challenges such as losing exclusivity for key drugs and high debt. However, its new drugs, Austedo and Ajovy, and a stable generics business are expected to drive growth. Teva has also made progress with its branded pipeline and biosimilars, partnering with companies like Sanofi and Alvotech. The companys stock is trading at an attractive valuation, making it a prudent investment for long-term investors.
CustomersPartners
growth-positive
Teva to Present at the Bank of America 2024 Global Healthcare Conference
Teva Pharmaceutical Industries Ltd. announced that its President and CEO, Richard Francis, will present at the Bank of America 2024 Global Healthcare Conference on September 19, 2024. The presentation will be available via a live webcast on Teva’s Investor Relations website, with an archived version accessible within 24 hours post-event. Teva is a global pharmaceutical leader with a strong focus on generics and innovative medicines. The company emphasizes its commitment to health and innovation, supported by a workforce of approximately 37,000 employees across 58 markets. The announcement underscores Tevas ongoing efforts to engage with investors and stakeholders, highlighting its strategic focus and future growth plans.
Management Changes
growth-negative
Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial
Baltimore has settled with Walgreens over claims that the pharmacy operator fueled opioid addiction in the city. This settlement is part of a series of agreements totaling $402.5 million ahead of a trial scheduled for next week. Although the exact terms with Walgreens were not disclosed, it is implied to be around $80 million, similar to a recent settlement with Teva Pharmaceutical. Walgreens disputes any liability but agreed to the settlement in the best interests of its stakeholders. Other defendants like Johnson & Johnson, McKesson, and Cencora are still scheduled to face trial. Baltimore has previously settled with other companies like CVS, Cardinal Health, and AbbVies Allergan unit.
Customers
growth-negative
Teva agrees to pay Baltimore City $80m for fuelling opioid epidemic
Teva Pharmaceuticals has reached an $80 million settlement with the city of Baltimore for its role in exacerbating the opioid crisis. This settlement validates Baltimores decision to opt out of a larger national settlement, which would have provided the city with only $11 million over 13 years. Instead, Teva will make an initial payment of $35 million by the end of 2024, with the remaining $45 million paid by July next year. The funds will be used for education, outreach, and support efforts related to the opioid crisis. Baltimores total recovery in opioid settlements now stands at $322.5 million, including previous settlements with Allergan, CVS, and Cardinal Health.
Customers
growth-negative
Update: Teva Pharmaceutical Faces Fine in EU for Dismissive Tactics Against Rivals
Teva Pharmaceutical is facing a fine from the European Union for employing dismissive tactics against its rivals. The details of the fine and the specific actions leading to it were not disclosed in the brief article. This development is likely to have a negative impact on the companys growth prospects as it may face financial penalties and reputational damage.
growth-positive
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires announced that health care stocks advanced in the late afternoon. The article encourages readers to upgrade to a Silver or Gold subscription plan to access premium news articles. This move is likely aimed at increasing the companys revenue through subscription services.
growth-neutral
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan has shown significant interest in Teva Pharmaceutical Industries Ltd and other companies within the specialty pharma sector, noting a resurgence in new product launches and a more stable pricing environment for generics and established brands. Despite this, the overall sector growth remains modest with a top-line CAGR of 0-2%. JP Morgan maintains a Neutral rating for Teva, citing a fully accounted branded pipeline and cautious outlook on its U.S. generic business. The firm also adjusted ratings for other companies, including Viatris, Perrigo, Amphastar, Amneal, and Organon, reflecting varying degrees of optimism and caution based on market conditions and company performance.
Investment
growth-positive
Teva Named One of the World's Most Sustainable Companies
Teva Pharmaceutical has been recognized as one of the most sustainable companies in the world by TIME magazine and Statista. The company has made significant strides in sustainability, achieving a 27% reduction in scope 1 and 2 emissions by 2023, ahead of its 2025 target. Teva aims for a 46% reduction by 2030 and net zero emissions by 2045. The company has issued $7.5 billion in sustainability-linked bonds and received high scores from various environmental rating agencies. Teva also emphasizes responsible antibiotic manufacturing and works closely with suppliers to meet high sustainability standards.
growth-positive
Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Teva Pharmaceutical Industries Ltd. announced that its President and CEO, Richard Francis, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024. The presentation will be available via live webcast on Teva’s Investor Relations website. Teva is a global pharmaceutical leader with a strong focus on generics and innovation. The company employs around 37,000 people across 58 markets. The announcement also includes a cautionary note regarding forward-looking statements, highlighting potential risks and uncertainties.
Management Changes
Growth-Positive
Teva Pharmaceutical Industries Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Teva Pharmaceutical Industries reported a revenue of US$4.16 billion, up 7.4% from 2Q 2023. The companys net loss narrowed by 3.0% from 2Q 2023 to US$846.0 million. However, the earnings per share (EPS) fell short of analyst estimates by 87%, while revenue exceeded estimates by 2.9%. Over the next three years, the companys revenue is forecast to grow at an average rate of 2.5% per annum. The companys shares are up 1.9% from a week ago.
Growth-Positive
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
The article discusses the trading volumes of three biotech companies: Pfizer, Merck, and Teva Pharmaceuticals. Pfizers second-quarter revenue exceeded expectations, leading to a surge in trading volume. Merck, on the other hand, saw a drop in shares despite steady financial metrics due to concerns about the demand for its HPV vaccine in China and the upcoming patent expiration of its cancer drug, Keytruda. Teva Pharmaceuticals, which has the worlds largest generic drug portfolio, also saw a significant trading volume. The companys approach to the pharmaceutical sector seems to be succeeding, with nearly 200 million people globally taking Teva medicine daily.
CustomersManagement Changes
growth-positive
TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up
Teva Pharmaceutical Industries reported Q2 2024 adjusted earnings of 61 cents per share, beating the Zacks Consensus Estimate of 57 cents. Revenues for the quarter were $4.16 billion, beating the Zacks Consensus Estimate of $3.99 billion. Sales growth was driven by higher revenues from generic products globally and the branded drug Austedo in the US and international markets. The companys stock gained 6.2% on July 31 as investors responded positively to the better-than-expected results and the raised financial outlook for 2024. Teva has raised its financial outlook for 2024, expecting net revenues in the band of $16-$16.4 billion.
CustomersPartnersExpand
growth-positive
Teva Pharmaceutical Industries (TEVA) Q2 2024 Earnings Call Transcript
Teva Pharmaceutical Industries reported its Q2 2024 earnings, highlighting significant growth across all business segments. The companys revenue increased by 11% to $4.2 billion, driven by its innovative and generics businesses, as well as its TAPI division. The companys Austedo product performed exceptionally well, with revenue growth of 32%. The company also raised its guidance for the year due to these strong results. The companys CEO, Richard Francis, discussed the companys pivot to growth strategy, which has led to six quarters of continuous growth. The company also plans to divest its TAPI division by H1 2025.
CustomersInvestmentExpand
Growth-Positive
Teva Pharmaceutical Industries (TEVA) Reports Q2 Earnings: What Key Metrics Have to Say
Teva Pharmaceutical Industries Ltd. reported a 7.4% YoY increase in revenue for Q2 2024, amounting to $4.16 billion, which was a 4.3% surprise over the Zacks Consensus Estimate of $3.99 billion. The EPS of $0.61 also surpassed the consensus estimate of $0.57, marking a 7.02% surprise. The company saw varying changes in geographic revenue, with a 23.8% increase in International Markets, a 6% increase in the United States, and a 26.6% increase in COPAXONE in the United States. However, there was a 40.6% decrease in BENDEKA / TREANDA in the United States.
Customers
growth-positive
Is Teva Pharmaceutical Industries (TEVA) Stock Undervalued Right Now?
Zacks Investment Research has highlighted Teva Pharmaceutical Industries as a strong value stock. The company is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock has a Forward P/E ratio of 6.39, compared to its industrys average Forward P/E of 10.02. Other valuation metrics such as P/B ratio and P/S ratio also indicate that Teva Pharmaceutical Industries is likely being undervalued at the moment. Considering these figures and the strength of its earnings outlook, Teva Pharmaceutical Industries is considered a great value stock at the moment.
Investment
growth-positive
Teva Pharma Flirts With Breakout As Generic Drugs Drive Beat-And-Raise
Teva Pharmas stock saw a significant increase in early trading on Wednesday, following a successful second quarter driven by generic drugs. The company also raised its future outlook.
Customers
growth-positive
Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance
Teva Pharmaceutical Industries Ltd reported Q2 2024 revenues of $4.2 billion, reflecting a 7% increase in U.S. dollars or 11% in local currency terms compared to Q2 2023. The companys generics business grew across all regions, with increases of 16% in the U.S., 8% in Europe, and 22% in International Markets. The company also reported positive Phase 3 efficacy results for olanzapine LAI (TEV 749) and announced the acceleration of the development timeline for duvakitug (Anti-TL1A). The companys full year 2024 business outlook has been raised to revenues of $16.0 - $16.4 billion.
CustomersExpand
growth-positive
Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings
Haemonetics Corporation is set to report its first-quarter fiscal 2025 results on August 8. The company has a strong history of beating earnings estimates, with an average surprise of 13.24% over the past four quarters. The Zacks Consensus Estimate for revenues is $335.9 million, a 7.9% increase from the previous year. The companys Hospital and Plasma business segments are expected to have contributed significantly to this growth, with the Hospital business revenues expected to increase by 29.9% year over year. The companys growth has also been fueled by the acquisitions of OpSens and Attune.
CustomersAcquisition
growth-positive
Unveiling Teva Pharmaceutical Industries (TEVA) Q2 Outlook: Wall Street Estimates for Key Metrics
Wall Street analysts predict that Teva Pharmaceutical Industries Ltd. will report quarterly earnings of $0.57 per share, a 1.8% increase YoY. Revenues are expected to reach $3.99 billion, up 2.8% from the same quarter last year. Despite a 1% downward revision in the consensus EPS estimate over the past 30 days, the companys stock has seen a 5.2% increase in the past month. Analysts also provided estimates for various revenue categories, including a projected 31.7% YoY increase in Geographic Revenue- International Markets and a 20.6% YoY increase in Geographic Revenue- United States- AUSTEDO.
Investment
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
growth-positive
Teva reports positive data from Phase III paediatric migraine prevention trial
Teva Pharmaceutical has reported positive results from the Phase III SPACE clinical trial of AJOVY (fremanezumab) in preventing episodic migraines in children and adolescent patients aged six to 17 years. The trial met its primary endpoint, with AJOVY showing statistically significant superior efficacy versus a placebo. The safety data from the trial was in line with those seen in adult populations, without any new safety concerns reported. Teva is continuing its research into the impact of AJOVY on paediatric subjects with chronic migraine.
InvestmentExpand
growth-positive
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
Teva Pharmaceutical Industries late-stage study of Ajovy (fremanezumab) for preventing episodic migraine in pediatric and adolescent patients has met its primary efficacy endpoint. Ajovy is already approved in several countries for prophylaxis of migraine in adults. The company is now looking to expand the eligible patient population to include children and adolescents aged six to 17 years. The results of the study are significant as there are currently no approved preventive migraine treatments for children and adolescents. Sales of Ajovy and Austedo, another drug in Tevas portfolio, grew 18% and 28% respectively in 2023.
CustomersExpand
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
Growth-Positive
3 No-Brainer Stocks to Buy With $200 Right Now
The article discusses the potential for growth in Airbnb, Teva Pharmaceutical Industries, and Pinterest, suggesting that these companies are good investment options. Airbnb is seen as a strong investment due to its potential for expansion and revenue growth beyond stays. Teva Pharmaceutical Industries has managed to reduce its debt significantly and refocus its operations on higher-margin, faster-growing novel therapies. Pinterests global monthly active users hit an all-time high of 518 million in the first quarter, indicating that the platforms improvements are paying off. The company is also expected to evolve into a significant e-commerce destination in the second half of the decade.
Investment
growth-positive
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
The article discusses the growth and challenges of the generic drug industry, focusing on companies like Amphastar Pharmaceuticals, Teva Pharmaceuticals, and Viatris. Despite facing macroeconomic headwinds like price erosion, these companies are benefiting from the rising volume of existing and new generic drugs. They are focusing on being the first to market their generic drugs to enjoy market exclusivity for a limited period and generate profits. The loss of patent exclusivity of branded drugs provides significant opportunities for these companies. However, they also face stiff competition and the need for patent settlements. The article also highlights the industrys positive prospects and mentions a few noteworthy stocks.
CustomersPartnersManagement Changes
growth-negative
FTC investigates Teva over contested product patents
The Federal Trade Commission (FTC) is investigating Teva Pharmaceuticals over certain patents that may have blocked competition for asthma and chronic obstructive pulmonary disease (COPD) medications. The FTC alleges that Teva has made minor tweaks to its products to maintain patent exclusivity. The patents in question are listed in the FDAs Orange Book, a compendium of approved drug products. The FTC has ordered Teva to provide internal communications, analysis, and financial data related to the contested patents by 24 July. The FTC first entered the dispute in April when it sent warning letters to several companies, including Teva.
Customers
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
Growth-Positive
Correction: Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity
The article discusses several major acquisitions. Boeing is set to acquire Spirit AeroSystems, Robinhood is acquiring Pluto, and BlackRock is acquiring Preqin. Additionally, the FTC is probing Teva. The article requires a subscription to access more details.
Acquisition
Growth-Negative
Update: Market Chatter: Teva Pharmaceuticals Faces FTC Probe on Patent Listings
Teva Pharmaceuticals is facing an FTC probe regarding its patent listings. The details of the probe and its potential impact on the company are not provided in the article.
Customers
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
Growth-Positive
Here's Why You Should Consider Buying Alvotech (ALVO) Stock
Alvotech, a company that makes biosimilar versions of branded medicines, has seen a transformational year in 2024, transitioning from an R&D company into a full-scale global commercial biologic company. The company gained approval for key biosimilar products like AVT04 and AVT02, biosimilars to J&J’s Stelara and AbbVie’s Humira respectively. Alvotech has a commercialization partnership with Teva Pharmaceuticals in the United States. The company also signed new commercialization agreements for Simlandi in the United States and for AVT03 in the United States and Europe. Alvotech raised its revenue guidance for 2024 to $400-$500 million from $300-$400 million.
PartnersExpand
Growth-Positive
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a Positive Rating from Analysts?
Teva Pharmaceutical Industries Limited is highlighted as a promising investment among Robinhood stocks under $20. The companys Pivot to Growth strategy has shown signs of success, with a consensus Moderate Buy recommendation and a high price forecast of $22. The companys entrance into the $33 billion biosimilars market also makes a bullish case for it. Tevas long-acting Olanzapine for schizophrenia has met all primary and secondary endpoints, with significant potential due to the unmet need for long-acting treatments in this space. The companys anti-IL15 program targeting celiac disease is also showing promise.
InvestmentCustomers
growth-negative
טבע מפטרת עשרות עובדים בישראל — ומעבירה משרות לחו"ל
Teva Pharmaceutical Industries is laying off dozens of employees in Israel and relocating jobs abroad as part of its Pivot to Growth strategy. Despite the layoffs, the companys stock has risen by 122% in the past 12 months and by 66% since January 2024. As of the end of 2023, Teva employed 37,851 people, including 3,385 in Israel.
LayoffsExpand
growth-positive
7 A-Rated Biotech Stocks Worth Betting on in June
The article discusses seven biotech companies that are considered good investment options due to their promising drug developments and strong stock performance. These companies include Eli Lilly & Co., Lexaria Bioscience, Novo Nordisk, Ocugen, Candel Therapeutics, Teva Pharmaceutical, and GSK. The companies have made significant advancements in healthcare, with several of their drugs receiving FDA approval. The article highlights the potential high returns for investors due to the companies groundbreaking innovations and the potential for their stock prices to increase significantly if their new drugs win regulatory approval.
Investment
growth-negative
Teva sues Corcept over mifepristone 'monopoly' for rare disorder
Teva Pharmaceuticals has filed a lawsuit against Corcept Therapeutics and Optime Care, accusing them of monopolizing the market for mifepristone-based Korlym, a drug used to treat Cushings syndrome. Teva alleges that Corcept and Optime have orchestrated a scheme to stifle competition from Teva by paying bribes and kickbacks to physicians to keep them prescribing brand Korlym. Teva launched its generic version of Korlym five months ago, but has captured close to zero market share. The lawsuit also accuses Corcept of artificially inflating the cost of Korlym.
CustomersPartners
growth-positive
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Teva Pharmaceutical Industries has faced significant revenue losses since losing exclusivity of its key multiple sclerosis medicine, Copaxone, in 2015. However, the company expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters. In the past year, shares of Teva have risen 135.3%. Teva also has a high debt load and faces some price-fixing charges. Despite these challenges, the company has made progress with its branded pipeline and expects to launch several new products in the coming years.
CustomersPartnersManagement Changes
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
growth-positive
FDA approves Teva Pharmaceuticals’ AUSTEDO XR for TD and HD chorea
The US Food and Drug Administration (FDA) has approved Teva Pharmaceuticals AUSTEDO XR extended-release tablets as a once-daily treatment for adults with tardive dyskinesia (TD) and Huntingtons disease (HD) chorea. The approval covers four new tablet strengths of 30, 36, 42, and 48mg. Patients may notice symptom improvement within two weeks of starting AUSTEDO XR. The drug is the most flexible once-daily dosing option of any vesicular monoamine transporter 2 (VMAT2) inhibitor. In April 2024, Teva Pharmaceuticals and Alvotech announced FDA approval for Selarsdi (ustekinumab-aekn) via subcutaneous injection.
CustomersPartners
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
growth-positive
טבע משקיעה 10 מיליון דולר בטכנולוגיה רפואית ישראלית
Teva Pharmaceutical Industries Ltd. announced an investment of $10 million in Sanara Capital, a medical technology (Health-Tech) fund from the Sanara group. This investment aligns with Tevas commitment to innovation, supporting its Pivot to Growth strategy, and expressing confidence in the Israeli biotech and biomed ecosystem. Sanara Capital is a venture capital fund that invests in Israeli startups in the fields of digital health, Bio-Convergence, and medical equipment. The fund was established two years ago and has so far invested in six companies.
InvestmentPartners
growth-positive
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Teva Pharmaceuticals and Alvotech have announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S. This is the first interchangeable high-concentration, citrate-free biosimilar to Humira for the treatment of various adult diseases. The launch of SIMLANDI is expected to create opportunities for cost savings across the healthcare system. Teva and Alvotech entered into a strategic partnership for the exclusive commercialization of five of Alvotech’s biosimilar product candidates in August 2020, which was later extended to include two additional biosimilars.
PartnersExpand
Growth-Negative
Insider Sale: Chief Accounting Officer Amir Weiss Sells 28,135 Shares of Teva Pharmaceutical ...
On May 16, 2024, Amir Weiss, the Chief Accounting Officer of Teva Pharmaceutical Industries Ltd, sold 28,135 shares of the company at a price of $16.73 each, totaling approximately $470,286.35. This sale is part of a broader trend observed over the past year, where Teva has seen a total of 17 insider sales and no insider buys. Over the past year, Weiss has sold a total of 61,882 shares of Teva, with no recorded purchases. The company currently holds a market cap of approximately $18.75 billion.
Public Trading
growth-negative
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The Federal Trade Commission (FTC) is targeting pharmaceutical companies, including Novo Nordisk, Teva Pharmaceutical Industries, and Amphastar Pharmaceuticals, alleging they are using junk patents to protect their investments and keep generic drugs at bay. The FTC is challenging over 300 patents filed by 10 pharma stocks. The regulatory body alleges these companies violated antitrust laws by improperly listing the patents. This move could potentially impact the companies growth and profitability.
CustomersPartners
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
Growth-Positive
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
Aldeyra Therapeutics, Inc. (ALDX) has been outperforming its peers in the Medical sector, according to Zacks Investment Research. The companys stock has returned 5.4% so far this year, compared to an average return of 3.8% for Medical companies. The Zacks Consensus Estimate for ALDXs full-year earnings has moved 66.3% higher over the past three months, indicating a stronger analyst sentiment and an improving earnings outlook. The company currently has a Zacks Rank of #2 (Buy).
Investment
Israel’s Once-Dominant Drugmaker Is Revived by Innovation
Growth-Positive
Israel’s Once-Dominant Drugmaker Is Revived by Innovation
Teva Pharmaceuticals stock has seen a significant increase, nearly doubling in the past year. This growth has been attributed to Wall Streets excitement about the companys branded portfolio.
Investment
growth-positive
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
Teva Pharmaceutical Industries (TEVA) is currently being highlighted as a strong value stock, according to Zacks Investment Research. The company is sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock has a Forward P/E ratio of 6.46, compared to its industrys average Forward P/E of 10.12. Other key valuation metrics such as PEG ratio, P/B ratio and P/S ratio also suggest that the stock is likely being undervalued at the moment. This, combined with the strength of its earnings outlook, makes TEVA an impressive value stock currently.
growth-negative
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2024 Earnings Call Transcript
Teva Pharmaceutical Industries Limited reported its Q1 2024 earnings, missing expectations with a reported EPS of $-0.12161, compared to the expected $0.51. The company also announced positive Phase 3 results from its olanzapine LAI trial. Despite the earnings miss, the company reported its fourth consecutive quarter of growth, attributing this to its Pivot to Growth strategy. The company also reported growth in its generics business and plans to launch biosimilar Humira and SIMLANDI in Q2. Teva reaffirmed its 2024 financial outlook.
Management ChangesInvestment
growth-negative
Affirm stock sinking, Good Buy or Goodbye: Market Domination
The article discusses the performance of several companies including Affirm, Tripadvisor, Teva Pharmaceutical Industries, Dutch Bros, and Uber. Affirms shares are sinking despite topping fiscal third-quarter revenue estimates. Tripadvisors shares are down after rejecting the idea of a potential sale. Teva Pharmaceutical Industries shares are surging after unveiling positive results from its Schizophrenia treatment study. Dutch Bros shares are rising after reporting positive first quarter results. Uber shares are down after the companys first quarter results revealed gross bookings fell below estimates.
CustomersPartnersManagement Changes
growth-positive
Teva and Medincell report positive data for TEV-‘749 in schizophrenia trial
Teva and Medincell have announced positive results from the Phase III SOLARIS trial evaluating TEV-‘749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia. The trial met its primary endpoint, showing significant symptom reduction in patients. The treatment, which uses Medincell’s SteadyTeq technology, was well tolerated across all dosing groups. The partners are now assessing the long-term safety of TEV-‘749 and the incidence of post-injection delirium/sedation syndrome in the SOLARIS open-label study.
Partners
growth-positive
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
Teva Pharmaceutical Industries Limited reported Q1 2024 earnings of 48 cents per share, missing the Zacks Consensus Estimate of 51 cents per share. However, revenues of $3.82 billion beat the estimate of $3.7 billion, rising 4% on a reported basis and 5% on a constant currency basis. Sales growth was driven by higher revenues from generic products globally and the branded drug Austedo. Teva and partner Alvotech announced FDA approval of Simlandi injection, a biosimilar version of AbbVie’s blockbuster immunology drug Humira. The FDA also approved Teva and Alvotech’s Selarsdi, a biosimilar version of J&J’s blockbuster immunology drug, Stelara.
PartnersCustomers
growth-positive
Teva Pharmaceutical Industries First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Teva Pharmaceutical Industries reported a revenue of US$3.82 billion, up 4.3% from 1Q 2023, and a net loss of US$139.0 million, which is a 32% improvement from 1Q 2023. The companys revenue exceeded analyst estimates by 2.1%, but its earnings per share (EPS) fell short by 149%. Over the next three years, the companys revenue is expected to grow at an average rate of 2.2% per annum. The companys shares have risen by 13% in the past week.
Customers
growth-positive
Teva Pharmaceutical Industries (TEVA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Teva Pharmaceutical Industries Ltd. reported a revenue of $3.82 billion for the quarter ended March 2024, a 4.3% increase from the same period last year. The EPS was $0.48, compared to $0.40 in the year-ago quarter. The reported revenue was higher than the Zacks Consensus Estimate of $3.7 billion, representing a surprise of +3.25%. However, the company delivered an EPS surprise of -5.88%, with the consensus EPS estimate being $0.51. The companys shares have returned -0.1% over the past month.
Customers
Growth-Positive
Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First Quarter
Tevas stock surged to a five-year high on Wednesday, May 8, 2024, despite missing first-quarter profit views. The drugmaker maintained its full-year guidance, which led to the surge in its stock price.
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
Growth-Positive
UPDATE 1-Teva Pharm Q1 profit misses estimates, revenue risea
Teva Pharmaceutical Industries has reported a smaller than expected rise in Q1 profit, citing higher impairments of tangible assets. However, sales of its generic and branded drugs, including treatments for migraines and Huntingtons disease, increased. The company earned 48 cents per diluted share excluding one-time items in the January-March quarter, up from 40 cents per share a year earlier. Revenue rose 4% to $3.82 billion. Teva is betting on a trio of branded drugs - Austedo, Ajovy and Uzedy - to help it recover from a difficult few years.
Customers
growth-positive
Teva Pharmaceutical Industries (TEVA) Q1 2024 Earnings Call Transcript
Teva Pharmaceutical Industries has reported its Q1 2024 earnings call, highlighting continuous growth for the fourth quarter in a row. The companys CEO, Richard Francis, attributed this success to the implementation of the Pivot to Growth strategy, which focuses on innovation, creating a sustainable generics powerhouse, and business focus. The company also reported positive phase 3 results from the olanzapine LAI trial, a long-acting treatment for schizophrenia. The companys CFO, Eli Kalif, confirmed a good start to the year with a 5% increase in revenue, a 12% increase in adjusted EBITDA, and an 18% increase in non-GAAP EPS.
InvestmentManagement ChangesExpand
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
growth-positive
Teva Pharm Q1 profit misses estimates, revenue risea
Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit due to higher impairments of tangible assets. However, sales of its generic and branded drugs, including treatments for migraines and Huntingtons disease, increased. The company earned 48 cents per diluted share excluding one-time items in the January-March quarter, up from 40 cents per share a year earlier. Revenue rose 4% to $3.82 billion. Teva is optimistic about its trio of branded drugs - Austedo, Ajovy and Uzedy - which it hopes will help the company recover from a challenging period.
CustomersPartners
Growth-Positive
Teva Earnings Are Soon. What Could Keep the Stock Gains Going.
Shares of Teva Pharmaceutical Industries have increased by nearly 35% this year, a significant change from the past decade where the companys American depositary receipt value either fell or stagnated. The companys executives are set to present the first-quarter results on Wednesday and will face questions from Wall Street about whether the company can sustain this upswing.
growth-positive
20 States with the Highest Fertility Rates in the US
The global fertility market is a rapidly growing industry, with the potential to reach $1.7 trillion in total demand for assisted reproductive technology (ART) services. The US fertility services market is also experiencing growth, with the market being valued at $22 billion in 2022 and is expected to reach $68.32 billion by 2032. Major players in the global infertility treatment market include Thermo Fisher Scientific Inc., Cook Group, and Vitrolife. The global contraceptives market is also experiencing significant growth, expected to grow from $33 billion in 2023 to $62 billion by 2033. Key players in this sector include Teva Pharmaceutical Industries Limited, Organon Group Of Companies, and Church & Dwight Co., Inc.
CustomersPartnersExpand
growth-positive
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
The article discusses the upcoming Q1 2024 earnings reports of five drug/generic companies: Viatris, Perrigo, Teva Pharmaceutical, Iovance Biotherapeutics, and ACADIA Pharmaceuticals. The majority of large drugmakers have already reported their results, with many beating estimates for both earnings and sales. Some companies have also raised their guidance for 2024. The Medical sector, which includes the pharma/biotech industry, is expected to see a decline in earnings of 25.1%, while sales are expected to rise 7.1% year over year.
CustomersInvestment
growth-positive
Teva Pharmaceutical Industries (NYSE:TEVA) shareholders have earned a 54% return over the last year
Teva Pharmaceutical Industries share price has increased by 54% in the last year, outperforming the market return of around 24%. Over the past three years, the stock price is 36% higher. Despite the company not currently being profitable, it has seen a revenue growth of 6.2% last year. The share price gain is in line with the revenue growth. The companys future profit levels are being predicted by numerous analysts.
Investment
growth-positive
Unlocking Q1 Potential of Teva Pharmaceutical Industries (TEVA): Exploring Wall Street Estimates for Key Metrics
Teva Pharmaceutical Industries Ltd. is expected to post an increase in quarterly earnings of 27.5% year-over-year, according to Wall Street analysts. The companys revenues are also forecasted to increase by 1% to $3.7 billion. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Analysts have also made projections for some of the companys key metrics, including Revenue- API sales to third parties and Geographic Revenue- North America. Over the past month, Teva Pharmaceutical Industries shares have recorded returns of +1.1%.
Investment
Neutral
A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation
The article discusses the upcoming earnings reports of several fast-moving companies including Disney, Toyota, Ferrari, and Constellation. The reports are expected as the earnings season is nearing its end.
None
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
growth-positive
Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...
Corcept Therapeutics Inc reported a significant increase in revenue and net income for Q1 2024, with a robust cash position of $451 million. The company has completed enrollment in four late-stage studies, advancing its pipeline, particularly with the drug relacorilant for Cushings syndrome. However, the company faces legal challenges, including a court ruling allowing Teva Pharmaceuticals to market a generic version of Korlym, potentially impacting future revenues. Despite this, the company has not observed a significant impact on its business yet. The companys future growth is heavily dependent on the successful approval and commercialization of new products like relacorilant.
CustomersInvestment
growth-positive
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript
Corcept Therapeutics Incorporated reported a Q1 2024 earnings beat with a reported EPS of $0.2503 against expectations of $0.21. The companys revenue in Q1 2024 was $146.8 million, a 39% increase compared to the same period in the previous year. The company also increased its 2024 revenue guidance to $620 million to $650 million. Corcept is currently in a legal dispute with Teva Pharmaceuticals over patent infringement. The company also reported progress in its research and development programs, including the completion of enrollment in four late-stage studies.
CustomersPartnersManagement ChangesExpand
Teva to Present at the 2024 Bank of America Healthcare Conference
growth-positive
Q1 2024 Corcept Therapeutics Inc Earnings Call
Corcept Therapeutics Inc reported its financial results for the first quarter of 2024, with a revenue of $146.8 million, a 39% increase compared to the first quarter of the prior year. The company expects its revenue growth to continue and has increased its 2024 revenue guidance to $620 million to $650 million. Corcept is also involved in a legal dispute with Teva Pharmaceuticals over patent infringement. The company is also making progress in its development stage programs, including the completion of enrollment in four late-stage studies and the release of open label data from its GRACE study.
CustomersInvestmentManagement Changes
growth-positive
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
Alvotech, a global biotech company, has announced a strategic agreement to manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals. This is in alignment with Alvotech’s U.S. commercialization agreement with Teva Pharmaceuticals. The biosimilar will be distributed under Quallent’s private label. The U.S. Food and Drug Administration (FDA) approved Alvotech’s biosimilar on February 24, 2024, for the treatment of various diseases. This is the first high-concentration, citrate-free biosimilar to Humira® granted an interchangeability status by the FDA.
PartnersExpand
growth-negative
UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
The U.S. Supreme Court has declined to hear an appeal by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz, which were previously declared invalid in a dispute with generic drugmakers Teva and Apotex. The decision upholds a previous ruling by the U.S. Court of Appeals for the Federal Circuit against Vanda. The case could have provided the Supreme Court with an opportunity to consider when a patent can be invalidated as obvious based on earlier publications describing the same invention.
CustomersPartners
growth-positive
11 Best Low Price Pharma Stocks To Invest In
The article discusses the performance of the pharmaceutical industry and highlights the best low price pharma stocks to invest in. It mentions that despite the overall pharma stock index being down, companies like Johnson & Johnson, AstraZeneca, and Pfizer have made significant strides. Johnson & Johnson is acquiring Shockwave Medical for $13.1 billion, AstraZeneca has received FDA approval for its cancer and asthma drugs, and Pfizer has announced positive phase three data for its respiratory disease vaccine. The article also lists the best low price pharma stocks to invest in, including Viatris Inc., Teva Pharmaceutical Industries Limited, and Elanco Animal Health Incorporated among others.
InvestmentAcquisition
growth-positive
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
The article discusses the current state and future prospects of the generic drugs industry, focusing on three companies: Teva Pharmaceuticals, Dr. Reddy’s Laboratories, and Viatris. These companies are expected to overcome macroeconomic challenges due to the continued demand for their products, new product launches, and cost optimization policies. The industry faces stiff competition and regulatory pressure, but opportunities arise from the loss of patent exclusivity of branded drugs. The companies are also focusing on first-to-file or first-to-market opportunities and complex generics. The article also mentions the industrys stock market performance and current valuation.
CustomersExpand
growth-positive
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
The generic drugs industry is facing stiff competition due to the presence of numerous drugmakers and regulatory pressure on drug quality and manufacturing. However, companies like Teva Pharmaceuticals, Dr. Reddy’s Laboratories, and Viatris are expected to overcome these challenges due to continued demand for their existing products, new product launches, and cost optimization policies. The industry relies heavily on the loss of patent exclusivity of branded drugs, which allows them to develop and market identical versions. The industry is also influenced by patent settlements and the successful resolution of patent challenges.
CustomersExpand
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
Neutral
Israeli economy has proven to thrive despite crisis: Expert
David Blumberg of Blumberg Capital discussed the resilience of the Israeli economy amidst recent attacks from Iran. Despite the conflict, he noted that Israels GDP per capita has grown consistently over the past 25 years, even outpacing some of the worlds largest economies. He attributed this growth to the countrys ability to thrive through downturns and the significant impact of the tech boom. Blumberg also highlighted the resilience of the Israeli people, who continue to go about their daily lives despite the conflict.
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
Growth-Positive
3 No-Brainer Stocks to Buy With $600 Right Now
The article discusses three companies, Realty Income, Teva Pharmaceutical Industries, and Block, that are considered good investment options. Realty Income, a retail real estate investment trust, has raised its payout for 106 consecutive quarters and has a superior commercial real estate portfolio. Teva Pharmaceutical Industries, a brand-name and generic-drug developer, has managed to clear many of its previous issues and is expected to expand sales in 2025. Block, a fintech innovator, has a growing popularity among larger businesses and is expected to drive cash flow and profits substantially higher throughout the remainder of the decade.
InvestmentAcquisition
growth-negative
Biden and Senator Sanders to highlight efforts lower cost of asthma inhalers
U.S. President Joe Biden and Senator Bernie Sanders are hosting a White House event to highlight their efforts to reduce the cost of asthma inhalers. They criticized four inhaler manufacturers, AstraZeneca, Boehringer, Teva Pharmaceuticals, and GSK, for their high prices in the U.S. compared to other countries. The Biden administration is also trying to increase competition by cracking down on falsely claimed patents. In March, three of the four companies decided to cap inhaler costs at $35. Biden will also discuss the Inflation Reduction Act, which includes a $2,000 cap on Medicare prescription drugs and a $35 cap on insulin.
Customers
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
growth-positive
UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Teva Pharmaceutical and Viatris have successfully convinced a US appeals court to reconsider their challenges to a patent covering Johnson & Johnsons schizophrenia drug, Invega Sustenna. This gives them a new opportunity to launch cheaper generic versions of the drug. The court suggested that the last remaining J&J patent may be invalid. J&J sold more than $4.1 billion worth of Invega Sustenna and related drugs worldwide last year, with nearly $2.9 billion in U.S. sales.
Customers
growth-positive
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Teva Pharmaceutical and Viatris have successfully convinced a U.S. appeals court to revive their challenges to a patent covering a Johnson & Johnson schizophrenia drug. This decision gives them a new opportunity to launch cheaper generic versions of the medicine. The U.S. Court of Appeals for the Federal Circuit stated that the last remaining J&J patent covering its Invega Sustenna may be invalid, and the case has been sent back to a New Jersey federal court for reconsideration.
Customers
growth-positive
Bausch (BHC) Soars 6.4%: Is Further Upside Left in the Stock?
Bausch Healths shares rose by 6.4% in the last trading session, closing at $10.49. This increase is likely due to the companys efforts to expand its portfolio and reduce its debt. Bausch exceeded expectations in both revenues and earnings in the fourth quarter. The companys Salix business continues to perform well, and the approval of additional drugs is expected to boost revenue. Bausch is expected to post quarterly earnings of $0.74 per share in its upcoming report, a year-over-year change of +42.3%. Revenues are expected to be $2.14 billion, up 9.9% from the year-ago quarter.
Expand
growth-positive
Institutional investors have a lot riding on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with 67% ownership
Institutional investors hold a 67% stake in Teva Pharmaceutical Industries, which could make the companys stock price vulnerable to their trading decisions. The company gained US$830m in market cap last week, and its one-year return to shareholders is currently 61%. The largest shareholder is Phoenix Investments & Finances Ltd with 5.4% of shares, followed by BlackRock, Inc. and Norges Bank Investment Management, each with 3.8%. The top 25 investors have a combined ownership of 50% in the company. The general public owns 33% of the company.
Investment
Growth-Positive
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
Corcept Therapeutics has seen steady progress with its drug, Korlym, which is approved for the treatment of hyperglycemia secondary to hypercortisolism. The drug has been a consistent revenue driver, recording sales of $482.4 million in 2023, up around 20% year over year. The company expects total revenues in the range of $600-$630 million in 2024. Corcept is also evaluating its lead pipeline candidate, relacorilant, in phase III of the GRACE study to treat Cushing’s syndrome. However, the company faced a setback after losing a patent infringement lawsuit against Teva Pharmaceuticals.
CustomersPartnersManagement Changes
growth-positive
25 Countries with the Lowest Fertility Rates
The article discusses the global infertility market, highlighting countries with the lowest fertility rates and the impact on their socio-economic landscape. It mentions major players in the infertility treatment market, including Thermo Fisher Scientific, Cook Group, Vitrolife, and others. The global fertility services market was valued at USD 22 billion in 2022 and is expected to reach USD 68.32 billion by 2032. The article also discusses the global contraceptive market, with key players such as Teva Pharmaceutical Industries Limited, Organon Group Of Companies, and Church & Dwight Co., Inc. dominating the sector. The global contraceptive markets size is expected to reach $45 billion by 2033.
CustomersInvestment
growth-positive
Q4 2023 Alvotech SA Earnings Call
Alvotech SA held its Q4 and full-year 2023 earnings conference call, discussing key highlights related to its full year 2023 results. The company announced that it has successfully cleared its inspection status with the US FDA, allowing it to access the largest pharma market in the world. This has led to the approval of SIMLANDI in the US and clears the way for its biosimilar to STELARA, which is expected to be approved by the FDA next month. Alvotech also plans to file at least three applications for new biosimilar candidates this year. The company also expanded its commercial network through existing and new strategic partnerships, including an expanded partnership with Teva in the US and Fuji Pharma in Japan.
CustomersPartnersExpand
growth-positive
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
GSK plc has announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, starting in 2025. This move follows similar actions by rivals AstraZeneca and Boehringer Ingelheim. The cap will apply to all of GSKs asthma and chronic obstructive pulmonary disease (COPD) inhalers. The decision comes amid pressure to reduce the costs of asthma inhalers to make them more affordable for American citizens.
Customers
growth-positive
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
AstraZeneca has announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, starting from June 2024. This move follows a similar decision by competitor Boehringer Ingelheim. The cap will apply to all of AstraZeneca’s inhaled respiratory products, including Airsupra, Bevespi Aerosphere, Breztri Aerosphere, and Symbicort. The decision is part of AstraZeneca’s expanded savings programs, aimed at making its inhalers more affordable for patients with asthma and chronic obstructive pulmonary disease (COPD).
Customers
Growth-Positive
Now That Two Inhaler Makers Are Capping Patient Costs, Will More Follow?
AstraZeneca has decided to cap the out-of-pocket costs for its Symbicort inhaler at $35. This move is in response to political and regulatory pressure on manufacturers of expensive treatments. This follows a similar move by Boehringer Ingelheim, a rival company that also sells inhalers. This comes after Senator Bernie Sanders launched an investigation into inhaler prices in January.
Customers
Growth-Negative
EVP, CFO Eliyahu Kalif Sells 77,550 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Eliyahu Kalif, the Executive Vice President and Chief Financial Officer of Teva Pharmaceutical Industries Ltd, has sold 77,550 shares of the company on March 6, 2024, according to an SEC filing. The transaction was executed at an average price of $13.52 per share, totaling $1,048,286. Over the past year, the insider has sold a total of 112,675 shares of Teva Pharmaceutical Industries Ltd and has not made any purchases of the stock. The companys shares were trading at $13.52 on the day of the insiders recent sale, giving the company a market capitalization of $14.842 billion.
Management Changes
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
growth-positive
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
Alvotech and Teva Pharmaceuticals have announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, a biosimilar to Humira, for the treatment of various adult diseases. This approval marks the first high-concentration, citrate-free biosimilar to Humira that has been granted an interchangeability status by the FDA. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market. Both companies expect to launch SIMLANDI in the U.S. soon.
PartnersExpand
Growth-Positive
UPDATE 2-Teva Pharm to stay as unified drugmaker, sees big interest in API business, says CEO
Teva Pharmaceutical Industries, the worlds largest generic drug maker, has announced it will remain a unified company for generic and branded drugs. The company also expects significant interest in its active pharmaceutical ingredients (API) business, which it plans to divest. The API business is worth $1 billion in an $85 billion global market. Tevas CEO, Richard Francis, believes the business will perform better as a standalone entity. The company is currently recovering from the loss of exclusivity to its multiple sclerosis drug Copaxone and a series of lawsuits. It is hoping that its branded drugs - Austedo, Ajovy, and Uzedy - will help it bounce back.
PartnersAcquisition
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
growth-positive
Q4 2023 Corcept Therapeutics Inc Earnings Call
Corcept Therapeutics Inc reported its financial results for the fourth quarter of 2023, with a revenue of $135.4 million, a 31% increase compared to the same period in the previous year. The company expects its revenue growth to continue and has reiterated its 2024 revenue guidance of $600 million to $630 million. The company also provided updates on its ongoing legal case against Teva Pharmaceuticals and its various clinical trials. The company is also planning to submit a New Drug Application for its drug, relacorilant, in the second quarter of 2024.
CustomersInvestmentExpand
growth-positive
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2023 Earnings Call Transcript
Corcept Therapeutics Incorporated reported its Q4 2023 earnings, beating expectations with an EPS of $0.28 against the expected $0.25. The companys revenue for the quarter was $135.4 million, a 31% increase compared to the same period in the previous year. The company also reiterated its 2024 revenue guidance of $600 million to $630 million. Corcept is involved in a legal battle with Teva Pharmaceuticals over patent infringement. The company also provided updates on various clinical trials, including those for hypercortisolism, ovarian cancer, prostate cancer, and ALS.
CustomersManagement Changes
growth-positive
Teva enlarges workforce for first time since 2016
Teva Pharmaceutical Industries Ltd. has increased its workforce for the first time since 2016, with a 3.8% increase in 2023. The company had 36,472 employees at the end of 2023, up 1,347 from 2022. The number of employees in Israel grew 4.5% last year to 3,385. The company has been gradually reducing its number of employees in Israel over the past decade, but 2023 saw a return to growth. Tevas debt has fallen by $1.4 billion to $19.8 billion, and its 2023 revenue grew 6.2% to $15.8 billion. The company expects 2024 revenue of $15.7-16.3 billion.
Expand
Growth-Positive
Decoding Teva Pharmaceutical Industries Ltd (TEVA): A Strategic SWOT Insight
Teva Pharmaceutical Industries Ltd, a global leader in generic and innovative pharmaceuticals, filed its 10-K report on February 12, 2024. The report reveals a comprehensive overview of its financial and strategic positioning. The companys diverse product portfolio spans across generics, biosimilars, and innovative medicines. The companys strengths include its position as a leading generic pharmaceutical company and its focused portfolio in central nervous system (CNS), oncology, and respiratory areas. However, it faces challenges such as intense competition, patent litigation risks, and macroeconomic uncertainties. Opportunities for growth include expansion in biosimilars and market diversification.
CustomersPartnersManagement ChangesExpand
Growth-Positive
Teva Pharmaceutical upgraded at Piper Sandler
Piper Sandler analysts have upgraded their rating on Teva Pharmaceutical from Neutral to Overweight, and increased the price target from $12 to $19. The upgrade is due to several factors, including an improved outlook on the companys capital structure and the strength of its neuroscience business. The analysts also cited the growing contribution from the brand portfolios as one of the reasons behind the upgrade. They also noted that Teva seems to be better positioned in biosimilars and generics than some of its competitors, which could give it a competitive edge.
Investment
Neutral
David Abrams Adjusts Portfolio, Meta Platforms Sees Notable Reduction
David Abrams, the investor behind Abrams Capital Management, has revealed his latest investment moves in the fourth quarter of 2023 through a recent 13F filing. Abrams made the decision to trim positions in three stocks, with Meta Platforms Inc and Teva Pharmaceutical Industries Ltd experiencing the most significant cuts. The reduction in Meta Platforms by 216,924 shares marked a 23.36% decrease in holdings and a 2.15% impact on the portfolio. Tevas shares were reduced by 1,969,597, a 24.72% decrease, affecting the portfolio by 0.66%.
Investment
Growth-Negative
Chief Accounting Officer Amir Weiss Sells 31,766 Shares of Teva Pharmaceutical Industries Ltd
Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries Ltd, sold 31,766 shares of the company on February 1, 2024, as per a SEC Filing. This is part of a pattern of insider sales, with 12 insider sells recorded over the past year and no insider buys during the same period. On the day of the sale, shares of Teva Pharmaceutical Industries Ltd were trading at $12.37, resulting in a market cap of $13.633 billion. The stock is considered significantly overvalued according to the GF Value metric.
Management Changes
growth-positive
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Just Reported And Analysts Have Been Lifting Their Price Targets
Teva Pharmaceutical Industries Limiteds shares rose 4.6% following the release of its full-year results. The companys revenues of $16 billion beat expectations by 3.2%, although statutory losses per share increased. Analysts have updated their earnings model following these results. They expect revenues in 2024 to be $15.7 billion, approximately in line with the last 12 months, and forecast a statutory profit of $0.30 per share. The consensus price target has been lifted 8.4% to $13.25. Analysts expect Tevas shrinking revenues to moderate over the period ending 2024 compared to the historical decline of 3.2% per annum over the past five years.
Investment
growth-positive
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
Teva Pharmaceutical Industries reported Q4 2023 earnings of $1 per share, beating the Zacks Consensus Estimate of 75 cents per share. Revenues for the quarter were $4.46 billion, beating the estimate of $3.97 billion. This represents a 15% increase on a reported basis and 14% on a constant currency basis. The growth was primarily driven by a $500 million upfront payment received from a collaboration with Sanofi. The company also announced plans to divest its API business to focus on its core business and innovation. For 2024, Teva issued revenue guidance in the range of $15.7-$16.3 billion.
CustomersPartnersManagement Changes
growth-positive
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q4 2023 Earnings Call Transcript
Teva Pharmaceutical Industries Limited reported its Q4 2023 earnings, beating expectations with a reported EPS of $1 against expectations of $0.75. The companys Pivot to Growth strategy, launched in 2023, has been successful, with the company reporting a 7% growth in sales revenue to $15.85 billion. The company also reported progress on reducing its net debt to EBITDA, which now stands at 3.45. The companys CEO, Richard Francis, highlighted the strong performance of its innovative and generics businesses. Teva also announced its intention to divest its TAPI business.
InvestmentManagement ChangesExpand
growth-positive
Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript
Teva Pharmaceutical Industries reported its Q4 2023 earnings, highlighting a transformational year for the company with the launch of the Pivot to Growth strategy. The company reported growth of 7% with sales revenue of $15.85 billion. Adjusted EBITDA was up 5%, non-GAAP EPS up 2%, and free cash flow up 6%. The company also made progress on its net debt to EBITDA, which now stands at 3.45%. Tevas CEO, Richard Francis, provided an overview of the companys full-year results, business performance, recent events, and focus and priorities going forward. The company also announced its intention to divest its TAPI business.
Management ChangesInvestment
Teva Plans to Divest Drug Ingredients Business in Next Step of Strategic Shift
Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
Teva Reports Growth in Fourth Quarter and Full Year 2023
growth-positive
Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Teva Pharmaceutical Industries Ltd. reported a revenue of $4.46 billion for the quarter ended December 2023, a 14.8% increase from the same period last year. The EPS was $1.00, compared to $0.71 in the year-ago quarter. The reported revenue and EPS both exceeded the Zacks Consensus Estimate. The companys revenue from various geographic regions and products also showed mixed year-over-year changes. The companys stock has returned +9.9% over the past month and currently has a Zacks Rank #3 (Hold).
Customers
Growth-Positive
UPDATE 2-Teva to divest active pharmaceutical ingredient business
Teva Pharmaceutical Industries, the worlds largest generic drugs maker, has announced plans to divest its active pharmaceutical ingredient (API) unit to focus on its core business. The API unit, which generated revenue of $1.05 billion in 2022 and serves over 1,000 clients globally, produces pharmaceutical ingredients used in both generic and branded medicines. The divestiture is part of Tevas strategy to reduce its $35 billion debt. The company has been focusing on the development of branded drugs and biosimilar therapies to drive growth.
CustomersManagement Changes
growth-positive
How Teva's CEO is implementing his 'pivot to growth' strategy
Teva Pharmaceuticals has reported its fourth-quarter earnings, surpassing Wall Street expectations. The company also confirmed its plans to sell its active pharmaceutical ingredients (API) business as part of CEO Richard Francis pivot to growth strategy. Francis believes that the API business, the second largest in the world, is constrained as part of Teva and should be addressing the external demand in the $85 billion global API market. The sale will also free up capital to invest in Tevas innovative and generics businesses.
Management ChangesAcquisition
growth-negative
UPDATE 1-Teva Pharm sees lower 2024 profit after large Q4 beat
Teva Pharmaceutical Industries has forecasted a lower profit in 2024, despite a strong Q4 2023 which benefited from a large upfront payment from Sanofi for a collaboration to develop a treatment for inflammatory bowel disease. Teva also announced plans to divest its active pharmaceutical ingredient (API) unit to focus on its core business. The companys revenue rose 15% to $4.5 billion in Q4 2023. Sanofi invested $1.5 billion in the development of Tevas anti-TL1A drug, with Teva receiving an upfront payment of $500 million.
PartnersManagement Changes
Growth-Positive
Teva to divest active pharmaceutical ingredient business
The article discusses various stocks that are currently undervalued or have shown strong earnings recently. Tourmaline Oils dividend stock is down 34% and is considered a good buy for investors. TELUS stock jumped after reporting strong earnings. Enbridge, a Canadian energy giant, is considered a first-choice investment despite a weak start in 2024. TFI stock is known for its acquisitions and is a top dividend stock. Shopify reported a Q4 profit of US$657 million, a significant increase from a loss of US$623 million a year earlier. Aritzia stock is gaining momentum.
Investment
Teva, GSK Put Up Bullish Fourth-Quarter Performances. Here's Where Novartis Fell Short.
growth-positive
Teva Pharma sees lower 2024 profit but higher sales after large Q4 beat
Teva Pharmaceuticals has predicted lower profits but higher sales for 2024 after a strong Q4 2023, boosted by a large upfront payment from Sanofi for a collaboration on an inflammatory bowel disease treatment. The company also announced plans to divest its active pharmaceutical ingredient (API) unit by 2025. CEO Richard Francis stated that the companys focus is on growing its innovative and generics business. Tevas shares rose 6.6% following the announcement. The company also expects to accelerate growth between 2025 and 2027 due to its product pipeline.
PartnersExpand
growth-positive
Teva Pharmaceutical Industries Ltd (TEVA) Reports Solid Growth in 2023 Earnings
Teva Pharmaceutical Industries Ltd reported a 7% increase in revenue for 2023, reaching $15.8 billion. The companys net debt decreased to $16.6 billion due to ongoing efforts to reduce it. The companys innovative brands, AUSTEDO and AJOVY, also saw significant growth. The companys Pivot to Growth strategy aims to divest non-core assets and invest in growth engines and innovation. For 2024, the company expects revenues of $15.7 - $16.3 billion and non-GAAP diluted EPS of $2.20 - $2.50.
CustomersInvestment
growth-positive
Teva to sell API activity, beats analysts on Q4
Teva Pharmaceutical Industries Ltd. has announced its intention to divest its active-pharmaceutical ingredient (API) business in the small-molecule API industry. The move is expected to be completed by the first half of 2025 and is aimed at maximizing current and potential revenue streams, focusing on capital reallocation towards growth and innovation, and better serving patients. The divestiture is expected to create additional value for Teva’s shareholders and other stakeholders. Teva also reported its Q4 and full year 2023 results, with Q4 revenue of $4.5 billion and non-GAAP net profit of $1.135 billion.
Management Changes
growth-positive
50 Most Populated Countries in the World in 2024
The article discusses the global population growth and its impact on various sectors. It highlights the role of companies like Microsoft Corporation, Corteva, Inc., and Teva Pharmaceutical Industries Ltd in addressing the challenges posed by population growth. Microsofts FarmBeats technology helps farmers conserve water and reduce costs through efficient resource allocation. Corteva is developing technologies to increase crop yields and recently announced a plant breeding innovation to combat corn disease. Teva Pharmaceutical produces womens healthcare products and contraceptives to help control fertility rates. The article also mentions the projected population figures for the 50 most populated countries in 2024.
CustomersPartners
growth-positive
Teva to spin out API business in pursuit of future growth
Teva Pharmaceutical Industries, an Israeli generics drugmaker, is planning to separate its active pharmaceutical ingredient (API) business, known as TAPI, as part of its growth and innovation strategy. TAPI is a significant player in the small molecule API industry, employing around 4,300 people worldwide. The company serves over 1,000 clients globally, including biotech and pharma firms, with a range of approximately 350 products.
Management Changes
growth-positive
Teva ends 2023 as Israeli co with biggest profit on Wall Street
Teva Pharmaceutical Industries Ltd. has been named Israels most profitable company on Wall Street in 2023, with a non-GAAP net profit of $1.76 billion in the first nine months of the year. The company is expected to end the year with a non-GAAP net profit of between $2.55 billion and $2.9 billion. However, the company recorded a net loss of almost $1 billion according to GAAP accounting rules. The difference is due to various accounting items not included in non-GAAP calculations. The companys revenue has consistently shrunk over the last five years, but this year it has returned to growth.
Management Changes
growth-positive
Teva buys rights for Israeli co Biolojic's asthma treatment
Teva Pharmaceutical Industries Ltd. and Biolojic Design have signed a collaboration agreement for the development of Biolojics antibody-based therapy for the treatment of asthma and atopic dermatitis. As part of the agreement, Teva will make an upfront payment and milestone payments. Biolojic is also eligible to receive tiered royalties in mid-single to low-double digit millions of dollars on product sales should Teva successfully commercialize the therapy. The drug is still in animal trials.
PartnersInvestment
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
growth-positive
TEVA PHARMACEUTICALS REPORTS STRONG Q3 2023 RESULTS RAISES REVENUE FORECAST
Teva Pharmaceuticals reported a 7% increase in revenues in Q3 2023, exceeding forecasts and reaching $3.85 billion. This growth was primarily driven by the American generic drug market, with sales increasing by 11% from the previous year. The company also saw a 30% surge in sales of the original drug Austedo and a 7% growth in the European generic market. Tevas operating profit grew by 5% in Q3 2023, amounting to $1.02 billion. The company raised its revenue forecast for 2023 to a range of $15.1 to $15.5 billion.
CustomersExpand
growth-positive
13 Most Undervalued Pharma Stocks To Buy According To Analysts
The article discusses the 13 most undervalued pharmaceutical stocks according to analysts. The pharmaceutical industry, worth $1.25 trillion in 2021, is expected to grow at a CAGR of 8% between 2021 and 2025. The top drug companies spent more than $83 billion in research and development in 2019. The top five pharmaceutical firms in America grew their revenue by $8.8 billion in FY 2022. However, growth might be slowing down as the coronavirus pandemic recedes and vaccine sales drop. The most notable undervalued pharma stocks are Perrigo Company plc, Viatris Inc., and Organon & Co.
Investment
Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program
growth-negative
Israeli drugmaker Teva loses appeal against EU fine -EU court ruling
The General Court of the European Union has ruled that Israeli drugmaker Teva and Cephalon must pay a 60.5 million euro fine. The fine was imposed by the European Commission for delaying the market entry of a cheaper generic version of Cephalons drug for sleep disorders that Teva sought to challenge in court. The court found that the payments provided in the settlement agreement had no plausible explanation other than to induce Teva to accept the restrictive clauses of that agreement and thus to refrain from competing with Cephalon.
Customers
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
growth-positive
UPDATE 1-Drugmaker Teva does not see big impact on business from Israel-Hamas war
Teva Pharmaceutical Industries, the worlds largest maker of generic drugs, does not expect Israels war with Hamas to significantly impact its business performance. The company stated that sales in Israel account for only 2% of its global revenue, and production in Israel constitutes less than 8% of total global manufacturing. Teva maintains contingency plans with backup production locations for key products. The company is focusing on the support and wellbeing of its employees in Israel, while ensuring business continuity to deliver medicines to patients worldwide. Teva is also collaborating with French drugmaker Sanofi to develop a treatment for inflammatory bowel disease.
CustomersPartners
Health Care Roundup: Market Talk
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
growth-positive
Sanofi (SNY) Signs Deal to Co-Develop Teva's IBD Candidate
Sanofi and Teva Pharmaceuticals have announced a strategic collaboration to co-develop and co-commercialize Tevas novel anti-TL1A therapy, TEV574, for the treatment of Ulcerative Colitis and Crohns disease. Sanofi will make an upfront payment of $500 million to Teva, with additional payments of up to $1 billion upon achieving certain developmental and launch-based milestones. The collaboration agreement states that Sanofi and Teva will equally share the development costs of TEV574 globally, as well as net profits and losses in major markets.
PartnersInvestment
Teva Leans Into Sanofi's 'Pipeline-In-A-Product' Expertise In $1.5 Billion Deal
growth-positive
Teva teams with Sanofi on inflammatory bowel treatment
Teva Pharmaceutical Industries and Sanofi have announced a collaboration to develop and commercialize TEV 574, a drug currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohns Disease. Under the terms of the agreement, Teva will receive an upfront payment of $500 million and up to $1 billion in development and launch milestones. The companies will share the development costs and net profits and losses in major markets. Initial program results are expected in 2024.
PartnersInvestment
Teva Announces Changes to Executive Management Team
growth-positive
US judge overturns Eli Lilly's $176.5 million loss in Teva patent case
Eli Lilly has won a legal victory against Teva Pharmaceutical, with a federal judge in Massachusetts overturning a $176.5 million jury verdict against Lilly. The jury had found that Lillys migraine drug Emgality infringed on three patents related to Tevas rival drug Ajovy. However, the judge ruled that the Teva patents were invalid. Eli Lilly earned over $650 million from Emgality sales worldwide last year, while Teva earned $377 million from Ajovy.
Customers
Growth-Negative
Unveiling Teva Pharmaceutical Industries (TEVA)'s Value: Is It Really Priced Right? A ...
Teva Pharmaceutical Industries Ltd has been performing well in the stock market with a daily gain of 3.98% and a three-month gain of 41.85%. However, the company reported a Loss Per Share of $2, leading to questions about its valuation. The companys current market price is $10.7 per share with a market cap of $12.30 billion, but the GF Value, an estimate of fair value, stands at $7.94, suggesting that the stock may be significantly overvalued. The companys financial strength is considered poor with a cash-to-debt ratio of 0.13. The company has been profitable 5 years over the past 10 years, with an operating margin of 16.96%.
Public Trading
3 No-Brainer Stocks to Buy With $20 Right Now
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
growth-positive
With 55% ownership of the shares, Teva Pharmaceutical Industries Limited (NYSE:TEVA) is heavily dominated by institutional owners
Institutional investors hold a 55% stake in Teva Pharmaceutical Industries, indicating a high level of confidence in the companys future. The largest shareholder is Phoenix Investments & Finances Ltd, with 4.0% of shares. The second and third largest shareholders hold 3.8% and 3.3% of the shares respectively. The general public, mostly individual investors, own 45% of the company. The article suggests that the high level of institutional ownership implies that Tevas stock price is sensitive to their trading actions and that these institutions stand to benefit the most if the stock rises.
Investment
growth-positive
Q2 2023 Alvotech SA Earnings Call
Alvotech held its Q2 2023 earnings call, discussing key highlights and updates. The company has resubmitted its interchangeable BLA for its proposed biosimilar to HUMIRA, AVT02, and expects it to be a significant contributor in 2024. Alvotech has also transitioned from a development stage company to a full-scale commercial operation, making significant investments in manufacturing and quality processes. The company has signed a new partnership with Advanz, which includes five biosimilar candidates, and expanded its collaboration with Teva to include two new biosimilar candidates. Alvotech also raised $140 million in a recent capital raise.
PartnersInvestment
growth-positive
Alkermes (ALKS) Grants Teva License to Market Generic Drug
Alkermes Plc has entered into negotiations with Teva Pharmaceuticals USA, Inc. to settle the ongoing patent litigation regarding Vivitrol. As per the settlement agreement, Alkermes has granted Teva a license to market a generic version of Vivitrol in the United States from January 15, 2027. Both parties have refrained from sharing additional details regarding the terms of the agreement. Shares of Alkermes climbed 7.1% in the last trading session, indicating investors positive response to the resolution of the dispute.
Partners
growth-negative
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)
Teva Pharmaceutical Industries Ltd. has settled its criminal price-fixing charges with the Department of Justice (DOJ) in the United States by signing a deferred prosecution agreement (DPA). The DOJ had charged Teva for conspiring to fix prices, rig bids, and allocate customers for generic drugs in the United States. As part of the settlement, Teva has agreed to pay a fine of $225 million over five years and sell its pravastatin generics business. Teva will also donate $50 million worth of two generic products to humanitarian organizations.
InvestmentCustomers
Teva Pharma: generics titan attempts to put the stopper in legal problems
growth-negative
TEVA to Pay $250 Million to Settle Price-Fixing Charges
Teva Pharmaceutical Industries has settled its criminal price-fixing charges with the US Department of Justice (DOJ) by signing a deferred prosecution agreement. The company was charged in 2020 for conspiring to fix prices, rig bids, and allocate customers for generic drugs in the US. As part of the agreement, Teva will pay a fine of $225 million over five years and sell its pravastatin generics business. The company will also donate $50 million worth of two generic products to humanitarian organizations. The DOJ has also signed a similar agreement with Indias Glenmark Pharmaceuticals.
InvestmentCustomers
Teva Settles Price Fixing Charges With U.S. DOJ
growth-negative
UPDATE 2-Teva to pay $225 mln, divest cholesterol drug to settle price-fixing charges
Teva Pharmaceutical has agreed to pay a $225 million fine and divest its generic version of a cholesterol drug to settle price-fixing charges brought by the U.S. Department of Justice (DOJ). The fine will be paid over five years, with $22.5 million due annually from 2024 to 2027 and $135 million due in 2028. The charges, filed in 2020, accused Teva and Indias Glenmark Pharmaceuticals of conspiring to fix the prices of generic drugs. Glenmark will also pay a $30 million penalty to resolve similar charges. Both companies admitted to participating in price-fixing.
Investment
Growth-negative
Teva to pay $225 million, divest cholesterol drug to settle price-fixing charges
Quebec entrepreneur and philanthropist Daniel Langlois, along with his partner Dominique Marchand, have been found dead in Dominica. The couple managed a resort in Dominica and had been missing for a few days before their bodies were found in a burnt-out car. Local authorities are questioning four people of interest in relation to the deaths, including Jonathan Lehrer, owner of Bois Collette Inc.
Management Changes
Teva Agrees to Pay $225 Million to Settle U.S. Price-Fixing Charges
growth-negative
Teva to pay $225M to settle cholesterol drug price-fixing charges
Teva Pharmaceuticals has agreed to pay $225 million to settle price-fixing charges related to sales of a major cholesterol-lowering drug, pravastatin. The U.S. Department of Justice also requires Teva to divest its business making and selling the drug. Another generic drug maker, Glenmark Pharmaceuticals, agreed to pay a $30 million criminal penalty and to divest its pravastatin business. The U.S. arm of Israel-based Teva blamed a single former employee for striking agreements with Teva competitors that limited competition between 2013 and 2015. The companies collectively agreed to pay $681 million in fines in addition to other penalties.
CustomersInvestment
growth-negative
Q2 2023 Societal CDMO Inc Earnings Call
Societal CDMO, Inc. held its Q2 2023 financial results conference call, discussing its contract development and manufacturing business, corporate activities, and financial results. Despite financing challenges faced by many of its customers, the company continues to attract new business and expand work with existing customers. However, the company recorded a decline in Q2 2023 revenues due to a short-term delay in 2023 Teva revenue and a revenue delta created by the Q2 2022 InfectoPharm inventory build. The company has revised its 2023 EBITDA guidance to between $12 million and $15 million, attributing this shift to the financing hardship being faced by many companies in the biotech and life science sectors.
CustomersPartners
growth-positive
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical
The article discusses the improving market prospects for generic drugmakers, including Amphastar Pharmaceuticals, Dr. Reddys Laboratories, and Teva Pharmaceutical. The companies have noted a reduction in generic price erosion in the US, a trend expected to continue for the rest of the year. The industry is focusing on new product launches or products with high gross margins to support their top and bottom line. The article also highlights three trends shaping the future of the generic drugs industry: loss of patent exclusivity of branded drugs, stiff competition, and patent settlements.
CustomersPartnersAcquisition
growth-positive
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
Generic drugmakers such as Amphastar Pharmaceuticals, Dr. Reddy’s Laboratories, and Teva Pharmaceutical have noted a reduction in generic price erosion in the United States for the quarter ending June 2023. This trend is expected to continue for the rest of the year. The companies are focusing on launching new products or products with high gross margins to support their top and bottom line. The loss of patent exclusivity of branded drugs provides significant opportunities for generic drugmakers. The industry is also seeing stiff competition and patent settlements. The industry is expected to see significant growth in the future.
CustomersPartnersAcquisition
growth-negative
Teva agrees to pay $126 million to US hospitals over opioids
Teva Pharmaceutical Industries Ltd has agreed to pay up to $126 million to U.S. hospitals over 18 years to settle claims that its marketing of opioid drugs raised the hospitals operating costs. The Israel-based drugmaker also agreed to supply $49 million of the anti-overdose drug naloxone. The settlement is subject to the agreement of the hospitals involved. The lawsuits claim that drugmakers downplayed the drugs risks and that distributors and pharmacies failed to prevent them from being diverted onto the illegal market.
CustomersInvestment
growth-negative
Teva agrees to pay $126 mln to US hospitals over opioids
Teva Pharmaceutical Industries Ltd has agreed to pay up to $126 million to U.S. hospitals over 18 years to settle claims that its marketing of opioid drugs raised the hospitals operating costs. The Israel-based drugmaker also agreed to supply $49 million of the anti-overdose drug naloxone. The settlement is yet to be finalized and depends on the agreement of the hospitals involved. This comes after Teva was sued by about 500 U.S. hospitals and other health care providers over opioids.
CustomersInvestment
growth-positive
TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up
Teva Pharmaceutical Industries Limited reported its second-quarter 2023 earnings, beating the Zacks Consensus Estimate. The companys earnings were 56 cents per share, a 17.6% decline year over year due to lower gross margin and higher financial expenses. However, revenues for the quarter were $3.88 billion, beating the Zacks Consensus Estimate of $3.69 billion. The companys North America segment sales were $1.99 billion, up 5% year over year. The company expects its newer drugs, Austedo, Uzedy, and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
CustomersManagement Changes
growth-positive
Teva stock pops on Q2 results, CEO sees 'significant' potential for trio of branded drugs
Teva Pharmaceuticals reported better-than-expected second quarter earnings, with a boost in revenue thanks to its name-brand drugs. CEO Richard Francis is particularly excited about the prospects for three brand name drugs, including migraine drug Ajovy. However, the company has been struggling with a shortage of workers and is actively hiring. Teva has also been dealing with a variety of lawsuits, including ones related to the opioid epidemic, but Francis believes that the company is moving past these legal issues and focusing on growth. The companys stock is up more than 10% following the earnings report.
CustomersManagement ChangesLayoffsExpand
Teva Retakes Its 200-Day Line After Second-Quarter Beat And Raise
Growth-Positive
Huntington's treatment helps Teva beat profit estimates as CEO eyes newer drug opportunities
Teva Pharmaceutical Industries has reported a higher-than-expected Q2 profit, driven by a significant increase in sales of its Austedo treatment for Huntingtons disease. The companys CEO, Richard Francis, is optimistic about the potential of Austedo, migraine product Ajovy, and newly launched schizophrenia drug Uzedy to help the company recover from previous challenges. Teva expects Austedo sales to reach around $1.2 billion in 2023, up from $971 million last year, and $2.5 billion by 2027. The company also plans to launch a biosimilar of AbbVies arthritis drug Humira next year.
CustomersManagement Changes
growth-positive
UPDATE 1-Teva CEO says not too late to launch Humira biosimilar in 2024
Teva Pharmaceutical Industries plans to launch a biosimilar of AbbVies arthritis drug Humira in 2024, despite competition from eight other companies that have launched Humira biosimilars in the US this year. Tevas CEO Richard Francis believes there is still opportunity in the market and that Tevas product will be attractive to pharmacy benefit managers. The companys Iceland production site still needs to pass an FDA inspection before approval. Teva also has 16 other biosimilars in its pipeline, including a version of Johnson & Johnsons psoriasis treatment Stelara.
CustomersPartners
Growth-Positive
Teva Pharmaceutical Industries (TEVA) Q2 2023 Earnings Call Transcript
Teva Pharmaceutical Industries has conducted its Q2 2023 earnings call, during which CEO Richard Francis provided an overview of the companys results and business performance. He also discussed recent trends and the companys priorities going forward. Additionally, Dr. Eric Hughes, the head of R&D and chief medical officer, discussed progress on the companys innovative pipeline.
Teva Reports Second Quarter 2023 Financial Results
Growth-Positive
Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries Ltd. (TEVA) Q2 Earnings
Teva Pharmaceutical Industries Ltd. reported a revenue of $3.88 billion for the quarter ended June 2023, a 2.4% increase from the same period last year. The companys EPS was $0.56, down from $0.68 in the year-ago quarter. The reported revenue exceeded the Zacks Consensus Estimate of $3.69 billion, representing a surprise of +4.98%. The companys EPS also surpassed the consensus estimate of $0.54, delivering a surprise of +3.70%. The companys shares have returned +10.8% over the past month.
Customers
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
Exelixis deal sets generic version of cancer drug for release in 2031
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
Patients Can’t Get Some Lifesaving Drugs. What’s Causing the Shortages.
growth-positive
11 Best Medical Stocks Under $10
The article discusses the growth and investment opportunities in the medical industry, particularly in biotechnology. It highlights the projected growth rates of various sectors within the industry, with the biotechnology sector expected to grow at a CAGR of 13.96% between 2023 and 2030. The article also lists the top medical stocks under $10, including CTI BioPharma Corp., EQRx, Inc., Adaptive Biotechnologies Corporation, GoodRx Holdings, Inc., Ginkgo Bioworks Holdings, Inc., and Elanco Animal Health Incorporated. The article also mentions the impact of the COVID-19 pandemic on the medical industry and the need for healthcare firms to adopt a more consumer-centric approach.
Investment
Growth-Positive
3 Bargain Stocks to Buy on the Dip
Three Motley Fool contributors have identified Bristol Myers Squibb, Pfizer, and Teva Pharmaceutical Industries as stocks to buy on the dip. They believe these prominent biopharmaceutical companies are good investment opportunities despite periods of dealing with the loss of patent exclusivity for some key products.
Investment
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients
Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
Pharmaceutical Giants Set $19 Billion Opioid Settlement as States Debate How to Spend It
Is AbbVie or Amgen the Better Bargain Buy Right Now?
Teva Concludes Nationwide Opioids Settlement Agreement
growth-negative
Teva to pay Nevada $193 million over role in opioid epidemic
Teva Pharmaceutical Industries has agreed to pay Nevada $193 million to settle claims that its marketing practices contributed to the opioid crisis. Nevada, along with other states and local governments, accused Teva and other drug manufacturers of downplaying the addiction risks of opioid pain medications. The settlement will be paid in installments from 2024 to 2043. Nevada has secured $849 million in opioid settlement money, according to the states Attorney Generals office.
CustomersInvestment
Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management
Growth-Positive
Teva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?
On May 18, Teva Pharmaceuticals announced a strategic pivot aimed at returning the company to growth after a period of stagnation. The company plans to leverage its biosimilar generic medicines pipeline and make significant investments in expanding its pipeline assets. The management is optimistic about marking a turnaround in the coming years and meeting its financial targets for 2027.
InvestmentExpand
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
growth-negative
Shareholders in Teva Pharmaceutical Industries (NYSE:TEVA) have lost 66%, as stock drops 6.3% this past week
The share price of Teva Pharmaceutical Industries Limited has dropped 66% over the past five years and 25% in the last quarter. The company is currently not profitable and has seen its revenue shrink by 6.0% per year over the last five years. This has led to a loss of 11% per year, which is not surprising given the lack of profit and revenue growth. The companys shareholders are down 18% for the year, while the market itself is up 1.0%. The companys future growth is uncertain.
Customers
growth-positive
Analysts are Upgrading These 10 Stocks
Analysts have upgraded several stocks including The Charles Schwab Corporation, Tapestry, Inc., Meta Platforms, Inc., PlayAGS, Inc., Teva Pharmaceutical Industries Limited, Sabre Corporation, Nevro Corp., and AvalonBay Communities, Inc. The upgrades were based on various factors such as expected stabilization of balance sheets, control over inventory, strong product demand, and significant progress in reducing net debt. The upgrades present potential growth opportunities for investors.
Investment
growth-positive
Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical
The article discusses the challenges and opportunities in the generic drugs industry, focusing on three companies: Amphastar Pharmaceuticals, Dr. Reddy’s Laboratories, and Teva Pharmaceutical. Despite macroeconomic headwinds like price erosion and inflation, these companies are focusing on new product launches and products with high gross margins. The loss of patent exclusivity of branded drugs provides significant opportunities for generic drugmakers. The article also highlights the stiff competition in the industry and the importance of patent settlements. Amphastar is expanding its portfolio of generics and biosimilars, Dr. Reddys is launching new products to mitigate the impact of pricing erosion, and Teva is seeing growth in its new branded drugs.
CustomersPartnersAcquisition
growth-positive
3 Generic Drug Stocks to Watch Amid Macro Headwinds
Despite the rising volume of existing generic drugs, generic drugmakers are facing challenges due to macroeconomic factors such as price erosion and inflation. As a result, companies like Amphastar Pharmaceuticals, Dr. Reddy’s Laboratories, and Teva Pharmaceutical are focusing on launching new products or products with high gross margins to support their top and bottom lines. The industry is also shaped by the loss of patent exclusivity of branded drugs, stiff competition, and patent settlements. The industry has outperformed the broader Zacks Medical sector but underperformed the S&P 500 Index in the past year.
CustomersPartnersAcquisition
growth-negative
15 Stocks Warren Buffett Sold
Berkshire Hathaway, led by Warren Buffett, sold $13.3 billion worth of stock in Q1 2023, while investing only a fraction of that amount in US equities. The company spent $4.4 billion buying back its own stock and $2.9 billion on publicly traded businesses. Berkshire is struggling to invest its $130.6 billion cash pile due to high valuations. Buffett expects earnings to decline in most of the companys businesses this year due to economic slowdown and rising interest rates. Berkshires stake in Apple Inc. was valued at $151 billion at the end of the quarter. The company has been exiting banking stocks and adjusting its portfolio due to the impact of the Covid-19 pandemic.
InvestmentManagement Changes
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting
growth-positive
Teva Pharm CEO sees $2.5 bln in revenue for Austedo drug by 2027
Teva Pharmaceutical Industries CEO, Richard Francis, has projected that sales of the companys drug Austedo will reach $2.5 billion by 2027. Austedo is a branded treatment for Huntingtons Disease and also aids those suffering from the movement disorder tardive dyskenisa. Francis noted that only 15% of the 800,000 people suffering from tardive dyskenisa take medication, indicating a significant opportunity for growth. The company expects Austedos revenue to reach $1.2 billion in 2023, up from $971 million in 2022. Francis also expressed his intention to maintain Teva as a generics powerhouse, while also growing its innovative drug pipeline.
CustomersExpand
growth-positive
UPDATE 1-Teva Pharm CEO sees $2.5 bln in revenue for Austedo drug by 2027
Teva Pharmaceutical Industries CEO, Richard Francis, has announced that the companys drug, Austedo, is expected to reach sales of $2.5 billion by 2027. Austedo, a treatment for Huntingtons Disease and movement disorder tardive dyskenisa, is expected to generate $1.2 billion in revenue in 2023, up from $971 million in 2022. Francis also stated that the company plans to increase its investment in Austedo, including expanding its sales force. Additionally, Francis aims to maintain Tevas status as a generics powerhouse, while also growing its innovative drug pipeline.
InvestmentExpand
Why Teva Pharmaceutical Stock Is Jumping Today
Teva Launches New "Pivot to Growth" Strategy
growth-positive
Teva targets growth through innovation
Teva Pharmaceutical Industries Ltd. has launched a new growth and innovation strategy called Pivot to Growth. The strategy was unveiled by the companys new CEO, Richard Francis, and is built on four key pillars: commercial portfolio and biosimilars, innovative pipeline, generics powerhouse, and focused capital allocation. The strategy will be implemented in three phases over five years, aiming to return to growth after five consecutive years of reduced revenue, accelerate growth through innovative products and biosimilars, and achieve sustainable growth from 2028 onwards.
Management ChangesExpand
Teva to Slim Down Generic Drug Business in Turnaround Effort. The Stock Is Jumping.
Growth-Positive
Teva profit plummets, stock slides | CTech
Teva Pharmaceutical Industries reported a Q1 profit that fell short of estimates but maintained its full-year outlook, expecting new product launches to boost earnings throughout 2023. The company projects adjusted EPS of $2.25-$2.55 and revenue of $14.8-$15.4 billion this year. CFO Eli Kalif highlighted growth in the innovative drugs segment and in generics outside the US. Teva plans to launch UZEDY, a treatment for schizophrenia in adults, in a market CEO Richard Francis estimates to be worth $4 billion. Despite a drop in North American sales of generic products, the company saw gains in its branded Huntingtons disease treatment Austedo and migraine product Ajovy.
CustomersManagement Changes
growth-negative
גלובס זירת העסקים של ישראל
Teva Pharmaceuticals, once considered the peoples stock in Israel, has seen a significant decline over the past decade. The companys downfall began with the acquisition of Actavis from Allergan for $40 billion, which was initially seen as a positive move but eventually led to financial difficulties and doubts about the companys ability to service its debt. The companys workforce has also decreased from nearly 57,000 in 2016 to close to 36,000 in 2021, with only 10% of its employees based in Israel. The company has also faced legal issues related to opioid painkiller marketing and price coordination in the US generic market.
AcquisitionLayoffsManagement Changes
growth-positive
Teva names Richard Francis as new CEO after Kåre Schultz departure | CTech
Teva, an Israeli pharmaceutical company, has announced the appointment of Richard Francis as its new President and CEO, effective from January 1, 2023. He will be replacing Kåre Schultz, who is retiring after more than five years in the role. Francis brings over 25 years of experience in the pharmaceutical industry, including roles as CEO of Sandoz and senior executive at Biogen. He is currently the CEO of Purespring Therapeutics and Forcefield Therapeutics, and an operating partner for Syncona Investment Management Limited.
Management Changes
Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities - Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFC
Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes
Growth-Positive
Teva Post Lupin Deal To Launch Austedo Generic Rival In 2033
Teva has settled its patent infringement lawsuit with Aurobindo Pharma over the latters attempt to commercialise a generic version of Austedo, Tevas most valuable medicine. As per the agreement, Aurobindo has a license to start selling its generic in the United States in April 2033 or earlier under specific conditions. Teva also reached an agreement with Lupin last month to allow the latter to sell its generic form of Austedo in April 2033. Austedo, approved by the FDA in 2017, is the only FDA-approved medication for chorea linked with Huntington’s disease and tardive dyskinesia.
Partners
growth-negative
Teva agrees opioid settlement with Rhode Island
Teva Pharmaceutical Industries Ltd. has reached a settlement with the Attorney General of Rhode Island over the states opioid-related claims. Under the terms of the settlement, Teva will pay Rhode Island $21 million over 13 years and provide the state with its recently launched generic opioid overdose treatment Narcan and a significant amount of buprenorphine naloxone, valued at a combined $78.5 million, over 10 years. The company stressed that the settlement agreement is not an admission of any liability or wrongdoing.
Customers
Growth-Negative
Teva announces debt recycling measures
Teva Pharmaceutical Industries Ltd. is planning to issue $2.06 billion of sustainability-linked senior notes and has begun tender offers to purchase up to $2.25 billion of notes. This move is aimed at managing and extending the maturity profile of its debt. The companys net debt at the end of 2022 was $21.2 billion. In recent years, Teva has reduced its net debt from a peak of about $37 billion, following the acquisition of Activis in 2016. This required the company to implement a wide-ranging streamlining plan, which involved major layoffs and shutting down plants.
InvestmentLayoffs
growth-positive
Teva and Tikun Olam-Cannbit sign medical cannabis deal
Teva Israel, a unit of Teva Pharmaceutical Industries, has signed its first commercial agreement for the marketing and distribution of medical cannabis oil. The agreement is with Israeli company Tikun Olam-Cannbit Pharmaceuticals, who will extract the THC and CBD oils from researched strains, in accordance with Tevas guidelines. The products will be marketed by Teva Israel to patients throughout Israel and the Palestinian Authority, and potentially Ukraine in the future. This partnership follows an in-depth review of the market in Israel and is expected to position both companies as leaders in the growing medical cannabis market.
PartnersExpand
growth-positive
Teva wins opioids case in California court
Teva Pharmaceutical Industries has won a legal victory in the US in connection with opioid pain relievers. A Superior Court Judge in Orange County, California found that Teva did not cause a public nuisance in four California counties and did not make any false or misleading statements in connection with marketing prescription opioids in California. The $50 billion lawsuit was filed by the four counties against several drug companies, including Teva. The decision represents a first legal victory for the drug companies in over 3,300 lawsuits filed against them by states and counties throughout the US.
Customers
growth-negative
Teva to lay off 200 in Israel
Teva Pharmaceutical Industries Ltd. has reached an agreement with the Histadrut and the workers committee at its Kfar Saba plant, where 198 employees will be laid off or take early retirement by the end of 2021. The agreement is yet to be signed but is expected to be finalized in the coming days. Most of the employees leaving will receive early pension terms, while others will be given generous compensation packages. They will also receive professional retraining and assistance in finding new jobs.
Layoffs
growth-positive
Teva readying to distribute Covid-19 vaccine in Israel
Teva Pharmaceutical Industries Ltd.s unit, Teva Israel-SLE, has signed an exclusive agreement with the Israeli government to distribute Covid-19 vaccines in the country. The company is preparing to distribute Pfizer and Moderna vaccines in the coming weeks, making Israel one of the first countries to receive the vaccines after the US. Teva Israel-SLE may seek partners to assist in the nationwide vaccination program. The vaccines will be distributed to health funds, care homes, and potentially other institutions.
Partners
Teva Announces New Analysis of Consistency in Migraine Days Over the Course of a Dosing Regimen for AJOVY® (fremanezumab-vfrm) Injection Published in Headache
https://www.marketwatch.com/press-release/teva-launches-two-digital-inhalers-in-the-us-airduo-digihaler-fluticasone-propionate-and-salmeterol-inhalation-powder-and-armonair-digihaler-fluticasone-propionate-inhalation-powder-2020-09-21?siteid=bigcharts&dist=bigcharts&tesla=yer%C2%AE-fluticasone-propionate-Inhalation-Powder
growth-positive
Teva is recruiting Israeli academia to help produce its next breakthrough drug
Israel-based pharmaceutical company Teva is partnering with major Israeli academic institutions to invest in early-stage research projects with the aim of developing breakthrough drugs. The company has initiated partnerships with 20 research initiatives across the country, providing funding and resources. The collaborations are taking place at institutions including the Technion - Israel Institute for Technology, the Weizmann Institute of Science, Bar Ilan University, Ben Gurion University of the Negev, and the Hebrew University of Jerusalem. The company did not disclose the amount it was investing in the projects.
PartnersInvestment
growth-negative
Teva announces 350 layoffs at Negev plant
Teva Pharmaceutical Industries Ltd. has announced it will lay off 350 employees at the Teva Tech plant in Ramat Hovav, Israel. The layoffs will be implemented over the next 18 months as part of major optimization procedures designed to ensure the plants future sustainability. The streamlining plan will be completed in the first quarter of 2022. The employees leaving the company will receive beneficial retirement terms and assistance in finding new jobs.
Layoffs
Teva joins forces with Icelandic firm to gain edge on biosimilars
growth-positive
Teva scales down Japanese operations
Teva Pharmaceutical Industries and Takeda Pharmaceutical are restructuring their joint venture to focus on 20 generic drugs and several branded assets, selling the rest of their products and operational assets to Nichi-Iko Pharmaceutical. The deal, expected to complete in early 2021, includes the sale of the Takayama manufacturing site. Financial details were not disclosed, but Nichi-Iko revealed that the assets it is buying were worth ¥33.3 billion ($314 million). The move is part of Tevas global portfolio optimisation strategy, implemented since Kare Schultz became CEO in 2017.
PartnersManagement Changes
Teva Announces Availability of ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder for Patients with Asthma and COPD BioSpace
growth-positive
Teva's Austedo wins marketing approval for China
Teva Pharmaceutical Industries Ltd. has received approval from the China National Medical Products Administration (NMPA) for its drug Austedo, used for the treatment of Huntingtons disease and Tardive Dyskinesia in adults. This approval comes after a fast-track review process, making China the second country after the US to approve Austedo. The NMPA also placed Austedo on the List of Overseas New Drugs Urgently Needed in Clinical Settings. This is the second approval and expected launch in China of a Teva specialty medicine, following the recent launch of Treanda.
CustomersExpand
growth-positive
Teva launches Rituxan biosimilar for Rheumatoid Arthritis
Teva Pharmaceutical Industries and Celltrion Healthcare have announced that their biosimilar Truxima is now available in the US for the treatment of Rheumatoid Arthritis and Polyangiitis. Truxima is the only biosimilar to Roches Rituxan available to treat rheumatoid arthritis in the US. The companies entered into an exclusive partnership in October 2016 for Teva to commercialize Truxima in the US and Canada. In May 2019, Truxima was approved by the US Food and Drug Administration to match all of the product’s oncology indications.
PartnersCustomers
growth-positive
Teva launches auto-injectable Ajovy in US
Teva Pharmaceutical Industries has launched its Ajovy auto-injector device for the preventive treatment of migraine in adults in the US. The company claims it is the only anti-CGRP preventive migraine treatment with quarterly and monthly subcutaneous dosing options. The Ajovy auto-injector is also available in Germany and is expected to be available in other European markets soon. The company hopes the auto-injectable version will help increase its market share of the migraine treatment. Teva reported positive clinical results for Ajovy in Japan, which brings marketing approval closer in that country.
CustomersExpand
growth-positive
Teva Israel CEO quits to head medical cannabis co Cannbit
Avinoam Sapir, former SVP and general manager of Teva Pharmaceutical Industries, has been appointed as the new CEO of Israeli medical cannabis company Cannbit Pharmaceuticals. Sapir replaces former MK Ifat Kariv and is expected to help Cannbit become a major player in the global market. The news of Sapirs appointment led to a 13% increase in Cannbits share price. Cannbit recently acquired Israeli medical cannabis company Tikun Olam.
Management ChangesAcquisition
growth-positive
US court upholds validity of Teva's Ajovy patents
The US Patent Trial and Appeal Board has upheld the validity of three Teva Pharmaceutical Industries Ltd. patents on migraine treatment Ajovy, which had been contested by Eli Lilly. This resulted in a 5.52% increase in Tevas share price. Ajovy, launched in the final quarter of 2018 in the US, has captured a 20% market share of the migraine treatment sector. Two months ago, Teva received FDA approval for an auto-injectable version of Ajovy and reported positive clinical results for Ajovy in Japan.
Customers
growth-positive
Teva drugs approved for emergency Covid-19 trials
Teva Pharmaceutical Industries Ltd.s share price soared 12.6% after the US Food and Drug Administration (FDA) approved use of chloroquine phosphate and hydroxychloroquine for emergency treatment of Covid-19 patients. Teva, one of the companies manufacturing the drug, announced earlier this month that it would donate ten million tablets to US hospitals. The FDA is recommending controlled clinical trials to test the drugs effectiveness in treating Covid-19. Citi wrote in response that among the companies manufacturing the drugs are Amneal, Dr. Reddys Laboratories, Laurus Labs, Mylan, Prasco Labs, Sandoz, Teva, and Zydus Cadila.
CustomersExpand
growth-positive
https://www.jpost.com/HEALTH-SCIENCE/Teva-donates-potential-coronavirus-treatment-to-hospitals-across-the-US-621688
Teva, an Israeli pharmaceutical company, has announced its plan to donate over six million doses of hydroxychloroquine sulfate tablets to hospitals across the United States, starting March 31, 2020. The tablets, approved by the US Food and Drug Administration for the treatment of malaria, lupus erythematosus, and rheumatoid arthritis, are currently under investigation for their efficacy against the coronavirus. The company is also reviewing its other products to determine if they could be used against the virus.
CustomersExpand
growth-positive
Teva asks FDA to define Copaxone as biologics drug
Teva Pharmaceutical Industries is investing efforts to protect its multiple sclerosis treatment, Copaxone, from generic competition. The company has asked the US Food and Drug Administration (FDA) to include Copaxone in the list of biologics drugs, which would make it more difficult for generic versions to be approved. Over the past two decades, Copaxone has been a significant source of revenue for Teva, with sales peaking at $4.2 billion in 2013. Despite a 64% drop in sales due to the availability of generic rivals, the drug still brought in $1.5 billion in 2019.
Investment
growth-positive
Teva digital asthma inhaler wins FDA nod
Teva Pharmaceutical Industries Ltd. has announced that the US Food and Drug Administration (FDA) has approved ArmonAir Digihaler (fluticasone propionate), a treatment for asthma in patients aged 12 and older. The Digihaler device, which dispenses inhalation powder, has built-in sensors and connects to a companion mobile application that provides information on inhaler use. The approval of ArmonAir Digihaler adds to Tevas portfolio of approved Digihaler products.
Customers
growth-positive
Teva CEO: We have to launch new products
Teva Pharmaceutical Industries Ltd. CEO, Kare Schultz, has stated that the company will need to launch new products to return to growth. The company has several promising drugs in the pipeline, some of which are being developed in Israel. Schultz also commented on the companys financial results for 2019, stating that it was a good year and that they met all of their guidance. The companys revenue totaled $16.9 billion and free cash flow was $2.1 billion. Schultz also mentioned that Teva has 35,000 products, some of which have a significant influence on their results.
CustomersManagement ChangesLayoffsInvestment
growth-negative
Teva Israel to Stop Distribution of Weight Loss Drug Amid Cancer Concerns
Eisai, the manufacturer of the weight loss drug Belviq, is withdrawing the drug from the U.S. market after a five-year trial found it increased the risk of cancer. Following a directive from the U.S. Food and Drug Administration (FDA), Teva Pharmaceutical Industries Ltd. will also cease distribution of the drug in Israel. The companies will begin recalling the drug in collaboration with the Israeli Ministry of Health. The FDA approved Belviq in 2012 for long-term weight loss in patients suffering from obesity. However, recent findings showed that the drug might increase the risk of cancer.
CustomersPartners
growth-positive
Teva Receives FDA Approval for Migraine Autoinjector
Teva Pharmaceutical Industries Ltd. has received approval from the U.S. Food and Drug Administration (FDA) for an autoinjector for its migraine-treatment drug Ajovy. The company is set to start selling the new version by the end of the current quarter or by the start of the next quarter. The company has yet to set a price for the autoinjector and therefore did not provide a revenue forecast. Ajovy is one of the two new brand name drugs Teva introduced into the market a little over a year ago.
CustomersPartners
growth-negative
Teva must return non-MS Copaxone rights to Proneuron
The Supreme Court of Israel has dismissed an appeal by Teva Pharmaceutical Industries against Proneuron over the rights to use the Copaxone molecule for treatment of diseases other than multiple sclerosis. The case began in 2006 over a clinical trial Teva conducted on patients with amyotrophic lateral sclerosis (ALS). Proneuron claimed that Teva had initiated the trial and endangered the lives of its participants. The court upheld a previous ruling that Tevas trial had not been planned well and did not meet the terms of the agreement, and ordered Teva to return the rights to the product to Proneuron.
Partners
growth-positive
Teva looks to China
Teva Pharmaceutical Industries Ltd. CEO, Kåre Schultz, presented at the annual Healthcare Conference held by JP Morgan, detailing the companys restructuring efforts and future growth strategy. Schultz reported that the company had reduced its debt from $34 billion to $26.9 billion, achieved its goal of $3 billion in annual cost savings, and laid off more than 12,000 employees. Schultz also highlighted Tevas entry into biosimilars and the Chinese market as key growth areas. Despite these positive developments, Tevas share price declined by 36% in 2019 and a further 8% since the beginning of 2020.
Management ChangesLayoffsInvestment
growth-positive
Teva seeks blockbuster drug to succeed Copaxone
Teva Pharmaceutical Industries Ltd. is looking to re-establish its partnerships with Israeli healthcare startups. Between 2005 and 2012, Teva was the dominant player in forging partnerships with Israeli healthcare startups, but this changed when Dr. Jeremy Levin was appointed CEO of Teva in 2012. Now, the company is looking to re-establish these partnerships and has already mapped 400 academic laboratories in Israel and held meetings with 70 of them. The company is focusing on neurology, respiratory diseases, and cancer, and within the cancer field the emphasis is on immunology.
PartnersInvestment
growth-negative
Teva to pay $54m to settle Copaxone bribery case in US
Teva Pharmaceutical Industries will pay $54 million to settle claims that it bribed doctors to prescribe its branded drugs, Copaxone and Azilect. The lawsuit was filed by two former sales representatives of the company, Charles Arnstein and Hossam Senousy, who claimed that Teva paid doctors to increase sales revenue. The payments were allegedly made as consultancy or speakers fees, and doctors were also asked to appear at scientific conferences to recommend the branded treatments. The settlement is seen as a victory for American taxpayers who are the ultimate victims when companies defraud the government.
Customers
growth-positive
Teva teams with Weizmann Institute, Tel Aviv U
Teva Pharmaceutical Industries has announced two strategic cooperative research partnerships with the Weizmann Institute of Science and Tel Aviv University. The partnerships are part of Tevas efforts to strengthen its ties with higher education institutions in Israel and position itself as a leading company in both generic drugs and the biopharmaceutical sector. The research will focus on developing new specific antibodies for cancer treatment and research and development in cancer and the brain.
Partners
growth-positive
Teva's Israeli Plant Receives FDA Stamp of Approval for Migraine Drug Manufacturing
Teva Pharmaceutical Industries Ltd. has received approval from the U.S. Food and Drug Administration to manufacture part of its migraine-treatment drug, Ajovy, in Israel. The companys manufacturing facility in Kfar Saba will oversee the process of filling the syringes with the biological drug and conduct quality control tests. Ajovy, along with Austedo for Huntingtons disease and tardive dyskinesia, is expected to make up for the dropping revenues of Copaxone. However, Ajovy is currently underperforming, bringing in $25 million in the third quarter of 2019.
Expand
growth-negative
Teva Announces $23.25 Billion Opioid Abuse Settlement Agreement
Teva Pharmaceutical Industries Ltd. has reached a settlement agreement with attorneys general from North Carolina, Pennsylvania, Tennessee, and Texas, and with certain private plaintiffs, for a global settlement framework of the opioid abuse-related lawsuits against it. The company will donate buprenorphine naloxone, a medication used to treat opioid use disorder, valued at around $23 billion and will also pay $250 million over the next 10 years. Teva also settled with Cuyahoga and Summit counties of Ohio, providing both counties with buprenorphine naloxone valued at $25 million and a cash payment of $25 million over the next three years.
CustomersInvestment
growth-negative
Teva Makes $15 Billion Settlement Offer in U.S. Opioid Case, Report Says
Teva Pharmaceutical Industries Ltd. has reportedly offered a $15 billion settlement to resolve around 2,500 lawsuits related to the U.S. opioid abuse epidemic. The lawsuits are due to be heard in a federal court in Cleveland, Ohio. The Israeli drugmakers main exposure comes from its 2016 acquisition of Allergans generic drug business Actavis, which was one of the top U.S. sellers of opioids between 2006 and 2012. Other drug distributors, including McKesson Corp., AmerisourceBergen Corp., and Cardinal Health Inc., are also facing lawsuits and are in talks to pay a collective $18 billion over 18 years to settle charges against them.
AcquisitionInvestment
Neutral
Teva EVP global operations steps down
Teva Pharmaceutical Industries Ltd. has announced the retirement of Dr. Carlo de Notaristefani and the appointment of Eric Drapé as Executive Vice President, Global Operations. Dr. de Notaristefani will step down from his role effective immediately. Drapé will be based out of Teva’s global headquarters in Israel. Drapé has served in various senior management positions at Teva since joining in 2014.
Management Changes
growth-positive
Teva enters Israel's cannabis market
Teva Pharmaceutical Industries Israeli distribution unit, Salomon, Levin, Elstein (S.L.E), has signed a strategic distribution agreement with Israeli medical cannabis producer InterCures unit Canndoc. The agreement is for three years with a two-year extension option. Under the terms of the agreement, S.L.E will distribute Canndocs GMP certified medical cannabis products to pharma clients, including hospitals, health funds, and all pharmacies in Israel. In the future, as regulatory approvals allow, S.L.E. will provide logistics capability for exporting Canndocs products to countries that support regulations for the sale and distribution of cannabis products for medical use.
Partners
growth-negative
Teva to merge communications into HR
Teva Pharmaceutical Industries Ltd. is set to merge its global brand and communications department into Global Human Resources following the departure of EVP Iris Beck-Codner. The department will now be under the leadership of Mark Sabag, EVP of Global Human Resources. This change comes less than two months after CFO Mike McClellan announced his departure from the company. Despite these changes, Tevas share price rose 6.1% on the NYSE.
Management Changes
Teva Announces CFO Leadership Transition
growth-positive
Teva to sell Oncotest to Rhenium
Teva Pharmaceutical Industries is planning to sell Oncotest, a company that provides genetic testing services for cancer treatment, to Israeli company Rhenium. The deal is believed to be worth tens of millions of dollars. Oncotest was founded in 1998 and is currently fully owned by Teva. As part of the deal, Oncotests CEO, Dr. Lior Soussan-Gutman, will continue in his role. Rhenium, a leading company in Israel for marketing laboratory test equipment, was founded in 1991 and is managed by Dror Israeli.
AcquisitionManagement Changes
growth-negative
Teva to Pay California $69 Million in Narcolepsy Drug Settlement
Teva Pharmaceutical Industries Ltd. has agreed to pay $69 million as part of a settlement with the state of California over allegations that the company paid competitors to delay the release of generic versions of its narcolepsy drug, Provigil, for nearly six years. This allowed Teva to maintain a monopoly. As part of the settlement, Teva has assumed all legal responsibility while denying any unlawful conduct. A second settlement was also announced with Teva and competitors Endo International PLC and Teikoku Pharma USA Inc. over a similar pay-to-delay deal.
Investment
Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder BioSpace
Teva Completes Facilities Purchase in Pennsylvania for North America Research & Development Campus
N/A
Teva announces launch of a generic version of Tracleer® in US
The provided text does not contain any relevant information about a company or event. It is a placeholder message indicating a verification process to confirm that the user is not a robot.
Teva Reaches $85 Million Settlement in Oklahoma Opioid Damages Suit
growth-negative
https://www.jpost.com/Israel-News/Teva-rejects-wrongdoing-in-drug-price-fixing-lawsuit-589455
Teva Pharmaceutical Industries’ shares dropped by 10.7% after 44 US states filed a lawsuit against the company and 19 other generic pharmaceutical companies over allegations of an extensive drug price-fixing conspiracy. The lawsuit alleges that Teva significantly raised prices on approximately 112 different generic drugs between July 2013 and January 2015, and colluded with competitors on at least 86 of them. Some price increases allegedly exceeded 1,000%. Teva has rejected the claims and vowed to fight the lawsuit.
CustomersLayoffs
growth-negative
Teva CEO unsure about 2020 growth
Teva Pharmaceutical Industries Ltd. CEO Kåre Schultz, who took office in 2017, had marked 2020 as the year the company would return to growth. However, Schultz is now uncertain about the companys growth prospects for 2020. In a recent financial statement, Schultz spoke about the success of the companys two-year restructuring program and its long-term organic growth drivers, but did not comment specifically on 2020. The company has been able to cut $3 billion in costs, but the fall in revenue from its multiple sclerosis treatment, Copaxone, has been worse than anticipated.
Management Changes
Growth-Negative
Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI
Teva Pharmaceutical Industries Ltd. has sold its plant in Kiryat Shmona, Israel to private equity firm FIMI Opportunity Funds for $47.5 million. The sale is part of Tevas 2017 plan to reduce its significant debt by selling non-core businesses and closing or selling many of its manufacturing plants. The plant, which employs 200 people, manufactures plastic products for the pharmaceutical industry, with its main product being the Tevadaptor, a device that protects workers from exposure to dangerous substances.
Acquisition
growth-negative
Teva abandons fremanezumab cluster headache trial
Teva Pharmaceutical Industries has announced that it is discontinuing its clinical development program for the use of fremanezumab in cluster headaches. This decision comes after an analysis of the Phase III study in episodic cluster headache revealed that the study’s primary endpoint is unlikely to be met. Despite this, Teva will continue to explore other uses for fremanezumab, including the treatment of post-traumatic headache.
Management Changes
growth-positive
Teva launches generic overactive bladder treatment
Teva Pharmaceutical Industries has launched a generic version of 5 mg and 10 mg VESIcare (solifenacin succinate) tablets in the US. The tablets are used to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. The original VESIcare tablets have annual sales of more than $955 million in the US. Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US.
CustomersExpand
growth-positive
FDA approves Teva opioid antidote nasal spray
Teva Pharmaceutical Industries Ltd. has received FDA approval for Narcan, a medication that can stop or reverse the effects of an opioid overdose. This is the first generic naloxone hydrochloride nasal spray that the FDA has approved. The FDA is prioritizing the review of generic drug applications for naloxone in response to the opioid crisis. The FDA is also exploring other ways to increase the availability of naloxone products intended for use in the community.
Customers
growth-positive
Teva rebrands to raise consumer awareness
Teva Pharmaceutical Industries Ltd. is undergoing a global rebranding effort, which includes a new logo and redesigned drug packaging. The rebranding is part of a larger reorganization effort to increase market awareness and business focus. The company found that only 2% of patients outside of Israel are aware of the Teva brand, despite marketing its products to 200 million users daily. The company is also planning to increase its digital activity and work with Israeli startups. The rebranding effort comes as the company is in the final stages of a cost-cutting initiative to save $3 billion annually.
CustomersExpand
growth-positive
Teva migraine drug Ajovy wins European approval
Teva Pharmaceutical Industries migraine treatment drug, Ajovy, has received approval for marketing in the 28 EU member countries, Iceland, Norway, and Lichtenstein. The approval is a positive development for Teva, which also recently had a patent for its multiple sclerosis drug, Copaxone, ratified by the European Patent Office. Ajovy, which was developed for adults who suffer from migraines at least four days a month, was obtained by Teva as part of its acquisition of Labrys in 2014. Revenue from Ajovy, which won FDA approval in September 2018, was $3 million last year but is expected to grow to $150 million this year.
CustomersAcquisition
growth-positive
Teva Makes Headway in European Copaxone Patent Case
Teva Pharmaceutical Industries Ltd. is making legal progress in Europe regarding its multiple sclerosis drug, Copaxone. The European Patent Office’s (EPO) Opposition Division has upheld Tevas main patent for the 40 mg version of Copaxone. Generic versions of the drug have been available in Europe since late 2017, leading to a decline in Tevas revenues. However, Teva has managed to obtain preliminary injunction orders in Belgium, Denmark, and Slovakia, where no generic version has been commercialized yet. The company plans to continue defending its intellectual property.
Customers
growth-positive
Teva launches generic iron overload treatment
Teva Pharmaceutical Industries has launched a generic version of EXJADE (deferasirox) 125 mg, 250 mg and 500 mg, tablets in the US. The tablets are used for the treatment of chronic iron overload due to blood transfusions in patients two years of age and older. Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US.
Customers
growth-positive
Teva reconnecting to Israel's startup ecosystem
Teva Pharmaceutical Industries Ltd. is reportedly showing renewed interest in Israeli drug development and digital healthcare startups under the leadership of CEO Kare Schultz. This marks a shift from previous management, which had severed many of the companys Israeli partnerships. The company is now reportedly reconnecting with the local industry and has initiated meetings with dozens of startups in sectors where Israel is strong.
PartnersManagement Changes
growth-negative
FIMI buys Teva plant in Kiryat Shmona
FIMI Opportunity Funds, controlled by Ishay Davidi, is buying Teva Pharmaceutical Industries Ltd.s Migada plant in Kiryat Shmona for $47.5 million. The plant, which produces equipment to protect against hazardous pharmaceuticals, was put up for sale as part of Tevas aggressive streamlining plan presented in December 2017. The plants products are sold in more than twenty countries. Teva has ensured continued employment for the plants workers under the new ownership.
AcquisitionManagement Changes
growth-positive
Morgan Stanley upgrades Teva
Morgan Stanley has upgraded its rating of Teva Pharmaceutical Industries from Equal-weight to Overweight for the first time in two years. The investment bank has also increased its price target for the stock from $20 to $27. Analyst David Risinger cited three factors for the positive recommendation: expectation of higher profits due to cost cutting, new products that should deliver sales above expectations, and the companys valuation rising as strong performance reduces its net debt/EBITDA ratio. Risinger also noted that Tevas free cash flow generation is promising.
Investment
http://www.marketwatch.com/story/teva-reinforces-leadership-position-in-respiratory-with-acquisition-of-gecko-health-innovations-2015-09-25
Growth-Negative
Teva in crisis: Group of investors may offer to buy part of Teva's Israel operations
An investor group, led by Dan and Shmuel Topaz, the founders and former owners of Ham-Let, and an unnamed multinational maker of medical devices, may offer to buy part of Teva Pharmaceuticals Israel operations, potentially saving hundreds of jobs. This comes as Teva workers prepare to increase their protests against expected mass layoffs and factory closures. The investor group believes that with the right resources, Teva Medical could grow 10% to 15% a year as a standalone company. Meanwhile, Teva workers and their unions have vowed to step up strikes and other labor actions.
LayoffsAcquisition
growth-positive
Teva buys Mexican co Rimsa for $2.3b
Teva Pharmaceutical Industries Ltd. is acquiring Mexican pharmaceutical manufacturing and distribution company Representaciones e Investigaciones Médicas, S.A. de C.V. (Rimsa) for $2.3 billion. The deal includes a portfolio of products, companies, intellectual property, assets, and pharmaceutical patents in Latin America and Europe. This acquisition will make Teva a leading pharmaceutical company in Mexico and provide a platform for growth in the region. Rimsa had revenue in 2014 of $227 million with an annual growth of 10.6% since 2011. The acquisition is expected to close by early first quarter, 2016.
AcquisitionExpand
Buffett buys $358 million stake in Teva
growth-negative
Teva loses $235m patent trial to GSK
Teva Pharmaceutical Industries has been ordered by a US court to pay $235 million in compensation to GlaxoSmithKline for violating the latters patent for its Coreg drug, used to treat chronic heart failure. The ruling came after Tevas claim that GlaxoSmithKlines patent for the drug was invalid was dismissed. The case highlights the risks for generic drug companies in launching versions of patented drugs.
Customers
growth-positive
Teva buys rights to chronic pain drug for $250m
Teva Pharmaceutical Industries and Regeneron Pharmaceuticals have announced a partnership to develop and commercialise pain drug fasinumab, which is currently in Phase III clinical development for osteoarthritis pain and in Phase II development for chronic low back pain. Under the terms of the agreement, Teva will pay Regeneron $250 million upfront and share equally in the global commercial value (excluding Japan, Korea and other Asian countries covered by a previous collaboration), as well as ongoing R&D costs of about $1 billion.
PartnersInvestment
growth-positive
Teva completes acquisition of Actavis Generics
Teva Pharmaceutical Industries has completed its acquisition of Allergans generics business, Actavis Generics. The deal, which was first agreed in July 2015, saw Allergan receive $33.43 billion in cash and approximately 100 million Teva shares worth about $5.3 billion. The acquisition is expected to generate multi-year top-line and bottom-line growth as well as significant cash flow. Teva now has approximately 338 product registrations pending FDA approval and is planning for 1,500 generic launches globally in 2017.
AcquisitionInvestment
http://www.tevapharm.com/news/teva_to_acquire_allergan_generics_for_40_5_billion_creating_a_transformative_generics_and_specialty_company_well_positioned_to_win_in_global_healthcare_07_15.aspx
growth-positive
Teva: 35% of senior management are women
Teva, the Israeli pharmaceutical company, has pledged to reduce its energy consumption by 20% and greenhouse gas emissions by 15% by 2020. The company also announced its Target Zero vision to achieve zero incidents, zero injuries, and zero releases into the environment. The report also revealed that 49% of all management positions are staffed by women and 35% of executives and senior management are women. In 2015, Teva launched 315 generic medicines and held 130 clinical trials. As the largest supplier of medicine in the United Kingdom, it saved local authorities $4.3 billion in 2014 while worldwide savings amounted to tens of billions of dollars.
CustomersManagement Changes
growth-positive
Teva launches generic contraceptive pill
Teva Pharmaceutical Industries has announced the launch of a generic equivalent of Ortho Tri-Cyclen Lo tablets in the US. The product, an oral contraceptive, will be available in a 28-day blister pack dispenser. The original Ortho Tri-Cyclen tablets, marketed by Janssen Pharmaceuticals, had annual sales of $488 million in the US.
Customers
growth-positive
Teva invests $30m in US co Wave Life Sciences
Teva Pharmaceutical Industries Ltd. has invested $30 million in US biotechnology company Wave Life Sciences during the latters Nasdaq IPO. This purchase gives Teva a 9% stake in Wave Life Sciences. The company also announced that it had received $10 million from Teva after meeting a milestone for the Trisenox drug. The agreement between CTI Biopharma and Teva resulted from Tevas acquisition of Cephalon, which previously acquired the rights to the drug from CTI Biopharma. A Russian court has also ordered Teva to pay $5.9 million to Biotec Group for violating an agreement between the two in 2010.
InvestmentAcquisitionPartners
growth-positive
Teva acquires Gecko Health Innovations
Teva Pharmaceutical Industries Ltd. has announced its acquisition of Gecko Health Innovations Inc., a company that develops software and product solutions to improve compliance and adherence in the management of respiratory diseases. Through this acquisition, Teva will acquire CareTRx, a cloud-based solution developed by Gecko Health Innovations, designed to simplify chronic respiratory disease management, connecting patients and caregivers through remote monitoring and real-time adherence tools. No financial details about the acquisition were disclosed.
Acquisition
growth-positive
Teva buys 51% stake in US co Immuneering for $60m
Teva Pharmaceutical Industries Ltd. has acquired a 51% stake in Immuneering Corporation, a genomic-analysis company based in Massachusetts. Immuneering uses advanced proprietary techniques to identify hidden signals and biological insights across an array of genetic, genomic, and proteomic data that can direct research for enhanced discovery, development and clinical success. The acquisition will give Teva exclusive rights to Immuneerings analytics to advance treatments for diseases of the Central Nervous System (CNS).
AcquisitionInvestment
growth-positive
Teva buying Allergan Generics for $40.5b
Teva Pharmaceutical Industries Ltd. has announced the acquisition of the generic drugs division of Allergan plc for a total of $40.5 billion in cash and shares. This is the largest ever acquisition by an Israeli company. The deal is expected to close in the first quarter of 2016. The acquisition is expected to provide substantial financial benefits for Teva including highly diversified revenues and profits, and substantial cost synergies and tax savings. Teva expects Allergan Generics to contribute approximately $2.7 billion in EBITDA in 2016, excluding synergies.
Acquisition
growth-positive
Teva completes acquisition of 4.6% Mylan stake
Teva Pharmaceutical Industries has announced that it has completed the purchase of a 4.61% stake in Mylan, giving it legal standing in the Netherlands where Mylan is based. This move is part of Tevas ongoing efforts to acquire Mylan. The company has stated that it will initiate proceedings before the Dutch Enterprise Chamber if necessary. Mylan has bid $34 billion to acquire Perrigo Company, while Teva has bid over $40 billion to acquire Mylan, contingent on the Perrigo acquisition not going through.
Acquisition
growth-positive
Teva launches generic osteoporosis drug
Teva Pharmaceutical Industries has launched the generic equivalent to 5 mg, 30 mg, and 35 mg Actonel (risedronate sodium) tablets in the US. The company was first to file, making the product eligible for 180 days of market exclusivity. The tablets are used to treat or prevent osteoporosis in women after menopause, in either men or women who are taking corticosteroid medicines, and to treat Pagets disease of the bone. The launch is part of Tevas focus on womens health.
CustomersExpand
growth-positive
Teva to acquire Auspex for $3.2b
Teva Pharmaceutical Industries Ltd. has announced its acquisition of Auspex Pharmaceuticals Inc. for a total consideration of $3.2 billion. The deal is expected to enhance Tevas revenue and earnings growth profile and strengthen its core central nervous system (CNS) franchise with the addition of Auspex’s portfolio of innovative medicines for people with movement disorders. The transaction has been unanimously approved by the boards of directors of both Teva and Auspex.
Acquisition
growth-positive
Teva close to major acquisition - report
Wall Street analysts predict that Teva Pharmaceutical Industries Ltd. is close to making a major acquisition, which may be announced by September. This follows hints from Teva executives, including CEO Erez Vigodman, that the company was considering acquisitions. Vigodman stated last month that Teva was ready to switch to a strategy of inorganic growth, following a long period of focusing on defending its Copaxone patent and implementing cost cutting measures. Analysts suggest that Teva has over $10 billion in debt capacity to spend on acquisitions.
Acquisition
growth-positive
Teva raises extra $658m in underwriters' options
Teva Pharmaceuticals has announced that it will raise an additional $658 million in underwriters options for its previously announced offerings of its American Depositary Shares. This will bring the total raised by the company in its current offering to $7.24 billion. The net proceeds from these offerings will be used towards the cash portion of its $40.5 billion acquisition of Allegans generic division and its $2.3 billion acquisition of Mexican pharmaceutical company Rimsa.
InvestmentAcquisition
